wikidoc - User contributions [en]

Flock worker's lung

2021-06-08T15:49:20Z

Roukoz Abou Karam:

__NOTOC__
{{Flock worker's lung}}
{{CMG}} {{AE}} {{USM}}

{{SK}}

==Overview==

Flock Worker's Lung(FWL) is an unusual disease [[interstitial disease]] characterized by [[lymphocytic bronchiolitis]] and [[peribronchiolitis]] in workers exposed to flock fibers. Flock is made for the application to adhesive-coated substrates by cutting short synthetic fibers from bundles of parallel nylon monofilaments or other polymers. They are usually prepared from synthetic materials.
The disease was identified initially in 1998 when a group of workers at a flocking plant developed unknown cause [[interstitial lung disease]]. The first cases to be identified were initially described as [[desquamative]] [[pneumonia]] and were attributed not with flock fibers, but to unspecified toxin exposure. As subsequent cases appeared, the clinical results with exposure to the flock seemed to be best characterized as [[lymphocytic]] [[bronchiolitis]]. Typically it presents with progressive [[dyspnea]], [[dry cough]], and constitutional symptoms. Some patients also show work-related symptoms, especially early in the process.

==Historical Perspective==

*Since 1975, distributed case reports have raised doubt of a respiratory danger related with different manufactured strands, including polyester, nylon, and acrylic dust.

*Early reports in 1974 and 1981 of working environment assessments by National Institute of Occupational Safety and Health (NIOSH) agents ascribed respiratory manifestations among laborers to irritant properties of nonrespirable flock fibers on the upper airways but did not pursue the possibility of [[lung disease]] associated with flock work <ref name="pmid23732577">{{cite journal |vauthors=Kreiss K |title=Occupational lung disease: from case reports to prevention |journal=Chest |volume=143 |issue=6 |pages=1529–1531 |date=June 2013 |pmid=23732577 |pmc=3673658 |doi=10.1378/chest.12-3001 |url=}}</ref>
*During 1990 and 1991, five workers from a nylon flock handling plant in Ontario presented with [[cough]] and [[dyspnea]].<ref name="pmid10351952">{{cite journal |vauthors=Eschenbacher WL, Kreiss K, Lougheed MD, Pransky GS, Day B, Castellan RM |title=Nylon flock-associated interstitial lung disease |journal=Am. J. Respir. Crit. Care Med. |volume=159 |issue=6 |pages=2003–8 |date=June 1999 |pmid=10351952 |doi=10.1164/ajrccm.159.6.9808002 |url=}}</ref>
*In 1995 and 1996, two workers from a similar nylon flock handling plant in Rhode Island presented independently to the same doctor with [[cough]] and [[dyspnea]].
*The underlying diagnosis for the lung ailment in these two employees was initially thought to be work-related [[Hypersensitivity pneumonitis]]. With additional case finding investigation at the Rhode Island location, a total of eight cases among the approximately 150 workers at the plant were identified by January 1998 based upon a screening questionnaire (symptoms of [[cough and dyspnea]]), [[pulmonary function]] abnormalities ([[restrictive pattern]] with [[reduced diffusion capacity]]), radiographic findings and/or histological findings on tissue obtained by open lung or [[transbronchial lung biopsy]]. Based upon the aggregate histopathological results from biopsied cases, the disease process was not thought to be [[hypersensitivity pneumonitis]].<ref name="pmid10351952">{{cite journal |vauthors=Eschenbacher WL, Kreiss K, Lougheed MD, Pransky GS, Day B, Castellan RM |title=Nylon flock-associated interstitial lung disease |journal=Am. J. Respir. Crit. Care Med. |volume=159 |issue=6 |pages=2003–8 |date=June 1999 |pmid=10351952 |doi=10.1164/ajrccm.159.6.9808002 |url=}}</ref>
*"Flock Workers's lung" officially came to known in 1998, when scientists from NIOSH distributed the aftereffects of an epidemiological examination of episodes in Ontario and Rhode Island..
*Previously, [[interstitial lung disease]] in flock workers was mistakenly ascribed to [[mycotoxins]] present in polluted adhesive.<ref name="pmid23732577" />

==Classification==
The disease currently still has not been stratified.
==Pathophysiology==

*Flock consists of short fibers that are cut from long filaments and glued to a backing material such as cloth to provide a fuzzy, carpet-like surface texture. They are usually made from synthetic materials such as nylon, rayon, or polypropylene. The cutting process results in the formation of [[airborne particles]] or fibers in the respirable range. Inhalation of flock dust causes [[interstitial lung disease]].<ref name="urlCDC - NIOSH Program Portfolio : Respiratory Diseases : Risks">{{cite web |url=https://www.cdc.gov/niosh/programs/resp/risks.html |title=CDC - NIOSH Program Portfolio : Respiratory Diseases : Risks |format= |work= |accessdate=}}</ref>
*Preliminary toxicological findings indicate that ultrafine respirable nylon fragments after a single [[intratracheal]] instillation trigger an [[acute inflammatory]] [[lung injury]] in rats. Yet flock finishing agents or other particulate matter components found in the soil of flock processing plants can not yet be removed.
*We have studied [[interstitial pneumonitis]] among nylon flock processors with a histopathological pattern — bronchiolar and peribronchiolar lymphocytic [[inflammation]] and [[lymphoid hyperplasia]] — that indicates an [[inflammatory]] and possibly [[immunological]] response to a [[respiratory toxicant]]. <ref name="EschenbacherKreiss1999">{{cite journal|last1=Eschenbacher|first1=William L.|last2=Kreiss|first2=Kathleen|last3=Lougheed|first3=M. Diane|last4=Pransky|first4=Glenn S.|last5=Day|first5=Brian|last6=Castellan|first6=Robert M.|title=Nylon Flock–Associated Interstitial Lung Disease|journal=American Journal of Respiratory and Critical Care Medicine|volume=159|issue=6|year=1999|pages=2003–2008|issn=1073-449X|doi=10.1164/ajrccm.159.6.9808002}}</ref>
*In one study microscopic examination of polypropylene fiber-exposed lungs revealed a dose-dependent increase in cellularity (especially macrophage infiltration), but no [[fibrosis]]. In another study, the researchers found high serum [[IL-8]] and [[TNF-α]] levels in the polypropylene flocking workers. Furthermore, these levels showed a negative correlation with ''D''L, [[CO]] levels. These results suggest that [[IL-8]] and [[TNF-α]] may act as key mediators for [[inflammatory]] [[lung injury]] in the [[pathogenesis]] of flock worker's lung.<ref name="Atis2005">{{cite journal|last1=Atis|first1=S.|title=The respiratory effects of occupational polypropylene flock exposure|journal=European Respiratory Journal|volume=25|issue=1|year=2005|pages=110–117|issn=0903-1936|doi=10.1183/09031936.04.00138403}}</ref>

[[File:SEM_flock_particles.png|300px|thumb|none|Electron Microscopic image showing Flock Fibers collected from the air sample of a card manufacturing factory. [https://http://onlinelibrary.wiley.com/doi/10.1002/ajim.20440/abstract]]]

==Causes==

*FWL results from the inhalation of airborne nylon fibers at work. Nylon fibers are used in making products for upholstery, automobiles, carpet, and apparel.

==Differentiating Flock Worker's Lung from other Diseases==

FWL presents like most Interstitial Lung Disease.
Differentiating FWL from other '''similar interstitial lung diseases''' can be done based on a history of exposure and work environment.

{| class="wikitable" style="margin: 1em auto 1em auto"
|+
!Occupation||Causative Agent||Disease||Differences on Imaging||Histopathology findings
|-
|Shipbuilding||Asbestos||[[Asbestosis]]||Affects Lower Lobes; Calcified supradiaphragmatic and [[pleural plaques]]||Asbestos Bodies
|-
|Dental technicians, jewelers, precious metal reclamation workers,||Beryllium||[[Chronic beryllium disease]]||Affects Upper lobes||[[Granulomatous]] histology
|-
|Glass manufacturing, Blue jean Manufacturing||Sand||[[Silicosis]]||Affects Upper lobes, nodular pattern; Eggshell calcifications of hilar lymph nodes||Fibrotic nodules with concentric "onion-skinned" arrangement of collagen fibers <ref name="pmid2838005">{{cite journal |vauthors= |title=Diseases associated with exposure to silica and nonfibrous silicate minerals. Silicosis and Silicate Disease Committee |journal=Arch. Pathol. Lab. Med. |volume=112 |issue=7 |pages=673–720 |date=July 1988 |pmid=2838005 |doi= |url=}}</ref>
|-
|Food Industry||Diacetyl||[[Bronchiolitis Obliterans]]||Patchy areas of decreased lung density, This pattern is often described as a "mosaic pattern" <ref name="pmid24806161">{{cite journal |vauthors=Barker AF, Bergeron A, Rom WN, Hertz MI |title=Obliterative bronchiolitis |journal=N. Engl. J. Med. |volume=370 |issue=19 |pages=1820–8 |date=May 2014 |pmid=24806161 |doi=10.1056/NEJMra1204664 |url=}}</ref>||Intraluminal buds called "Masson bodies" fill the lumen, which results in bronchiolar plugging <ref name="pmid26335918">{{cite journal |vauthors=Aguilar PR, Michelson AP, Isakow W |title=Obliterative Bronchiolitis |journal=Transplantation |volume=100 |issue=2 |pages=272–83 |date=February 2016 |pmid=26335918 |doi=10.1097/TP.0000000000000892 |url=}}</ref>
|-
|Domestic use for heating||Biomass fuel||[[Interstitial Lung Disease]]||Distribution of the nodules is seen to be [[centrilobular]]||Bronchoscopy reveals a large number of anthracotic pigments in the airways <ref name="urlBeyond pneumonoconiosis: Recently described occupational interstitial lung diseases | PNEUMON - Official Journal of Hellenic Thoracic Society">{{cite web |url=http://www.pneumon.org/july-september-2010-vol-23-issue-3/showfulltext789/1/newsid789/356 |title=Beyond pneumonoconiosis: Recently described occupational interstitial lung diseases | PNEUMON - Official Journal of Hellenic Thoracic Society |format= |work= |accessdate=}}</ref>

|-
|Coal Industry||Coal dust||[[Coal Workers Pneumoconiosis]]||Affects Upper lobes, nodular pattern||[[Macrophages]] laden with carbon
|-
|Animal Breeding||Phytoset||[[Hypersensitivity Pneumonitis]]||Affects Middle and Lower lobes , nodular pattern||[[Multinucleated giant cell]]
|-
|Synthetic flock manufacturing||Nylon, rayon, or polypropylene||Flock Worker's Lung||Diffuse nodular opacities, very similar to [[Hypersensitivity Pneumonitis]]||Increase Eosinophil and Lymphocyte count seen in BAL <ref name="EschenbacherKreiss1999">{{cite journal|last1=Eschenbacher|first1=William L.|last2=Kreiss|first2=Kathleen|last3=Lougheed|first3=M. Diane|last4=Pransky|first4=Glenn S.|last5=Day|first5=Brian|last6=Castellan|first6=Robert M.|title=Nylon Flock–Associated Interstitial Lung Disease|journal=American Journal of Respiratory and Critical Care Medicine|volume=159|issue=6|year=1999|pages=2003–2008|issn=1073-449X|doi=10.1164/ajrccm.159.6.9808002}}</ref>

|}

==Epidemiology and Demographics==

*Cases have been reported in the United States, Canada, Turkey, and Spain.
*In a study flocking workers when compared to controls, whereas age, sex, tobacco use and working years were not found to be significantly associated with respiratory symptoms. <ref name="Atis2005" />

==Risk Factors==

*In textile workers, the lung of the flock worker is seen chronically exposed to short nylon fibers usually flocked onto textile products. Flock is created by cutting guillotine or rotary cutting. It has been believed that rotary cutting is more dangerous than guillotine cutting.<ref name="urlChronic Hypersensitivity Pneumonitis Associated with Inhaled Exposure to Nylon Powder for 3-D Printing: A Variant of Nylon Flock Workers Lung Disease? | D46. CASE REPORTS IN ENVIRONMENTAL AND OCCUPATIONAL HEALTH">{{cite web |url=https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A7071 |title=Chronic Hypersensitivity Pneumonitis Associated with Inhaled Exposure to Nylon Powder for 3-D Printing: A Variant of Nylon Flock Worker's Lung Disease? | D46. CASE REPORTS IN ENVIRONMENTAL AND OCCUPATIONAL HEALTH |format= |work= |accessdate=}}</ref>.<ref name="Atis2005" />
*Working in manufacturing and maintenance, on a flocking scale, and more days and hours a week, cleaning with compressed air, and increased current and accumulated exposure to respiratory dust were found to be strongly correlated with disease symptoms.
*Multivariate research found that becoming a worker flocking with polypropylene was a predictive factor for pulmonary function disability.<ref name="pmid23732577" />
*An analysis showed that the risk of respiratory symptoms increased by almost 4 times in polypropylene flocking workers when compared to controls.<ref name="Atis2005">{{cite journal|last1=Atis|first1=S.|title=The respiratory effects of occupational polypropylene flock exposure|journal=European Respiratory Journal|volume=25|issue=1|year=2005|pages=110–117|issn=0903-1936|doi=10.1183/09031936.04.00138403}}</ref>

==Natural History, Complications and Prognosis==
FWL's natural history reflects the following trends

*Total Symptom Resolution;
*Abnormalities to both the radiographic and pulmonary functions;
*Permanent yet manageable signs and restrictive [[pulmonary function]] deficits;
*And progressive pulmonary deterioration, causing death from [[respiratory failure]] and [[secondary hypertension]]. The presence and development of FWL is correlated with low baseline diffusing potential of the lung for carbon monoxide. <ref name="TurcotteChee2013">{{cite journal|last1=Turcotte|first1=Scott E.|last2=Chee|first2=Alex|last3=Walsh|first3=Ronald|last4=Grant|first4=F. Curry|last5=Liss|first5=Gary M.|last6=Boag|first6=Alexander|last7=Forkert|first7=Lutz|last8=Munt|first8=Peter W.|last9=Lougheed|first9=M. Diane|title=Flock Worker's Lung Disease|journal=Chest|volume=143|issue=6|year=2013|pages=1642–1648|issn=00123692|doi=10.1378/chest.12-0920}}</ref>
*In general, after [[steroid therapy]] and leaving the place of operation, improvement occurred over a period of months or years, with some experiencing recurrent [[dyspnea]], activity restriction or chronic supplemental oxygen needs.<ref name="BarrosoIbañez2002">{{cite journal|last1=Barroso|first1=E.|last2=Ibañez|first2=M.D.|last3=Aranda|first3=F.I.|last4=Romero|first4=S.|title=Polyethylene flock-associated interstitial lung disease in a Spanish female|journal=European Respiratory Journal|volume=20|issue=6|year=2002|pages=1610–1612|issn=0903-1936|doi=10.1183/09031936.02.00030102}}</ref>
*There was also 3 times increase in [[lung cancer]] incidence. <ref name="KernKern2011">{{cite journal|last1=Kern|first1=David G.|last2=Kern|first2=Eli|last3=Crausman|first3=Robert S.|last4=Clapp|first4=Richard W.|title=A Retrospective Cohort Study of Lung Cancer Incidence in Nylon Flock Workers, 1998–2008|journal=International Journal of Occupational and Environmental Health|volume=17|issue=4|year=2011|pages=345–351|issn=1077-3525|doi=10.1179/oeh.2011.17.4.345}}</ref>

==Diagnosis==
===Diagnostic Criteria===
A case of flock worker's lung is defined as:

#A histological diagnosis of [[non-specific interstitial pneumonia]], with or without [[interstitial fibrosis]], characterized by [[bronchiolocentric]] [[nodular]] and diffuse [[interstitial lymphoid infiltration]] and non-uniform [[alveolar]] filling by [[macrophages]];
#Other histologic manifestations of [[Interstitial Lung Disease]] (ILD) not attributable to another disease; or
#A grossly abnormal distribution of cell types on bronchoalveolar lavage (BAL) with restrictive lung function and HRCT findings of either diffuse ground-glass opacity or micronodularity, in the absence of a tissue specimen.<ref name="urlChronic Interstitial Lung Disease in Nylon Flocking Industry Workers -- Rhode Island, 1992-1996">{{cite web |url=https://www.cdc.gov/mmwr/preview/mmwrhtml/00049601.htm |title=Chronic Interstitial Lung Disease in Nylon Flocking Industry Workers -- Rhode Island, 1992-1996 |format= |work= |accessdate=}}</ref>

===History and Symptoms===

*The nylon flock exposed workers most commonly presented with [[chronic respiratory symptoms]] over several years, but [[subacute]] presentations also occurred. For example, in a Canadian outbreak, 5 of 88 exposed workers developed the disease after exposure occurring over several days

*[[Restrictive ventilatory defects]] are most common, but [[obstructive defects]] have been reported. <ref name="SaulerGulati2012">{{cite journal|last1=Sauler|first1=Maor|last2=Gulati|first2=Mridu|title=Newly Recognized Occupational and Environmental Causes of Chronic Terminal Airways and Parenchymal Lung Disease|journal=Clinics in Chest Medicine|volume=33|issue=4|year=2012|pages=667–680|issn=02725231|doi=10.1016/j.ccm.2012.09.002}}</ref>

A study showed 20 individual from different geographic locations having FWL shared symptoms of

*[[dyspnea]] and [[cough]], with and without [[sputum production]].
*These symptoms were present for months to years before clinical presentation, which, for some cases, seemed precipitated by an acute exacerbation in the preceding few days. Symptom onsets for the patients occurred over a 15-yr period, with no apparent concentration of onsets for any plant location.
*Few nonrespiratory symptoms were noted. [[Weight loss]] was noted in two patients and two workers had [[arthralgia]] or [[myalgias]]. Eight of the 20 patients were noted to have [[asthma]], increased bronchial responsiveness to [[methacholine]], or increased [[bronchodilator]] responsiveness.<ref name="pmid10351952" />

===Physical Examination===

*Physical examination in one study showed that both patients with FWL and control groups were evaluated as normal.<ref name="Atis2005">{{cite journal|last1=Atis|first1=S.|title=The respiratory effects of occupational polypropylene flock exposure|journal=European Respiratory Journal|volume=25|issue=1|year=2005|pages=110–117|issn=0903-1936|doi=10.1183/09031936.04.00138403}}</ref>
*Others have reported

:*[[inspiratory crackles]] on [[auscultation]] <ref name="BarrosoIbañez2002">{{cite journal|last1=Barroso|first1=E.|last2=Ibañez|first2=M.D.|last3=Aranda|first3=F.I.|last4=Romero|first4=S.|title=Polyethylene flock-associated interstitial lung disease in a Spanish female|journal=European Respiratory Journal|volume=20|issue=6|year=2002|pages=1610–1612|issn=0903-1936|doi=10.1183/09031936.02.00030102}}</ref>

:*[[Pulmonary function test]] results revealing a [[restrictive pattern]] <ref name="EschenbacherKreiss1999">{{cite journal|last1=Eschenbacher|first1=William L.|last2=Kreiss|first2=Kathleen|last3=Lougheed|first3=M. Diane|last4=Pransky|first4=Glenn S.|last5=Day|first5=Brian|last6=Castellan|first6=Robert M.|title=Nylon Flock–Associated Interstitial Lung Disease|journal=American Journal of Respiratory and Critical Care Medicine|volume=159|issue=6|year=1999|pages=2003–2008|issn=1073-449X|doi=10.1164/ajrccm.159.6.9808002}}</ref>

===Laboratory Findings===

*There are no specific laboratory findings associated with FWL.

===Imaging Findings===

*[[High-resolution CT scan]] remained a highly [[sensitive diagnostic test]]. [[Pulmonary function tests]] and plain [[chest X-ray]] were less sensitive.<ref name="KernKuhn2000">{{cite journal|last1=Kern|first1=David G.|last2=Kuhn|first2=Charles|last3=Ely|first3=E. Wesley|last4=Pransky|first4=Glenn S.|last5=Mello|first5=Curtis J.|last6=Fraire|first6=Armando E.|last7=Müller|first7=Joachim|title=Flock Worker's Lung|journal=Chest|volume=117|issue=1|year=2000|pages=251–259|issn=00123692|doi=10.1378/chest.117.1.251}}</ref>
*The most common findings in FWL on [[CT scan]] were ground-glass opacities and [[micronodules]], with a peripheral predominance in some.<ref name="WeilandLynch2003">{{cite journal|last1=Weiland|first1=David A.|last2=Lynch|first2=David A.|last3=Jensen|first3=Steven P.|last4=Newell|first4=John D.|last5=Miller|first5=David E.|last6=Crausman|first6=Robert S.|last7=Kuhn|first7=Charles|last8=Kern|first8=David G.|title=Thin-Section CT Findings in Flock Worker’s Lung, a Work-related Interstitial Lung Disease|journal=Radiology|volume=227|issue=1|year=2003|pages=222–231|issn=0033-8419|doi=10.1148/radiol.2271011063}}</ref>

[[File:Ct scan.jpeg|300px|thumb|none|A Normal CT Scan. [https://https://radiopaedia.org/articles/ct-chest-non-contrast-technique?lang=u;Radiology Reference Article &#124]]]

[[File:Flock workers Lung Ct scan.jpg|300px|thumb|none|CT Scan seen in hypersensitivity pneumonitis which is very similar to FWL. [https://https://commons.wikimedia.org/wiki/File:Neumonitis_por_hipersensibilidad_2.jpg]]]

===Other Diagnostic Studies===

*[[Transbronchial biopsy]] may prove helpful in the consideration of alternate diagnoses, but [[wedge biopsy]] by [[thoracotomy]] or [[thoracoscopy]] is necessary to adequately examine the characteristic lesion of this [[interstitial lung disease]] in relation to the [[pulmonary lobular architecture]]. <ref name="EschenbacherKreiss1999">{{cite journal|last1=Eschenbacher|first1=William L.|last2=Kreiss|first2=Kathleen|last3=Lougheed|first3=M. Diane|last4=Pransky|first4=Glenn S.|last5=Day|first5=Brian|last6=Castellan|first6=Robert M.|title=Nylon Flock–Associated Interstitial Lung Disease|journal=American Journal of Respiratory and Critical Care Medicine|volume=159|issue=6|year=1999|pages=2003–2008|issn=1073-449X|doi=10.1164/ajrccm.159.6.9808002}}</ref>

==Treatment==
===Medical Therapy===

*Cessation of nylon exposure and [[corticosteroid]] therapy, for exacerbation of [[respiratory]] problems, has been observed to lead symptomatic improvement but overall lung functions are still seen to decline in certain cases.<ref name="urlChronic Hypersensitivity Pneumonitis Associated with Inhaled Exposure to Nylon Powder for 3-D Printing: A Variant of Nylon Flock Workers Lung Disease? | D46. CASE REPORTS IN ENVIRONMENTAL AND OCCUPATIONAL HEALTH" /><ref name="BarrosoIbañez2002" />

===Prevention===

*Several observations affirmed that the exposure preceded the disease and that the disease improved with exposure cessation to the implicated work environments.<ref name="pmid23732577" />
*NIOSH has made recommendations to companies that manufacture flock and make flock containing products that aim to reduce workers’ exposure to flock dust. These include: engineering controls and alternative methods to cleaning the workplace with compressed air, which re-aerosolizes settled dust, improved cutter maintenance, and implementation of [[medical surveillance]] programs have reduced the number of reported cases.<ref name="urlCDC - NIOSH Program Portfolio : Respiratory Diseases : Risks" /><ref name="SaulerGulati2012" />

==References==
{{Reflist|2}}

[[Category:Pulmonology]]

Pneumoconiosis historical perspective

2021-05-12T18:39:56Z

Roukoz Abou Karam:

__NOTOC__
{{Pneumoconiosis}}
{{CMG}}; {{AE}} [[User:Dushka|Dushka Riaz, MD]]

==Overview==
Because the various [[pneumoconiosis]] present after exposure to specific particles and dust, their historical perspective varies according to the [[antigen]]. Generally, once patients began to present following exposure to a particle, safety measures and awareness followed.

==Historical Perspective==

===Discovery===

*There is evidence in ancient Egypt and Greece for a [[disease]] caused by [[silica]] [[inhalation]]. <ref name="pmid5318957">{{cite journal| author=Brown HV| title=The history of industrial hygiene: a review with special reference to silicosis. | journal=Am Ind Hyg Assoc J | year= 1965 | volume= 26 | issue= 3 | pages= 212-26 | pmid=5318957 | doi=10.1080/00028896509342723 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=5318957 }} </ref><ref name="pmid7480684">{{cite journal| author=Akira M| title=Uncommon pneumoconioses: CT and pathologic findings. | journal=Radiology | year= 1995 | volume= 197 | issue= 2 | pages= 403-9 | pmid=7480684 | doi=10.1148/radiology.197.2.7480684 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7480684 }} </ref>
*[[Berylliosis]] was coined in 1946, when fluorescent lamp workers began presenting with pulmonary [[granulomatous]] diseases. <ref name="pmid21000285">{{cite journal| author=HARDY HL, TABERSHAW IR| title=Delayed chemical pneumonitis occurring in workers exposed to beryllium compounds. | journal=J Ind Hyg Toxicol | year= 1946 | volume= 28 | issue= | pages= 197-211 | pmid=21000285 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21000285 }} </ref>

===Impact on Cultural History===

*Many countries have banned the use of [[asbestosis]] and the [[United States]] has significantly decreased its use since the 1970s. <ref name="pmid9142077">{{cite journal| author=Wagner GR| title=Asbestosis and silicosis. | journal=Lancet | year= 1997 | volume= 349 | issue= 9061 | pages= 1311-5 | pmid=9142077 | doi=10.1016/S0140-6736(96)07336-9 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9142077 }} </ref>
*The UK limited its use of [[silica]] since 1949. <ref name="pmid7573613">{{cite journal| author=Wagner GR| title=The inexcusable persistence of silicosis. | journal=Am J Public Health | year= 1995 | volume= 85 | issue= 10 | pages= 1346-7 | pmid=7573613 | doi=10.2105/ajph.85.10.1346 | pmc=1615617 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7573613 }} </ref>

==References==

{{Reflist|2}}

[[Category:Pulmonology]]
[[Category:Mine safety]]
[[Category:Coal]]
[[Category:Occupational diseases]]
[[Category:Disease]]

{{WH}}
{{WS}}

Pulmonology status update

2021-05-11T16:45:20Z

Roukoz Abou Karam: /* In progress chapters */

__NOTOC__

{{CMG}}; {{AE}} {{Hudakarman}}
{{Organ System Project}}
System leader: '''[[User:Roukoz Abou Karam|Roukoz Abou Karam, M.D.]]'''
==Status Updates==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Resident survival guide Progress
|-
|Completed
|9
|-
|In progress
|1
|-
|Remaining
|2
|-
! colspan="2" style="background:#efefef;" |Primary care chapter Progress
|-
|Completed
|6
|-
|In progress
|5
|-
|Remaining
|0
|}

==Primary Care Topics==

{| class="wikitable sortable"
! colspan="4" |Primary care chapters
! colspan="3" |Primary care resident survival guides
|-
!Specialty
!Topic
!Author
!Status
!Resident Survival Guide Page
!Author
!Status
|-
|Pulmonary||[[Asthma|Asthma exacerbation]]
|
|Complete||[[Asthma exacerbation resident survival guide]]||Abdurahman, Vidit||Complete
|-
|Pulmonary||[[Chronic obstructive pulmonary disease|COPD exacerbation]]
|Roukoz Abou Karam
|Complete||[[COPD exacerbation resident survival guide]]|| ||Complete
|-
|Pulmonary
|[[Cough]]
|Abiodun Akanmode
|Complete
|[[Cough resident survival guide]]
|Sara Haddadi
|In progress
|-
|Pulmonary
|[[Dyspnea]]
|Roukoz Abou Karam
|In progress
|[[Dyspnea resident survival guide]]
|Eiman
|Needs review
|-
|Pulmonary
|[[Chest pain]]
|Aisha Adigun
|Complete
|[[Chest pain resident survival guide]]
|
|Complete
|-
|Pulmonary
|[[Hemoptysis]]
|
|Complete
|[[Hemoptysis resident survival guide]]
|Teresa
|Complete
|-
|Pulmonary||[[Anaphylaxis]]
|Dushka Riaz
|Complete||[[Anaphylaxis resident survival guide]]||Vidit||Complete
|-
|Pulmonary||[[Acute respiratory distress syndrome]]
|Roukoz Abou Karam
|Complete||[[Acute respiratory distress syndrome resident survival guide]]||Ayokunle||Complete
|-
|Pulmonary||[[Pleural effusion]]
|Dushka Riaz
|Complete||[[Pleural effusion resident survival guide]]||Twinkle||Complete
|-
|Pulmonary||[[Pulmonary embolism]]
|
|Complete||[[Pulmonary embolism resident survival guide]]|| ||Complete
|-
|Pulmonary
|[[Lung mass]]
|
|Complete
|[[Lung mass resident survival guide]]
|Akshun Kalia
|Complete
|} 

==Status Update==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Progress
|-
|Completed
|41
|-
|In progress
|9
|-
|Remaining
|20
|}
==List of Chapters Requiring Content==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="21" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonolgy
| style="padding: 5px 5px; background: #F5F5F5;" |[[Amniotic fluid embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchoscopy]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hepatopulmonary syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hydrothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |in progress
| style="padding: 5px 5px; background: #F5F5F5;" |Kunwardeep
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hypoxemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Mediastinal disorders
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mediastinal mass|Mediastinal masses]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Pleural disorders
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pleural plaque]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pleurodynia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Pressure associated lung diseases
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Altitude sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Barotrauma]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Nitrogen narcosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary function tests]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary nodule]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Idiopathic pulmonary hemosiderosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary lymphangioleiomyomatosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|}

==In progress chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="22" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonology
| style="padding: 5px 5px; background: #F5F5F5;" |[[Decompression sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Hazem
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Air embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mounika Lakumalla
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmed Elsaiey
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hepatopulmonary syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Soroush
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Tracheitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dushka
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumoconiosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dushka
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Berylliosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Omid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Farmer's lung]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Aisha
| style="padding: 5px 5px; background: #F5F5F5;" |Ali Musadiq
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Decompression sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Jaspinder Kaur
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmed Elsaiey
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Chylothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Joanna Ekabua
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz Abou Karam
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Thoracentesis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ayeesha
| style="padding: 5px 5px; background: #F5F5F5;" |Ali Musadiq
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Flock worker's lung]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Israr Khan
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz Abou Karam
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-

|}

==Completed chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="45" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonology
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cystic fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Shamila
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary hypertension]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ajay
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory failure]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Khurram/Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary edema]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Famaz/Manpreet
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Neurogenic pulmonary edema]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Shamila
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchiectasis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hemoptysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Occupational lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Restrictive lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Obstructive lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Interstitial lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf/Anmol
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Idiopathic pulmonary fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmad E
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary alveolar proteinosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mahda
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cryptogenic organizing pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Manpreet
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Interstitial pneumonitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Chandra
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Small cell lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mesothelioma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mazia/feham/fatima
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid/Fehman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hypersensitivity pneumonitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sargun
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Non small cell lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mohsin
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Adenocarcinoma of the lung|Adenocarcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sudarshana
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Large cell carcinoma of the lung|Large cell carcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Aditiya
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Squamous cell carcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lung mass]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Akshun
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cyanosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Chandra/Medhat/Amandeep
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory acidosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Krishna
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory alkalosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Madhu
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Diaphragmatic paralysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mahda
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchogenic cyst]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Joanna Ekabua
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Eosinophilic pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Medhat
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Fat embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Fehman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mechanical ventilation]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ajay
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Atelectasis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sudarshana
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pancoast tumor]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mazia
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Blood gas analysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Medhat
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[CO poisoning]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Fatima
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Aspiration pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory patterns]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Eiman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hyperventilation]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Amresh/Akshun/Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|}

Acute megakaryoblastic leukemia

2021-05-07T16:37:13Z

Roukoz Abou Karam: /* Differentiating AMKL from other Diseases */

__NOTOC__
{{SI}}

Acute megakaryoblastic leukemia
{{CMG}}; {{AE}} [[User:Israrkhan|Israr Khan, M.D.]][mailto:israrkhan.dawar@gmail.com]

{{SK}} Leukemia, megakaryoblastic, acute; megakaryoblastic leukemia, acute; AMKL; leukemia, myeloid, acute, M7; megakaryocytic leukemia; megakaryocytic leukemia, acute; myeloid leukemia, acute, M7

==Overview==
Acute megakaryoblastic leukemia is a rare type of [[hematological malignancy]] that results from the clonal proliferation of [[Megakaryoblast|megakaryoblasts]] in the [[bone marrow]]. Prof. Dr. Von Boros first described it in 1931. In 1985, the [[French-British-American classification]] of [[Acute myeloid leukemia]] (AML) included it as (M7 subtype). Later in 2008, acute megakaryoblastic leukemia was classified under AML otherwise not specified category by [[World Health Organization]]. It results from a mutation involving several genes, particularly the [[GATA1]] gene, and [[transforming growth factor-β]] (TG-β). AMKL has commonly associated with [[Down syndrome]]. It has a bimodal distribution and is more common in children (<4) 15% than adults 0.6%. AMKL has a wide range of presentations which has either acute or insidious onset. It is characterized by fever, irritability, headache, fatigue, bone pain, generalized body aches, bruises, and difficulty walking. Physical exam findings include pallor, [[Hepatosplenomegaly]] (HSM), and [[lymphadenopathy]], bruises and [[purpura]], and sometimes temporal or orbital swelling. It is diagnosed by bone marrow biopsy showing 30% or more leukemic cells of megakaryocytic lineage and detection of platelet-specific [[peroxidase antibodies]]. Other lab findings include pancytopenia and megakaryocytic progenitors in the [[peripheral smear]]. Other diagnostic studies include; [[Immunophenotyping]] using MoAb to megakaryocyte restricted antigen (CD41 and CD61), complex karyotypic ([[t(1;22)(p13;q13]]) involvement, radiologic features of the osteolytic lesion, metaphyseal lucency, pathologic fractures using [[Chest X-ray|CXR]], [[CT scan]], [[bone scan]], and [[MRI]] modalities. Currently, [[chemotherapy]] and [[Allo-BMT|allogeneic bone marrow transplant]] (Allo-BMT) are mainstay therapy. However, treatment-related toxicity is a big challenge. Different drug combination regimens are available for AMKL. The commonly used drugs are [[Ara-Cytarabine|Cytarabine]], [[mitoxantrone]], [[etoposide]], [[vincristine]], [[fludarabine]], and [[Piraubicin|pirarubicin]]. The prognosis of AMKL in Down syndrome patients is favorable as compared with non-Down syndrome patients.

The following complications can be observed in patients with AMKL; [[periosteal elevation]], [[osteolytic lesions]], especially in long bones, e.g., [[femur]], [[osteoporosis]] with pathologic fractures, [[Sweet syndrome]] (SS), [[leukemia cutis]], and [[hypercalcemia]].
 
==Historical Perspective==

J. Von Boros first described acute megakaryoblastic leukemia in 1931.
==Classification==

For established [[French-British-American]] (FAB) classification, refer to [[Acute myeloid leukemia classification|acute myeloid leukemia classification.]]
==Pathophysiology==

*It is associated with [[GATA1]], and risks are increased in individuals with [[Down syndrome]]. However, not all cases are associated with Down syndrome, and other [[genes]] can also be associated with AMKL. However, not all cases are associated with Down syndrome, and other [[genes]] can also be associated with AMKL.

*According to the report of the [[French-American-British]] Cooperative Group, this category of AML (M7 subtype) is associated with 30% or more blasts in the bone marrow. Blasts are identified as being of megakaryocyte lineage by; expression of [[megakaryocyte]] specific [[antigen]]s and platelet [[peroxidase]] reaction on [[electron microscopy]].

*[[Myelofibrosis]] is usually associated with AMKL; however, the exact underlying pathophysiology is controversial. The investigators did not find any direct correlation between acute myelofibrosis and the [[fibroblasts]] obtained from the bone marrow of patients with AMKL. Nevertheless, it was proposed that some humoral factors may play a key role in developing bone marrow fibrosis.

*[[Transforming Growth Factor-β]] (TG-β) was identified to be the significant contributor in AMKL associated myelofibrosis in addition to some other unknown factors due to the strong stimulatory effects on [[collagen]].

==Causes==
Mutations involving

*GATA1 [[gene]]

*Transforming [[Growth Factor]]-β (TG-β)
*[[Karyotype]] (t(1;22)(p13;q13)

 
==Differentiating AMKL from other Diseases==

Distinguishing features from other subtypes of AML are following:

*[[Thrombocytopenia]] is more common and severe in AMKL compared with [[myelodysplastic syndrome]] (MDS). Blast cells in the bone marrow are <30% in MDS versus >30% in AMKL.

*Presence of megakaryocytic specific antigens ([[CD41,]] [[CD61]]) and markers ([[glycoprotein 1b]]) and platelets [[peroxidase]] activity. [[Karyotype]] analysis also helpful due to its complex and unusual karyotypic presentation t(1;22)(p13;q13).

===Differential Diagnoses:===

====[[Acute myeloid leukemia]] otherwise not specified as per WHO classification:====

#''Acute myeloid leukemia with minimal differentiation''
#''Acute myeloid leukemia without maturation''
#''Acute myeloid leukemia with maturation''
#''Acute myelomonocytic leukemia''
#''Acute monoblastic/monocytic leukemia''
#'' Acute erythroid leukemia''
#''Pure erythroid leukemia''
#''Erythroleukemia, erythroid/myeloid''
#'' Acute basophilic leukemia''
#''Acute panmyelosis with myelofibrosis (a.k.a acute myelofibrosis)''

==Epidemiology and Demographics==

*AMKL is the most common subtype of AML reported in [[Down syndrome]] patients. It is more common in children compared with adults. The [[prevalence]] in children and adults is ~15% and 0.6%, respectively.

*Down syndrome patients carry a 200 fold increased risk of developing AMKL vs. non-Down syndrome patients. Similarly, another review proposed a 500 fold increased risk. It almost exclusively occurs in the first 3 years of life.
*[[Transient leukemia]] (TL) occurs in approximately 10% of Down syndrome infants, which is also attributed to transient [[myeloproliferative disorder]]. In most cases, TL spontaneously resolves; however, during the first four years of life, it progresses to acute megakaryoblastic leukemia in 13% to 33% of patients.

==Risk Factors==

*Risk of development of AMKL increases in patients with [[Down syndrome]] .

==Natural History==

*Clonal proliferation of early [[megakaryoblasts]] in the bone marrow results in acute megakaryoblastic leukemia (AMKL). It has a bimodal onset of presentation—occurs both in the pediatric age group (<4 years) and adults.
*In childhood, it is more prevalent in patients with Down syndrome. While it is rare in adults, approximately 0.6% (24/3603) reported in the [[GIMEMA trial]].
*Cases of AMKL secondary to [[chronic myelogenous leukemia]] and [[essential thrombocytosis]] have been reported in the medical literature.

==Complications==

#Periorbital swelling
#[[Periosteal elevation]]
#Osteolytic lesions, especially in long bones, e.g., femur
#[[Osteoporosis]] with pathologic fractures
#[[Sweet syndrome]] (SS)
#[[Leukemia cutis]]
#[[Hypercalcemia]]

==Prognosis==
Due to the rarity of this subtype of hematological malignancy, limited data is available on the natural course or [[prognosis]].

*Apart from AMKL in [[Down syndrome]] patients, the prognosis of AMKL is poor. The efficacy profile of AMKL in Down syndrome patients is favorable, but it comes with a lot of treatment-related toxicity.

*According to the Children’s Oncology Group (COG) AML0431 trial results, the 5-year event-free survival and [[overall survival]] rates were 90% and 93% in 204 eligible Down syndrome with AMKL patients.

*Similarly, the reported 3-year overall survival rate was 100% among 3 AMKL with Down syndrome patients while (47±12%) in non-Down syndrome patients.

*The 5-year overall survival rate in AMKL was 10.6% versus 17.5% in non-M7 [[Acute Myeloid leukemia|Acute myeloid leukemia]] subtypes. Currently, [[chemotherapy]] and [[Allo-BMT|allogenic bone marrow transplant]] (Allo-BMT) are main therapy. Treatment-related toxicity is a big challenge. To address this issue, elaborated large future clinical studies are required.

==Diagnosis==
===Diagnostic Study of Choice===

* [[Bone marrow biopsy]] showing 30% or more leukemic cells of megakaryocytic progenitors.

===History and Symptoms===

*[[Acute megakaryoblastic leukemia]] (AMKL) has a wide array of presentations. The onset is either acute or insidious. The degree of [[pancytopenia]] varies among patients. Other features include [[fever]], irritability, [[headache]], fatigue, bone pain, [[hepatosplenomegaly]] (HSM), and [[lymphadenopathy]], pallor, generalized pain, temporal swelling, [[bruising]], and difficulty walking.

*Greater than 50% of [[leukemia]] patients demonstrate skeletal features and are mostly related to the AMKL subtype.

===Physical Examination===

*Physical exam findings include:

[[Down syndrome]] features are present in patients with Down syndrome associated AMKL.

===Laboratory Findings===

The diagnosis of AMKL (M7) is based on the following:

#[[Bone marrow]] [[biopsy]] demonstrating 30% or more leukemic cells of megakaryocytic lineage
#Conducting tests that detect [[platelet-specific antibodies]] which could be [[monoclonal]] or [[polyclonal]].
#Bone marrow biopsy is recommended in patients who developed [[myelofibrosis]]. Visualization of blasts and mature megakaryocytes on biopsy sections is diagnostic.

===Other Diagnostic Studies===

*In adults, the features include
**[[Pancytopenia]] with low [[blast]] counts in the blood
**[[Myelofibrosis]]
**An absence of [[lymphadenopathy]] and [[hepatosplenomegaly]]
**Poor response to [[chemotherapy]],and short clinical course.

*In children, the same clinical presentation but with variable course especially in very young children; both [[leukocytosis]] and [[organomegaly]] may be present in children with M7. Complete remission and long term survival are more common in children than adults.

*The morphology of cells was observed by means of Bone marrow smear
*The [[immunophenotype]] was detected by [[flow cytometry]] and [[immunohistochemistry]] assay.

*In blood and bone marrow smears megakaryoblasts are usually medium sized to large cells with a high nuclear- cytoplasmic ratio. Nuclear [[chromatin]] is dense and homogeneous. There is scanty, variable basophilic cytoplasm which may be vacuolated. An irregular cytoplasmic border is often noted in some of the [[megakaryoblasts]] and occasionally projections resembling budding atypical platelets are present. The megakaryoblasts lack [[myeloperoxidase]] activity and stain negatively with [[Sudan black B]] (SBB).

*They are alpha [[naphthyl butyrate esterase]] negative and manifest variable alpha naphthyl acetate esterase activity usually in scattered clumps or granules in the cytoplasm. [[PAS]] staining also varies from negative to focal or granular positivity, to strongly positive staining.

*A marrow aspirate is difficult to obtain in many cases because of variable degree of [[myelofibrosis]].

*More precise identification by immunophenotyping or with [[electron microscopy]] (EM). [[Immunophenotyping]] using MoAb to megakaryocyte restricted antigen (CD41 and CD61) may be diagnostic.

===Karyotype analysis:===

*It is essential owing to the fact that AMKL has complex [[karyotype]] with peculiar presentation ([[t(1;22)(p13;q13]]).

===Radiographic features:===

*Using [[Chest X-ray]] ('''CXR'''), '''[[skeletal survey]]''', '''[[CT scan]]''', and '''[[bone scan]]''' are:
*Showing osteolytic lesions in the ribs, diffuse [[metaphysical lucency]], [[periostitis]] with periosteal reaction, and pathologic fractures involving long bones, such as femoral bones, and increase uptake in the involved bones.

==Treatment==
===Medical Therapy===

*According to the AML-BFM (Berlin–Frankfurt–Münster) 98 and AML-BFM ((Berlin–Frankfurt–Münster) 93 clinical studies, intensive AML targeted [[chemotherapy]] in Down syndrome-associated AMKL results in high event-free survival rates versus non-Down syndrome patients. However, they are also prone to develop treatment-related toxicity at standard doses due to chemo sensitivity.

The treatment is divided into [[induction therapy]] and [[consolidation]] therapy.

*'''Induction therapy''' — involves two cycles (four weeks apart ) of [[Cytarabine|Ara-Cytarabine]] (Ara-C) at 100 mg/m2 /day continuous infusion for 7 days, [[vincristine]] at 0.7 mg/m2 on day 7, and [[pirarubicin]] at 25 mg/m2 by 60 min infusion on days 2, and 4 (AVC1).
*'''Consolidation therapy''' — follows once complete remission is achieved with the following regimen; [[etoposide]] & high-dose Ara-C (EC), [[mitoxantrone]] and continuous-dose Ara-C (MC), and pirarubicin, vincristine, and continuous-dose Ara-C (AVC2).

The doses are given below:

'''''MC regimen:'''''

*Ara-C at 100 mg/m2 /day continuous infusion for 5 days and
*Mitoxantrone at 3.5 mg/m2 by 60 min infusion on days 2–4

'''''EC regimen'''''

*High-dose Ara-C 1 g/m2 every 12 hrs on days 1–5,
*Etoposide 66 mg/m2 by 2 h infusion on days 2–4), and

'''''AVC2 regimen'''''

*Ara-C at 100 mg/m2 /day on days 1–5,
*Pirarubicin 35 mg/m2 by 60 min infusion on day 2, and
*Vincristine at 0.7 mg/m2 on day 5

In relapsed state, re-induction with [[fludarabine]] and Ara-C combination or same AVC regimen can be utilized. Allogenic bone marrow transplant (Allo-BMT) from a suitable donor is justified if the patients achieved second complete remission. Currently, there is no recommended definitive therapy for non-Down syndrome with AMKL cohort. Novel therapeutic interventions are undertaken.

*Some study groups proposed that non-[[Down syndrome]] with AMKL is a high-risk condition; therefore, allogeneic [[hematopoietic stem cell]] transplantation (Allo-HSCT) during first complete remission is recommended to benefit the patients. In contrast, no benefit of Allo-HSCT is evident over chemotherapy without remission.

*In AML-BFM 04 trial, patients were randomized to receive induction therapy with either (Ara-C), [[liposomal daunorubicin]], and etoposide (ADxE) or Ara-C, [[idarubicin]], and etoposide (AIE) regimen. Consolidation therapy with [[2-chloro-2-deoxyadenosine]] (2-CDA) and Ara-C and idarubicin was preceded by second induction therapy with HAM (high-dose Ara-C, mitoxantrone, cytarabine i.th). However, no significant results were obtained regarding event-free survival (EFS) and overall survival (OS).

===Surgery===
There is no established surgical [[intervention]] for acute megakaryoblastic [[leukemia]].

===Prevention===
There is no established method for [[prevention]] of acute megakaryoblastic [[leukemia]].

==References==

[[Category:Hematology]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
<references />

Acute megakaryoblastic leukemia

2021-05-07T16:36:54Z

Roukoz Abou Karam: /* Differentiating AMKL from other Diseases */

__NOTOC__
{{SI}}

Acute megakaryoblastic leukemia
{{CMG}}; {{AE}} [[User:Israrkhan|Israr Khan, M.D.]][mailto:israrkhan.dawar@gmail.com]

{{SK}} Leukemia, megakaryoblastic, acute; megakaryoblastic leukemia, acute; AMKL; leukemia, myeloid, acute, M7; megakaryocytic leukemia; megakaryocytic leukemia, acute; myeloid leukemia, acute, M7

==Overview==
Acute megakaryoblastic leukemia is a rare type of [[hematological malignancy]] that results from the clonal proliferation of [[Megakaryoblast|megakaryoblasts]] in the [[bone marrow]]. Prof. Dr. Von Boros first described it in 1931. In 1985, the [[French-British-American classification]] of [[Acute myeloid leukemia]] (AML) included it as (M7 subtype). Later in 2008, acute megakaryoblastic leukemia was classified under AML otherwise not specified category by [[World Health Organization]]. It results from a mutation involving several genes, particularly the [[GATA1]] gene, and [[transforming growth factor-β]] (TG-β). AMKL has commonly associated with [[Down syndrome]]. It has a bimodal distribution and is more common in children (<4) 15% than adults 0.6%. AMKL has a wide range of presentations which has either acute or insidious onset. It is characterized by fever, irritability, headache, fatigue, bone pain, generalized body aches, bruises, and difficulty walking. Physical exam findings include pallor, [[Hepatosplenomegaly]] (HSM), and [[lymphadenopathy]], bruises and [[purpura]], and sometimes temporal or orbital swelling. It is diagnosed by bone marrow biopsy showing 30% or more leukemic cells of megakaryocytic lineage and detection of platelet-specific [[peroxidase antibodies]]. Other lab findings include pancytopenia and megakaryocytic progenitors in the [[peripheral smear]]. Other diagnostic studies include; [[Immunophenotyping]] using MoAb to megakaryocyte restricted antigen (CD41 and CD61), complex karyotypic ([[t(1;22)(p13;q13]]) involvement, radiologic features of the osteolytic lesion, metaphyseal lucency, pathologic fractures using [[Chest X-ray|CXR]], [[CT scan]], [[bone scan]], and [[MRI]] modalities. Currently, [[chemotherapy]] and [[Allo-BMT|allogeneic bone marrow transplant]] (Allo-BMT) are mainstay therapy. However, treatment-related toxicity is a big challenge. Different drug combination regimens are available for AMKL. The commonly used drugs are [[Ara-Cytarabine|Cytarabine]], [[mitoxantrone]], [[etoposide]], [[vincristine]], [[fludarabine]], and [[Piraubicin|pirarubicin]]. The prognosis of AMKL in Down syndrome patients is favorable as compared with non-Down syndrome patients.

The following complications can be observed in patients with AMKL; [[periosteal elevation]], [[osteolytic lesions]], especially in long bones, e.g., [[femur]], [[osteoporosis]] with pathologic fractures, [[Sweet syndrome]] (SS), [[leukemia cutis]], and [[hypercalcemia]].
 
==Historical Perspective==

J. Von Boros first described acute megakaryoblastic leukemia in 1931.
==Classification==

For established [[French-British-American]] (FAB) classification, refer to [[Acute myeloid leukemia classification|acute myeloid leukemia classification.]]
==Pathophysiology==

*It is associated with [[GATA1]], and risks are increased in individuals with [[Down syndrome]]. However, not all cases are associated with Down syndrome, and other [[genes]] can also be associated with AMKL. However, not all cases are associated with Down syndrome, and other [[genes]] can also be associated with AMKL.

*According to the report of the [[French-American-British]] Cooperative Group, this category of AML (M7 subtype) is associated with 30% or more blasts in the bone marrow. Blasts are identified as being of megakaryocyte lineage by; expression of [[megakaryocyte]] specific [[antigen]]s and platelet [[peroxidase]] reaction on [[electron microscopy]].

*[[Myelofibrosis]] is usually associated with AMKL; however, the exact underlying pathophysiology is controversial. The investigators did not find any direct correlation between acute myelofibrosis and the [[fibroblasts]] obtained from the bone marrow of patients with AMKL. Nevertheless, it was proposed that some humoral factors may play a key role in developing bone marrow fibrosis.

*[[Transforming Growth Factor-β]] (TG-β) was identified to be the significant contributor in AMKL associated myelofibrosis in addition to some other unknown factors due to the strong stimulatory effects on [[collagen]].

==Causes==
Mutations involving

*GATA1 [[gene]]

*Transforming [[Growth Factor]]-β (TG-β)
*[[Karyotype]] (t(1;22)(p13;q13)

 
==Differentiating AMKL from other Diseases==

Distinguishing features from other subtypes of AML are following:
*[[Thrombocytopenia]] is more common and severe in AMKL compared with [[myelodysplastic syndrome]] (MDS). Blast cells in the bone marrow are <30% in MDS versus >30% in AMKL.<ref name="ZipurskyThorner1994">{{cite journal|last1=Zipursky|first1=A.|last2=Thorner|first2=P.|last3=De Harven|first3=E.|last4=Christensen|first4=H.|last5=Doyle|first5=J.|title=Myelodysplasia and acute megakaryoblastic leukemia in down's syndrome|journal=Leukemia Research|volume=18|issue=3|year=1994|pages=163–171|issn=01452126|doi=10.1016/0145-2126(94)90111-2}}</ref>

*Presence of megakaryocytic specific antigens ([[CD41,]] [[CD61]]) and markers ([[glycoprotein 1b]]) and platelets [[peroxidase]] activity. [[Karyotype]] analysis also helpful due to its complex and unusual karyotypic presentation (t(1;22)(p13;q13).<ref name="O Olatunji2018">{{cite journal|last1=O Olatunji|first1=Philip|title=A case of acute megakaryoblastic leukaemia (FAB M7), a rare type of acute myeloid leukemia (AML), in a teenager|journal=Malawi Medical Journal|volume=30|issue=4|year=2018|pages=298|issn=1995-7262|doi=10.4314/mmj.v30i4.15}}</ref><ref name="DöhnerEstey2010">{{cite journal|last1=Döhner|first1=Hartmut|last2=Estey|first2=Elihu H.|last3=Amadori|first3=Sergio|last4=Appelbaum|first4=Frederick R.|last5=Büchner|first5=Thomas|last6=Burnett|first6=Alan K.|last7=Dombret|first7=Hervé|last8=Fenaux|first8=Pierre|last9=Grimwade|first9=David|last10=Larson|first10=Richard A.|last11=Lo-Coco|first11=Francesco|last12=Naoe|first12=Tomoki|last13=Niederwieser|first13=Dietger|last14=Ossenkoppele|first14=Gert J.|last15=Sanz|first15=Miguel A.|last16=Sierra|first16=Jorge|last17=Tallman|first17=Martin S.|last18=Löwenberg|first18=Bob|last19=Bloomfield|first19=Clara D.|title=Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet|journal=Blood|volume=115|issue=3|year=2010|pages=453–474|issn=0006-4971|doi=10.1182/blood-2009-07-235358}}</ref><ref name="De MarchiAraki2019">{{cite journal|last1=De Marchi|first1=Federico|last2=Araki|first2=Marito|last3=Komatsu|first3=Norio|title=Molecular features, prognosis, and novel treatment options for pediatric acute megakaryoblastic leukemia|journal=Expert Review of Hematology|volume=12|issue=5|year=2019|pages=285–293|issn=1747-4086|doi=10.1080/17474086.2019.1609351}}</ref>

===Differential Diagnoses:===

====[[Acute myeloid leukemia]] otherwise not specified as per WHO classification:====
<ref name="DöhnerEstey20105">{{cite journal|last1=Döhner|first1=Hartmut|last2=Estey|first2=Elihu H.|last3=Amadori|first3=Sergio|last4=Appelbaum|first4=Frederick R.|last5=Büchner|first5=Thomas|last6=Burnett|first6=Alan K.|last7=Dombret|first7=Hervé|last8=Fenaux|first8=Pierre|last9=Grimwade|first9=David|last10=Larson|first10=Richard A.|last11=Lo-Coco|first11=Francesco|last12=Naoe|first12=Tomoki|last13=Niederwieser|first13=Dietger|last14=Ossenkoppele|first14=Gert J.|last15=Sanz|first15=Miguel A.|last16=Sierra|first16=Jorge|last17=Tallman|first17=Martin S.|last18=Löwenberg|first18=Bob|last19=Bloomfield|first19=Clara D.|title=Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet|journal=Blood|volume=115|issue=3|year=2010|pages=453–474|issn=0006-4971|doi=10.1182/blood-2009-07-235358}}</ref>
#''Acute myeloid leukemia with minimal differentiation''
#''Acute myeloid leukemia without maturation''
#''Acute myeloid leukemia with maturation''
#''Acute myelomonocytic leukemia''
#''Acute monoblastic/monocytic leukemia''
#'' Acute erythroid leukemia''
#''Pure erythroid leukemia''
#''Erythroleukemia, erythroid/myeloid''
#'' Acute basophilic leukemia''
#''Acute panmyelosis with myelofibrosis (a.k.a acute myelofibrosis)''

==Epidemiology and Demographics==

*AMKL is the most common subtype of AML reported in [[Down syndrome]] patients. It is more common in children compared with adults. The [[prevalence]] in children and adults is ~15% and 0.6%, respectively.

*Down syndrome patients carry a 200 fold increased risk of developing AMKL vs. non-Down syndrome patients. Similarly, another review proposed a 500 fold increased risk. It almost exclusively occurs in the first 3 years of life.
*[[Transient leukemia]] (TL) occurs in approximately 10% of Down syndrome infants, which is also attributed to transient [[myeloproliferative disorder]]. In most cases, TL spontaneously resolves; however, during the first four years of life, it progresses to acute megakaryoblastic leukemia in 13% to 33% of patients.

==Risk Factors==

*Risk of development of AMKL increases in patients with [[Down syndrome]] .

==Natural History==

*Clonal proliferation of early [[megakaryoblasts]] in the bone marrow results in acute megakaryoblastic leukemia (AMKL). It has a bimodal onset of presentation—occurs both in the pediatric age group (<4 years) and adults.
*In childhood, it is more prevalent in patients with Down syndrome. While it is rare in adults, approximately 0.6% (24/3603) reported in the [[GIMEMA trial]].
*Cases of AMKL secondary to [[chronic myelogenous leukemia]] and [[essential thrombocytosis]] have been reported in the medical literature.

==Complications==

#Periorbital swelling
#[[Periosteal elevation]]
#Osteolytic lesions, especially in long bones, e.g., femur
#[[Osteoporosis]] with pathologic fractures
#[[Sweet syndrome]] (SS)
#[[Leukemia cutis]]
#[[Hypercalcemia]]

==Prognosis==
Due to the rarity of this subtype of hematological malignancy, limited data is available on the natural course or [[prognosis]].

*Apart from AMKL in [[Down syndrome]] patients, the prognosis of AMKL is poor. The efficacy profile of AMKL in Down syndrome patients is favorable, but it comes with a lot of treatment-related toxicity.

*According to the Children’s Oncology Group (COG) AML0431 trial results, the 5-year event-free survival and [[overall survival]] rates were 90% and 93% in 204 eligible Down syndrome with AMKL patients.

*Similarly, the reported 3-year overall survival rate was 100% among 3 AMKL with Down syndrome patients while (47±12%) in non-Down syndrome patients.

*The 5-year overall survival rate in AMKL was 10.6% versus 17.5% in non-M7 [[Acute Myeloid leukemia|Acute myeloid leukemia]] subtypes. Currently, [[chemotherapy]] and [[Allo-BMT|allogenic bone marrow transplant]] (Allo-BMT) are main therapy. Treatment-related toxicity is a big challenge. To address this issue, elaborated large future clinical studies are required.

==Diagnosis==
===Diagnostic Study of Choice===

* [[Bone marrow biopsy]] showing 30% or more leukemic cells of megakaryocytic progenitors.

===History and Symptoms===

*[[Acute megakaryoblastic leukemia]] (AMKL) has a wide array of presentations. The onset is either acute or insidious. The degree of [[pancytopenia]] varies among patients. Other features include [[fever]], irritability, [[headache]], fatigue, bone pain, [[hepatosplenomegaly]] (HSM), and [[lymphadenopathy]], pallor, generalized pain, temporal swelling, [[bruising]], and difficulty walking.

*Greater than 50% of [[leukemia]] patients demonstrate skeletal features and are mostly related to the AMKL subtype.

===Physical Examination===

*Physical exam findings include:

[[Down syndrome]] features are present in patients with Down syndrome associated AMKL.

===Laboratory Findings===

The diagnosis of AMKL (M7) is based on the following:

#[[Bone marrow]] [[biopsy]] demonstrating 30% or more leukemic cells of megakaryocytic lineage
#Conducting tests that detect [[platelet-specific antibodies]] which could be [[monoclonal]] or [[polyclonal]].
#Bone marrow biopsy is recommended in patients who developed [[myelofibrosis]]. Visualization of blasts and mature megakaryocytes on biopsy sections is diagnostic.

===Other Diagnostic Studies===

*In adults, the features include
**[[Pancytopenia]] with low [[blast]] counts in the blood
**[[Myelofibrosis]]
**An absence of [[lymphadenopathy]] and [[hepatosplenomegaly]]
**Poor response to [[chemotherapy]],and short clinical course.

*In children, the same clinical presentation but with variable course especially in very young children; both [[leukocytosis]] and [[organomegaly]] may be present in children with M7. Complete remission and long term survival are more common in children than adults.

*The morphology of cells was observed by means of Bone marrow smear
*The [[immunophenotype]] was detected by [[flow cytometry]] and [[immunohistochemistry]] assay.

*In blood and bone marrow smears megakaryoblasts are usually medium sized to large cells with a high nuclear- cytoplasmic ratio. Nuclear [[chromatin]] is dense and homogeneous. There is scanty, variable basophilic cytoplasm which may be vacuolated. An irregular cytoplasmic border is often noted in some of the [[megakaryoblasts]] and occasionally projections resembling budding atypical platelets are present. The megakaryoblasts lack [[myeloperoxidase]] activity and stain negatively with [[Sudan black B]] (SBB).

*They are alpha [[naphthyl butyrate esterase]] negative and manifest variable alpha naphthyl acetate esterase activity usually in scattered clumps or granules in the cytoplasm. [[PAS]] staining also varies from negative to focal or granular positivity, to strongly positive staining.

*A marrow aspirate is difficult to obtain in many cases because of variable degree of [[myelofibrosis]].

*More precise identification by immunophenotyping or with [[electron microscopy]] (EM). [[Immunophenotyping]] using MoAb to megakaryocyte restricted antigen (CD41 and CD61) may be diagnostic.

===Karyotype analysis:===

*It is essential owing to the fact that AMKL has complex [[karyotype]] with peculiar presentation ([[t(1;22)(p13;q13]]).

===Radiographic features:===

*Using [[Chest X-ray]] ('''CXR'''), '''[[skeletal survey]]''', '''[[CT scan]]''', and '''[[bone scan]]''' are:
*Showing osteolytic lesions in the ribs, diffuse [[metaphysical lucency]], [[periostitis]] with periosteal reaction, and pathologic fractures involving long bones, such as femoral bones, and increase uptake in the involved bones.

==Treatment==
===Medical Therapy===

*According to the AML-BFM (Berlin–Frankfurt–Münster) 98 and AML-BFM ((Berlin–Frankfurt–Münster) 93 clinical studies, intensive AML targeted [[chemotherapy]] in Down syndrome-associated AMKL results in high event-free survival rates versus non-Down syndrome patients. However, they are also prone to develop treatment-related toxicity at standard doses due to chemo sensitivity.

The treatment is divided into [[induction therapy]] and [[consolidation]] therapy.

*'''Induction therapy''' — involves two cycles (four weeks apart ) of [[Cytarabine|Ara-Cytarabine]] (Ara-C) at 100 mg/m2 /day continuous infusion for 7 days, [[vincristine]] at 0.7 mg/m2 on day 7, and [[pirarubicin]] at 25 mg/m2 by 60 min infusion on days 2, and 4 (AVC1).
*'''Consolidation therapy''' — follows once complete remission is achieved with the following regimen; [[etoposide]] & high-dose Ara-C (EC), [[mitoxantrone]] and continuous-dose Ara-C (MC), and pirarubicin, vincristine, and continuous-dose Ara-C (AVC2).

The doses are given below:

'''''MC regimen:'''''

*Ara-C at 100 mg/m2 /day continuous infusion for 5 days and
*Mitoxantrone at 3.5 mg/m2 by 60 min infusion on days 2–4

'''''EC regimen'''''

*High-dose Ara-C 1 g/m2 every 12 hrs on days 1–5,
*Etoposide 66 mg/m2 by 2 h infusion on days 2–4), and

'''''AVC2 regimen'''''

*Ara-C at 100 mg/m2 /day on days 1–5,
*Pirarubicin 35 mg/m2 by 60 min infusion on day 2, and
*Vincristine at 0.7 mg/m2 on day 5

In relapsed state, re-induction with [[fludarabine]] and Ara-C combination or same AVC regimen can be utilized. Allogenic bone marrow transplant (Allo-BMT) from a suitable donor is justified if the patients achieved second complete remission. Currently, there is no recommended definitive therapy for non-Down syndrome with AMKL cohort. Novel therapeutic interventions are undertaken.

*Some study groups proposed that non-[[Down syndrome]] with AMKL is a high-risk condition; therefore, allogeneic [[hematopoietic stem cell]] transplantation (Allo-HSCT) during first complete remission is recommended to benefit the patients. In contrast, no benefit of Allo-HSCT is evident over chemotherapy without remission.

*In AML-BFM 04 trial, patients were randomized to receive induction therapy with either (Ara-C), [[liposomal daunorubicin]], and etoposide (ADxE) or Ara-C, [[idarubicin]], and etoposide (AIE) regimen. Consolidation therapy with [[2-chloro-2-deoxyadenosine]] (2-CDA) and Ara-C and idarubicin was preceded by second induction therapy with HAM (high-dose Ara-C, mitoxantrone, cytarabine i.th). However, no significant results were obtained regarding event-free survival (EFS) and overall survival (OS).

===Surgery===
There is no established surgical [[intervention]] for acute megakaryoblastic [[leukemia]].

===Prevention===
There is no established method for [[prevention]] of acute megakaryoblastic [[leukemia]].

==References==

[[Category:Hematology]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
<references />

Acute megakaryoblastic leukemia

2021-05-07T16:34:29Z

Roukoz Abou Karam: /* Pathophysiology */

__NOTOC__
{{SI}}

Acute megakaryoblastic leukemia
{{CMG}}; {{AE}} [[User:Israrkhan|Israr Khan, M.D.]][mailto:israrkhan.dawar@gmail.com]

{{SK}} Leukemia, megakaryoblastic, acute; megakaryoblastic leukemia, acute; AMKL; leukemia, myeloid, acute, M7; megakaryocytic leukemia; megakaryocytic leukemia, acute; myeloid leukemia, acute, M7

==Overview==
Acute megakaryoblastic leukemia is a rare type of [[hematological malignancy]] that results from the clonal proliferation of [[Megakaryoblast|megakaryoblasts]] in the [[bone marrow]]. Prof. Dr. Von Boros first described it in 1931. In 1985, the [[French-British-American classification]] of [[Acute myeloid leukemia]] (AML) included it as (M7 subtype). Later in 2008, acute megakaryoblastic leukemia was classified under AML otherwise not specified category by [[World Health Organization]]. It results from a mutation involving several genes, particularly the [[GATA1]] gene, and [[transforming growth factor-β]] (TG-β). AMKL has commonly associated with [[Down syndrome]]. It has a bimodal distribution and is more common in children (<4) 15% than adults 0.6%. AMKL has a wide range of presentations which has either acute or insidious onset. It is characterized by fever, irritability, headache, fatigue, bone pain, generalized body aches, bruises, and difficulty walking. Physical exam findings include pallor, [[Hepatosplenomegaly]] (HSM), and [[lymphadenopathy]], bruises and [[purpura]], and sometimes temporal or orbital swelling. It is diagnosed by bone marrow biopsy showing 30% or more leukemic cells of megakaryocytic lineage and detection of platelet-specific [[peroxidase antibodies]]. Other lab findings include pancytopenia and megakaryocytic progenitors in the [[peripheral smear]]. Other diagnostic studies include; [[Immunophenotyping]] using MoAb to megakaryocyte restricted antigen (CD41 and CD61), complex karyotypic ([[t(1;22)(p13;q13]]) involvement, radiologic features of the osteolytic lesion, metaphyseal lucency, pathologic fractures using [[Chest X-ray|CXR]], [[CT scan]], [[bone scan]], and [[MRI]] modalities. Currently, [[chemotherapy]] and [[Allo-BMT|allogeneic bone marrow transplant]] (Allo-BMT) are mainstay therapy. However, treatment-related toxicity is a big challenge. Different drug combination regimens are available for AMKL. The commonly used drugs are [[Ara-Cytarabine|Cytarabine]], [[mitoxantrone]], [[etoposide]], [[vincristine]], [[fludarabine]], and [[Piraubicin|pirarubicin]]. The prognosis of AMKL in Down syndrome patients is favorable as compared with non-Down syndrome patients.

The following complications can be observed in patients with AMKL; [[periosteal elevation]], [[osteolytic lesions]], especially in long bones, e.g., [[femur]], [[osteoporosis]] with pathologic fractures, [[Sweet syndrome]] (SS), [[leukemia cutis]], and [[hypercalcemia]].
 
==Historical Perspective==

J. Von Boros first described acute megakaryoblastic leukemia in 1931.
==Classification==

For established [[French-British-American]] (FAB) classification, refer to [[Acute myeloid leukemia classification|acute myeloid leukemia classification.]]
==Pathophysiology==

*It is associated with [[GATA1]], and risks are increased in individuals with [[Down syndrome]]. However, not all cases are associated with Down syndrome, and other [[genes]] can also be associated with AMKL. However, not all cases are associated with Down syndrome, and other [[genes]] can also be associated with AMKL.

*According to the report of the [[French-American-British]] Cooperative Group, this category of AML (M7 subtype) is associated with 30% or more blasts in the bone marrow. Blasts are identified as being of megakaryocyte lineage by; expression of [[megakaryocyte]] specific [[antigen]]s and platelet [[peroxidase]] reaction on [[electron microscopy]].

*[[Myelofibrosis]] is usually associated with AMKL; however, the exact underlying pathophysiology is controversial. The investigators did not find any direct correlation between acute myelofibrosis and the [[fibroblasts]] obtained from the bone marrow of patients with AMKL. Nevertheless, it was proposed that some humoral factors may play a key role in developing bone marrow fibrosis.

*[[Transforming Growth Factor-β]] (TG-β) was identified to be the significant contributor in AMKL associated myelofibrosis in addition to some other unknown factors due to the strong stimulatory effects on [[collagen]].

==Causes==
Mutations involving

*GATA1 [[gene]]

*Transforming [[Growth Factor]]-β (TG-β)
*[[Karyotype]] (t(1;22)(p13;q13)

 
==Differentiating AMKL from other Diseases==

Distinguishing features from other subtypes of AML are following:

*[[Thrombocytopenia]] is more common and severe in AMKL compared with [[myelodysplastic syndrome]] (MDS). Blast cells in the bone marrow are <30% in MDS versus >30% in AMKL.
*Presence of megakaryocytic specific antigens ([[CD41,]] [[CD61]]) and markers ([[glycoprotein 1b]]) and platelets [[peroxidase]] activity. [[Karyotype]] analysis also helpful due to its complex and unusual karyotypic presentation (t(1;22)(p13;q13).

===Differential Diagnoses:===

====[[Acute myeloid leukemia]] otherwise not specified as per WHO classification:====

#''Acute myeloid leukemia with minimal differentiation''
#''Acute myeloid leukemia without maturation''
#''Acute myeloid leukemia with maturation''
#''Acute myelomonocytic leukemia''
#''Acute monoblastic/monocytic leukemia''
#'' Acute erythroid leukemia''
#''Pure erythroid leukemia''
#''Erythroleukemia, erythroid/myeloid''
#'' Acute basophilic leukemia''
#''Acute panmyelosis with myelofibrosis (a.k.a acute myelofibrosis)''

==Epidemiology and Demographics==

*AMKL is the most common subtype of AML reported in [[Down syndrome]] patients. It is more common in children compared with adults. The [[prevalence]] in children and adults is ~15% and 0.6%, respectively.

*Down syndrome patients carry a 200 fold increased risk of developing AMKL vs. non-Down syndrome patients. Similarly, another review proposed a 500 fold increased risk. It almost exclusively occurs in the first 3 years of life.
*[[Transient leukemia]] (TL) occurs in approximately 10% of Down syndrome infants, which is also attributed to transient [[myeloproliferative disorder]]. In most cases, TL spontaneously resolves; however, during the first four years of life, it progresses to acute megakaryoblastic leukemia in 13% to 33% of patients.

==Risk Factors==

*Risk of development of AMKL increases in patients with [[Down syndrome]] .

==Natural History==

*Clonal proliferation of early [[megakaryoblasts]] in the bone marrow results in acute megakaryoblastic leukemia (AMKL). It has a bimodal onset of presentation—occurs both in the pediatric age group (<4 years) and adults.
*In childhood, it is more prevalent in patients with Down syndrome. While it is rare in adults, approximately 0.6% (24/3603) reported in the [[GIMEMA trial]].
*Cases of AMKL secondary to [[chronic myelogenous leukemia]] and [[essential thrombocytosis]] have been reported in the medical literature.

==Complications==

#Periorbital swelling
#[[Periosteal elevation]]
#Osteolytic lesions, especially in long bones, e.g., femur
#[[Osteoporosis]] with pathologic fractures
#[[Sweet syndrome]] (SS)
#[[Leukemia cutis]]
#[[Hypercalcemia]]

==Prognosis==
Due to the rarity of this subtype of hematological malignancy, limited data is available on the natural course or [[prognosis]].

*Apart from AMKL in [[Down syndrome]] patients, the prognosis of AMKL is poor. The efficacy profile of AMKL in Down syndrome patients is favorable, but it comes with a lot of treatment-related toxicity.

*According to the Children’s Oncology Group (COG) AML0431 trial results, the 5-year event-free survival and [[overall survival]] rates were 90% and 93% in 204 eligible Down syndrome with AMKL patients.

*Similarly, the reported 3-year overall survival rate was 100% among 3 AMKL with Down syndrome patients while (47±12%) in non-Down syndrome patients.

*The 5-year overall survival rate in AMKL was 10.6% versus 17.5% in non-M7 [[Acute Myeloid leukemia|Acute myeloid leukemia]] subtypes. Currently, [[chemotherapy]] and [[Allo-BMT|allogenic bone marrow transplant]] (Allo-BMT) are main therapy. Treatment-related toxicity is a big challenge. To address this issue, elaborated large future clinical studies are required.

==Diagnosis==
===Diagnostic Study of Choice===

* [[Bone marrow biopsy]] showing 30% or more leukemic cells of megakaryocytic progenitors.

===History and Symptoms===

*[[Acute megakaryoblastic leukemia]] (AMKL) has a wide array of presentations. The onset is either acute or insidious. The degree of [[pancytopenia]] varies among patients. Other features include [[fever]], irritability, [[headache]], fatigue, bone pain, [[hepatosplenomegaly]] (HSM), and [[lymphadenopathy]], pallor, generalized pain, temporal swelling, [[bruising]], and difficulty walking.

*Greater than 50% of [[leukemia]] patients demonstrate skeletal features and are mostly related to the AMKL subtype.

===Physical Examination===

*Physical exam findings include:

[[Down syndrome]] features are present in patients with Down syndrome associated AMKL.

===Laboratory Findings===

The diagnosis of AMKL (M7) is based on the following:

#[[Bone marrow]] [[biopsy]] demonstrating 30% or more leukemic cells of megakaryocytic lineage
#Conducting tests that detect [[platelet-specific antibodies]] which could be [[monoclonal]] or [[polyclonal]].
#Bone marrow biopsy is recommended in patients who developed [[myelofibrosis]]. Visualization of blasts and mature megakaryocytes on biopsy sections is diagnostic.

===Other Diagnostic Studies===

*In adults, the features include
**[[Pancytopenia]] with low [[blast]] counts in the blood
**[[Myelofibrosis]]
**An absence of [[lymphadenopathy]] and [[hepatosplenomegaly]]
**Poor response to [[chemotherapy]],and short clinical course.

*In children, the same clinical presentation but with variable course especially in very young children; both [[leukocytosis]] and [[organomegaly]] may be present in children with M7. Complete remission and long term survival are more common in children than adults.

*The morphology of cells was observed by means of Bone marrow smear
*The [[immunophenotype]] was detected by [[flow cytometry]] and [[immunohistochemistry]] assay.

*In blood and bone marrow smears megakaryoblasts are usually medium sized to large cells with a high nuclear- cytoplasmic ratio. Nuclear [[chromatin]] is dense and homogeneous. There is scanty, variable basophilic cytoplasm which may be vacuolated. An irregular cytoplasmic border is often noted in some of the [[megakaryoblasts]] and occasionally projections resembling budding atypical platelets are present. The megakaryoblasts lack [[myeloperoxidase]] activity and stain negatively with [[Sudan black B]] (SBB).

*They are alpha [[naphthyl butyrate esterase]] negative and manifest variable alpha naphthyl acetate esterase activity usually in scattered clumps or granules in the cytoplasm. [[PAS]] staining also varies from negative to focal or granular positivity, to strongly positive staining.

*A marrow aspirate is difficult to obtain in many cases because of variable degree of [[myelofibrosis]].

*More precise identification by immunophenotyping or with [[electron microscopy]] (EM). [[Immunophenotyping]] using MoAb to megakaryocyte restricted antigen (CD41 and CD61) may be diagnostic.

===Karyotype analysis:===

*It is essential owing to the fact that AMKL has complex [[karyotype]] with peculiar presentation ([[t(1;22)(p13;q13]]).

===Radiographic features:===

*Using [[Chest X-ray]] ('''CXR'''), '''[[skeletal survey]]''', '''[[CT scan]]''', and '''[[bone scan]]''' are:
*Showing osteolytic lesions in the ribs, diffuse [[metaphysical lucency]], [[periostitis]] with periosteal reaction, and pathologic fractures involving long bones, such as femoral bones, and increase uptake in the involved bones.

==Treatment==
===Medical Therapy===

*According to the AML-BFM (Berlin–Frankfurt–Münster) 98 and AML-BFM ((Berlin–Frankfurt–Münster) 93 clinical studies, intensive AML targeted [[chemotherapy]] in Down syndrome-associated AMKL results in high event-free survival rates versus non-Down syndrome patients. However, they are also prone to develop treatment-related toxicity at standard doses due to chemo sensitivity.

The treatment is divided into [[induction therapy]] and [[consolidation]] therapy.

*'''Induction therapy''' — involves two cycles (four weeks apart ) of [[Cytarabine|Ara-Cytarabine]] (Ara-C) at 100 mg/m2 /day continuous infusion for 7 days, [[vincristine]] at 0.7 mg/m2 on day 7, and [[pirarubicin]] at 25 mg/m2 by 60 min infusion on days 2, and 4 (AVC1).
*'''Consolidation therapy''' — follows once complete remission is achieved with the following regimen; [[etoposide]] & high-dose Ara-C (EC), [[mitoxantrone]] and continuous-dose Ara-C (MC), and pirarubicin, vincristine, and continuous-dose Ara-C (AVC2).

The doses are given below:

'''''MC regimen:'''''

*Ara-C at 100 mg/m2 /day continuous infusion for 5 days and
*Mitoxantrone at 3.5 mg/m2 by 60 min infusion on days 2–4

'''''EC regimen'''''

*High-dose Ara-C 1 g/m2 every 12 hrs on days 1–5,
*Etoposide 66 mg/m2 by 2 h infusion on days 2–4), and

'''''AVC2 regimen'''''

*Ara-C at 100 mg/m2 /day on days 1–5,
*Pirarubicin 35 mg/m2 by 60 min infusion on day 2, and
*Vincristine at 0.7 mg/m2 on day 5

In relapsed state, re-induction with [[fludarabine]] and Ara-C combination or same AVC regimen can be utilized. Allogenic bone marrow transplant (Allo-BMT) from a suitable donor is justified if the patients achieved second complete remission. Currently, there is no recommended definitive therapy for non-Down syndrome with AMKL cohort. Novel therapeutic interventions are undertaken.

*Some study groups proposed that non-[[Down syndrome]] with AMKL is a high-risk condition; therefore, allogeneic [[hematopoietic stem cell]] transplantation (Allo-HSCT) during first complete remission is recommended to benefit the patients. In contrast, no benefit of Allo-HSCT is evident over chemotherapy without remission.

*In AML-BFM 04 trial, patients were randomized to receive induction therapy with either (Ara-C), [[liposomal daunorubicin]], and etoposide (ADxE) or Ara-C, [[idarubicin]], and etoposide (AIE) regimen. Consolidation therapy with [[2-chloro-2-deoxyadenosine]] (2-CDA) and Ara-C and idarubicin was preceded by second induction therapy with HAM (high-dose Ara-C, mitoxantrone, cytarabine i.th). However, no significant results were obtained regarding event-free survival (EFS) and overall survival (OS).

===Surgery===
There is no established surgical [[intervention]] for acute megakaryoblastic [[leukemia]].

===Prevention===
There is no established method for [[prevention]] of acute megakaryoblastic [[leukemia]].

==References==

[[Category:Hematology]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
<references />

Acute megakaryoblastic leukemia

2021-05-07T16:34:07Z

Roukoz Abou Karam: /* Pathophysiology */

__NOTOC__
{{SI}}

Acute megakaryoblastic leukemia
{{CMG}}; {{AE}} [[User:Israrkhan|Israr Khan, M.D.]][mailto:israrkhan.dawar@gmail.com]

{{SK}} Leukemia, megakaryoblastic, acute; megakaryoblastic leukemia, acute; AMKL; leukemia, myeloid, acute, M7; megakaryocytic leukemia; megakaryocytic leukemia, acute; myeloid leukemia, acute, M7

==Overview==
Acute megakaryoblastic leukemia is a rare type of [[hematological malignancy]] that results from the clonal proliferation of [[Megakaryoblast|megakaryoblasts]] in the [[bone marrow]]. Prof. Dr. Von Boros first described it in 1931. In 1985, the [[French-British-American classification]] of [[Acute myeloid leukemia]] (AML) included it as (M7 subtype). Later in 2008, acute megakaryoblastic leukemia was classified under AML otherwise not specified category by [[World Health Organization]]. It results from a mutation involving several genes, particularly the [[GATA1]] gene, and [[transforming growth factor-β]] (TG-β). AMKL has commonly associated with [[Down syndrome]]. It has a bimodal distribution and is more common in children (<4) 15% than adults 0.6%. AMKL has a wide range of presentations which has either acute or insidious onset. It is characterized by fever, irritability, headache, fatigue, bone pain, generalized body aches, bruises, and difficulty walking. Physical exam findings include pallor, [[Hepatosplenomegaly]] (HSM), and [[lymphadenopathy]], bruises and [[purpura]], and sometimes temporal or orbital swelling. It is diagnosed by bone marrow biopsy showing 30% or more leukemic cells of megakaryocytic lineage and detection of platelet-specific [[peroxidase antibodies]]. Other lab findings include pancytopenia and megakaryocytic progenitors in the [[peripheral smear]]. Other diagnostic studies include; [[Immunophenotyping]] using MoAb to megakaryocyte restricted antigen (CD41 and CD61), complex karyotypic ([[t(1;22)(p13;q13]]) involvement, radiologic features of the osteolytic lesion, metaphyseal lucency, pathologic fractures using [[Chest X-ray|CXR]], [[CT scan]], [[bone scan]], and [[MRI]] modalities. Currently, [[chemotherapy]] and [[Allo-BMT|allogeneic bone marrow transplant]] (Allo-BMT) are mainstay therapy. However, treatment-related toxicity is a big challenge. Different drug combination regimens are available for AMKL. The commonly used drugs are [[Ara-Cytarabine|Cytarabine]], [[mitoxantrone]], [[etoposide]], [[vincristine]], [[fludarabine]], and [[Piraubicin|pirarubicin]]. The prognosis of AMKL in Down syndrome patients is favorable as compared with non-Down syndrome patients.

The following complications can be observed in patients with AMKL; [[periosteal elevation]], [[osteolytic lesions]], especially in long bones, e.g., [[femur]], [[osteoporosis]] with pathologic fractures, [[Sweet syndrome]] (SS), [[leukemia cutis]], and [[hypercalcemia]].
 
==Historical Perspective==

J. Von Boros first described acute megakaryoblastic leukemia in 1931.
==Classification==

For established [[French-British-American]] (FAB) classification, refer to [[Acute myeloid leukemia classification|acute myeloid leukemia classification.]]
==Pathophysiology==

*It is associated with [[GATA1]], and risks are increased in individuals with [[Down syndrome]]. However, not all cases are associated with Down syndrome, and other [[genes]] can also be associated with AMKL.<ref name="pmid12586620">{{cite journal |author=Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A |title=GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome |journal=Blood |volume=101 |issue=11 |pages=4301–4 |year=2003 |pmid=12586620 |doi=10.1182/blood-2003-01-0013 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=12586620}}</ref> However, not all cases are associated with Down syndrome,<ref name="pmid18275433">{{cite journal |author=Hama A, Yagasaki H, Takahashi Y, ''et al'' |title=Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome |journal=Br. J. Haematol. |volume=140 |issue=5 |pages=552–61 |year=2008 |pmid=18275433 |doi=10.1111/j.1365-2141.2007.06971.x |url=http://dx.doi.org/10.1111/j.1365-2141.2007.06971.x}}</ref> and other [[genes]] can also be associated with AMKL.<ref name="pmid17360941">{{cite journal |author=Gu TL, Mercher T, Tyner JW, ''et al'' |title=A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia |journal=Blood |volume=110 |issue=1 |pages=323–33 |year=2007 |pmid=17360941 |doi=10.1182/blood-2006-10-052282 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=17360941}}</ref>

*According to the report of the [[French-American-British]] Cooperative Group, this category of AML (M7 subtype) is associated with 30% or more blasts in the bone marrow. Blasts are identified as being of megakaryocyte lineage by; expression of [[megakaryocyte]] specific [[antigen]]s and platelet [[peroxidase]] reaction on [[electron microscopy]].<ref name="Bennett19852">{{cite journal|last1=Bennett|first1=John M.|title=Criteria for the Diagnosis of Acute Leukemia of Megakaryocyte Lineage (M7)|journal=Annals of Internal Medicine|volume=103|issue=3|year=1985|pages=460|issn=0003-4819|doi=10.7326/0003-4819-103-3-460}}</ref>

*[[Myelofibrosis]] is usually associated with AMKL; however, the exact underlying pathophysiology is controversial. The investigators did not find any direct correlation between acute myelofibrosis and the [[fibroblasts]] obtained from the bone marrow of patients with AMKL. Nevertheless, it was proposed that some humoral factors may play a key role in developing bone marrow fibrosis.<ref name="ClareElson1982">{{cite journal|last1=Clare|first1=Nanette|last2=Elson|first2=David|last3=Manhoff|first3=Louis|title=Cytogenetic Studies of Peripheral Myeloblasts and Bone Marrow Fibroblasts in Acute Myelofibrosis|journal=American Journal of Clinical Pathology|volume=77|issue=6|year=1982|pages=762–766|issn=0002-9173|doi=10.1093/ajcp/77.6.762}}</ref>

*[[Transforming Growth Factor-β]] (TG-β) was identified to be the significant contributor in AMKL associated myelofibrosis in addition to some other unknown factors due to the strong stimulatory effects on [[collagen]].<ref name="TeruiNiitsu1990">{{cite journal|last1=Terui|first1=T|last2=Niitsu|first2=Y|last3=Mahara|first3=K|last4=Fujisaki|first4=Y|last5=Urushizaki|first5=Y|last6=Mogi|first6=Y|last7=Kohgo|first7=Y|last8=Watanabe|first8=N|last9=Ogura|first9=M|last10=Saito|first10=H|title=The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis|journal=Blood|volume=75|issue=7|year=1990|pages=1540–1548|issn=0006-4971|doi=10.1182/blood.V75.7.1540.1540}}</ref>

==Causes==
Mutations involving

*GATA1 [[gene]]

*Transforming [[Growth Factor]]-β (TG-β)
*[[Karyotype]] (t(1;22)(p13;q13)

 
==Differentiating AMKL from other Diseases==

Distinguishing features from other subtypes of AML are following:

*[[Thrombocytopenia]] is more common and severe in AMKL compared with [[myelodysplastic syndrome]] (MDS). Blast cells in the bone marrow are <30% in MDS versus >30% in AMKL.
*Presence of megakaryocytic specific antigens ([[CD41,]] [[CD61]]) and markers ([[glycoprotein 1b]]) and platelets [[peroxidase]] activity. [[Karyotype]] analysis also helpful due to its complex and unusual karyotypic presentation (t(1;22)(p13;q13).

===Differential Diagnoses:===

====[[Acute myeloid leukemia]] otherwise not specified as per WHO classification:====

#''Acute myeloid leukemia with minimal differentiation''
#''Acute myeloid leukemia without maturation''
#''Acute myeloid leukemia with maturation''
#''Acute myelomonocytic leukemia''
#''Acute monoblastic/monocytic leukemia''
#'' Acute erythroid leukemia''
#''Pure erythroid leukemia''
#''Erythroleukemia, erythroid/myeloid''
#'' Acute basophilic leukemia''
#''Acute panmyelosis with myelofibrosis (a.k.a acute myelofibrosis)''

==Epidemiology and Demographics==

*AMKL is the most common subtype of AML reported in [[Down syndrome]] patients. It is more common in children compared with adults. The [[prevalence]] in children and adults is ~15% and 0.6%, respectively.

*Down syndrome patients carry a 200 fold increased risk of developing AMKL vs. non-Down syndrome patients. Similarly, another review proposed a 500 fold increased risk. It almost exclusively occurs in the first 3 years of life.
*[[Transient leukemia]] (TL) occurs in approximately 10% of Down syndrome infants, which is also attributed to transient [[myeloproliferative disorder]]. In most cases, TL spontaneously resolves; however, during the first four years of life, it progresses to acute megakaryoblastic leukemia in 13% to 33% of patients.

==Risk Factors==

*Risk of development of AMKL increases in patients with [[Down syndrome]] .

==Natural History==

*Clonal proliferation of early [[megakaryoblasts]] in the bone marrow results in acute megakaryoblastic leukemia (AMKL). It has a bimodal onset of presentation—occurs both in the pediatric age group (<4 years) and adults.
*In childhood, it is more prevalent in patients with Down syndrome. While it is rare in adults, approximately 0.6% (24/3603) reported in the [[GIMEMA trial]].
*Cases of AMKL secondary to [[chronic myelogenous leukemia]] and [[essential thrombocytosis]] have been reported in the medical literature.

==Complications==

#Periorbital swelling
#[[Periosteal elevation]]
#Osteolytic lesions, especially in long bones, e.g., femur
#[[Osteoporosis]] with pathologic fractures
#[[Sweet syndrome]] (SS)
#[[Leukemia cutis]]
#[[Hypercalcemia]]

==Prognosis==
Due to the rarity of this subtype of hematological malignancy, limited data is available on the natural course or [[prognosis]].

*Apart from AMKL in [[Down syndrome]] patients, the prognosis of AMKL is poor. The efficacy profile of AMKL in Down syndrome patients is favorable, but it comes with a lot of treatment-related toxicity.

*According to the Children’s Oncology Group (COG) AML0431 trial results, the 5-year event-free survival and [[overall survival]] rates were 90% and 93% in 204 eligible Down syndrome with AMKL patients.

*Similarly, the reported 3-year overall survival rate was 100% among 3 AMKL with Down syndrome patients while (47±12%) in non-Down syndrome patients.

*The 5-year overall survival rate in AMKL was 10.6% versus 17.5% in non-M7 [[Acute Myeloid leukemia|Acute myeloid leukemia]] subtypes. Currently, [[chemotherapy]] and [[Allo-BMT|allogenic bone marrow transplant]] (Allo-BMT) are main therapy. Treatment-related toxicity is a big challenge. To address this issue, elaborated large future clinical studies are required.

==Diagnosis==
===Diagnostic Study of Choice===

* [[Bone marrow biopsy]] showing 30% or more leukemic cells of megakaryocytic progenitors.

===History and Symptoms===

*[[Acute megakaryoblastic leukemia]] (AMKL) has a wide array of presentations. The onset is either acute or insidious. The degree of [[pancytopenia]] varies among patients. Other features include [[fever]], irritability, [[headache]], fatigue, bone pain, [[hepatosplenomegaly]] (HSM), and [[lymphadenopathy]], pallor, generalized pain, temporal swelling, [[bruising]], and difficulty walking.

*Greater than 50% of [[leukemia]] patients demonstrate skeletal features and are mostly related to the AMKL subtype.

===Physical Examination===

*Physical exam findings include:

[[Down syndrome]] features are present in patients with Down syndrome associated AMKL.

===Laboratory Findings===

The diagnosis of AMKL (M7) is based on the following:

#[[Bone marrow]] [[biopsy]] demonstrating 30% or more leukemic cells of megakaryocytic lineage
#Conducting tests that detect [[platelet-specific antibodies]] which could be [[monoclonal]] or [[polyclonal]].
#Bone marrow biopsy is recommended in patients who developed [[myelofibrosis]]. Visualization of blasts and mature megakaryocytes on biopsy sections is diagnostic.

===Other Diagnostic Studies===

*In adults, the features include
**[[Pancytopenia]] with low [[blast]] counts in the blood
**[[Myelofibrosis]]
**An absence of [[lymphadenopathy]] and [[hepatosplenomegaly]]
**Poor response to [[chemotherapy]],and short clinical course.

*In children, the same clinical presentation but with variable course especially in very young children; both [[leukocytosis]] and [[organomegaly]] may be present in children with M7. Complete remission and long term survival are more common in children than adults.

*The morphology of cells was observed by means of Bone marrow smear
*The [[immunophenotype]] was detected by [[flow cytometry]] and [[immunohistochemistry]] assay.

*In blood and bone marrow smears megakaryoblasts are usually medium sized to large cells with a high nuclear- cytoplasmic ratio. Nuclear [[chromatin]] is dense and homogeneous. There is scanty, variable basophilic cytoplasm which may be vacuolated. An irregular cytoplasmic border is often noted in some of the [[megakaryoblasts]] and occasionally projections resembling budding atypical platelets are present. The megakaryoblasts lack [[myeloperoxidase]] activity and stain negatively with [[Sudan black B]] (SBB).

*They are alpha [[naphthyl butyrate esterase]] negative and manifest variable alpha naphthyl acetate esterase activity usually in scattered clumps or granules in the cytoplasm. [[PAS]] staining also varies from negative to focal or granular positivity, to strongly positive staining.

*A marrow aspirate is difficult to obtain in many cases because of variable degree of [[myelofibrosis]].

*More precise identification by immunophenotyping or with [[electron microscopy]] (EM). [[Immunophenotyping]] using MoAb to megakaryocyte restricted antigen (CD41 and CD61) may be diagnostic.

===Karyotype analysis:===

*It is essential owing to the fact that AMKL has complex [[karyotype]] with peculiar presentation ([[t(1;22)(p13;q13]]).

===Radiographic features:===

*Using [[Chest X-ray]] ('''CXR'''), '''[[skeletal survey]]''', '''[[CT scan]]''', and '''[[bone scan]]''' are:
*Showing osteolytic lesions in the ribs, diffuse [[metaphysical lucency]], [[periostitis]] with periosteal reaction, and pathologic fractures involving long bones, such as femoral bones, and increase uptake in the involved bones.

==Treatment==
===Medical Therapy===

*According to the AML-BFM (Berlin–Frankfurt–Münster) 98 and AML-BFM ((Berlin–Frankfurt–Münster) 93 clinical studies, intensive AML targeted [[chemotherapy]] in Down syndrome-associated AMKL results in high event-free survival rates versus non-Down syndrome patients. However, they are also prone to develop treatment-related toxicity at standard doses due to chemo sensitivity.

The treatment is divided into [[induction therapy]] and [[consolidation]] therapy.

*'''Induction therapy''' — involves two cycles (four weeks apart ) of [[Cytarabine|Ara-Cytarabine]] (Ara-C) at 100 mg/m2 /day continuous infusion for 7 days, [[vincristine]] at 0.7 mg/m2 on day 7, and [[pirarubicin]] at 25 mg/m2 by 60 min infusion on days 2, and 4 (AVC1).
*'''Consolidation therapy''' — follows once complete remission is achieved with the following regimen; [[etoposide]] & high-dose Ara-C (EC), [[mitoxantrone]] and continuous-dose Ara-C (MC), and pirarubicin, vincristine, and continuous-dose Ara-C (AVC2).

The doses are given below:

'''''MC regimen:'''''

*Ara-C at 100 mg/m2 /day continuous infusion for 5 days and
*Mitoxantrone at 3.5 mg/m2 by 60 min infusion on days 2–4

'''''EC regimen'''''

*High-dose Ara-C 1 g/m2 every 12 hrs on days 1–5,
*Etoposide 66 mg/m2 by 2 h infusion on days 2–4), and

'''''AVC2 regimen'''''

*Ara-C at 100 mg/m2 /day on days 1–5,
*Pirarubicin 35 mg/m2 by 60 min infusion on day 2, and
*Vincristine at 0.7 mg/m2 on day 5

In relapsed state, re-induction with [[fludarabine]] and Ara-C combination or same AVC regimen can be utilized. Allogenic bone marrow transplant (Allo-BMT) from a suitable donor is justified if the patients achieved second complete remission. Currently, there is no recommended definitive therapy for non-Down syndrome with AMKL cohort. Novel therapeutic interventions are undertaken.

*Some study groups proposed that non-[[Down syndrome]] with AMKL is a high-risk condition; therefore, allogeneic [[hematopoietic stem cell]] transplantation (Allo-HSCT) during first complete remission is recommended to benefit the patients. In contrast, no benefit of Allo-HSCT is evident over chemotherapy without remission.

*In AML-BFM 04 trial, patients were randomized to receive induction therapy with either (Ara-C), [[liposomal daunorubicin]], and etoposide (ADxE) or Ara-C, [[idarubicin]], and etoposide (AIE) regimen. Consolidation therapy with [[2-chloro-2-deoxyadenosine]] (2-CDA) and Ara-C and idarubicin was preceded by second induction therapy with HAM (high-dose Ara-C, mitoxantrone, cytarabine i.th). However, no significant results were obtained regarding event-free survival (EFS) and overall survival (OS).

===Surgery===
There is no established surgical [[intervention]] for acute megakaryoblastic [[leukemia]].

===Prevention===
There is no established method for [[prevention]] of acute megakaryoblastic [[leukemia]].

==References==

[[Category:Hematology]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
<references />

Acute megakaryoblastic leukemia

2021-05-04T15:12:44Z

Roukoz Abou Karam:

__NOTOC__
{{SI}}

Acute megakaryoblastic leukemia
{{CMG}}; {{AE}} [[User:Israrkhan|Israr Khan, M.D.]][mailto:israrkhan.dawar@gmail.com]

{{SK}} Leukemia, megakaryoblastic, acute; megakaryoblastic leukemia, acute; AMKL; leukemia, myeloid, acute, M7; megakaryocytic leukemia; megakaryocytic leukemia, acute; myeloid leukemia, acute, M7

==Overview==
Acute megakaryoblastic leukemia is a rare type of [[hematological malignancy]] that results from the clonal proliferation of [[Megakaryoblast|megakaryoblasts]] in the [[bone marrow]]. Prof. Dr. Von Boros first described it in 1931. In 1985, the [[French-British-American classification]] of [[Acute myeloid leukemia]] (AML) included it as (M7 subtype). Later in 2008, acute megakaryoblastic leukemia was classified under AML otherwise not specified category by [[World Health Organization]]. It results from a mutation involving several genes, particularly the [[GATA1]] gene, and [[transforming growth factor-β]] (TG-β). AMKL has commonly associated with [[Down syndrome]]. It has a bimodal distribution and is more common in children (<4) 15% than adults 0.6%. AMKL has a wide range of presentations which has either acute or insidious onset. It is characterized by fever, irritability, headache, fatigue, bone pain, generalized body aches, bruises, and difficulty walking. Physical exam findings include pallor, [[Hepatosplenomegaly]] (HSM), and [[lymphadenopathy]], bruises and [[purpura]], and sometimes temporal or orbital swelling. It is diagnosed by bone marrow biopsy showing 30% or more leukemic cells of megakaryocytic lineage and detection of platelet-specific [[peroxidase antibodies]]. Other lab findings include pancytopenia and megakaryocytic progenitors in the [[peripheral smear]]. Other diagnostic studies include; [[Immunophenotyping]] using MoAb to megakaryocyte restricted antigen (CD41 and CD61), complex karyotypic ([[t(1;22)(p13;q13]]) involvement, radiologic features of the osteolytic lesion, metaphyseal lucency, pathologic fractures using [[Chest X-ray|CXR]], [[CT scan]], [[bone scan]], and [[MRI]] modalities. Currently, [[chemotherapy]] and [[Allo-BMT|allogeneic bone marrow transplant]] (Allo-BMT) are mainstay therapy. However, treatment-related toxicity is a big challenge. Different drug combination regimens are available for AMKL. The commonly used drugs are [[Ara-Cytarabine|Cytarabine]], [[mitoxantrone]], [[etoposide]], [[vincristine]], [[fludarabine]], and [[Piraubicin|pirarubicin]]. The prognosis of AMKL in Down syndrome patients is favorable as compared with non-Down syndrome patients.

The following complications can be observed in patients with AMKL; [[periosteal elevation]], [[osteolytic lesions]], especially in long bones, e.g., [[femur]], [[osteoporosis]] with pathologic fractures, [[Sweet syndrome]] (SS), [[leukemia cutis]], and [[hypercalcemia]].
 
==Historical Perspective==

J. Von Boros first described acute megakaryoblastic leukemia in 1931.
==Classification==

For established [[French-British-American]] (FAB) classification, refer to [[Acute myeloid leukemia classification|acute myeloid leukemia classification.]]
==Pathophysiology==

*It is associated with [[GATA1]], and risks are increased in individuals with [[Down syndrome]]. However, not all cases are associated with Down syndrome, and other [[genes]] can also be associated with AMKL.

*According to the report of the [[French-American-British]] Cooperative Group, this category of AML (M7 subtype) is associated with 30% or more blasts in the bone marrow. Blasts are identified as being of megakaryocyte lineage by; expression of [[megakaryocyte]] specific [[antigen]]s and platelet [[peroxidase]] reaction on [[electron microscopy]].

*[[Myelofibrosis]] is usually associated with AMKL; however, the exact underlying pathophysiology is controversial. The investigators did not find any direct correlation between acute myelofibrosis and the [[fibroblasts]] obtained from the bone marrow of patients with AMKL. Nevertheless, it was proposed that some humoral factors may play a key role in developing bone marrow fibrosis.

*[[Transforming Growth Factor-β]] (TG-β) was identified to be the significant contributor in AMKL associated myelofibrosis in addition to some other unknown factors due to the strong stimulatory effects on [[collagen]].

==Causes==
Mutations involving

*GATA1 [[gene]]

*Transforming [[Growth Factor]]-β (TG-β)
*[[Karyotype]] (t(1;22)(p13;q13)

 
==Differentiating AMKL from other Diseases==

Distinguishing features from other subtypes of AML are following:

*[[Thrombocytopenia]] is more common and severe in AMKL compared with [[myelodysplastic syndrome]] (MDS). Blast cells in the bone marrow are <30% in MDS versus >30% in AMKL.
*Presence of megakaryocytic specific antigens ([[CD41,]] [[CD61]]) and markers ([[glycoprotein 1b]]) and platelets [[peroxidase]] activity. [[Karyotype]] analysis also helpful due to its complex and unusual karyotypic presentation (t(1;22)(p13;q13).

===Differential Diagnoses:===

====[[Acute myeloid leukemia]] otherwise not specified as per WHO classification:====

#''Acute myeloid leukemia with minimal differentiation''
#''Acute myeloid leukemia without maturation''
#''Acute myeloid leukemia with maturation''
#''Acute myelomonocytic leukemia''
#''Acute monoblastic/monocytic leukemia''
#'' Acute erythroid leukemia''
#''Pure erythroid leukemia''
#''Erythroleukemia, erythroid/myeloid''
#'' Acute basophilic leukemia''
#''Acute panmyelosis with myelofibrosis (a.k.a acute myelofibrosis)''

==Epidemiology and Demographics==

*AMKL is the most common subtype of AML reported in [[Down syndrome]] patients. It is more common in children compared with adults. The [[prevalence]] in children and adults is ~15% and 0.6%, respectively.

*Down syndrome patients carry a 200 fold increased risk of developing AMKL vs. non-Down syndrome patients. Similarly, another review proposed a 500 fold increased risk. It almost exclusively occurs in the first 3 years of life.
*[[Transient leukemia]] (TL) occurs in approximately 10% of Down syndrome infants, which is also attributed to transient [[myeloproliferative disorder]]. In most cases, TL spontaneously resolves; however, during the first four years of life, it progresses to acute megakaryoblastic leukemia in 13% to 33% of patients.

==Risk Factors==

*Risk of development of AMKL increases in patients with [[Down syndrome]] .

==Natural History==

*Clonal proliferation of early [[megakaryoblasts]] in the bone marrow results in acute megakaryoblastic leukemia (AMKL). It has a bimodal onset of presentation—occurs both in the pediatric age group (<4 years) and adults.
*In childhood, it is more prevalent in patients with Down syndrome. While it is rare in adults, approximately 0.6% (24/3603) reported in the [[GIMEMA trial]].
*Cases of AMKL secondary to [[chronic myelogenous leukemia]] and [[essential thrombocytosis]] have been reported in the medical literature.

==Complications==

#Periorbital swelling
#[[Periosteal elevation]]
#Osteolytic lesions, especially in long bones, e.g., femur
#[[Osteoporosis]] with pathologic fractures
#[[Sweet syndrome]] (SS)
#[[Leukemia cutis]]
#[[Hypercalcemia]]

==Prognosis==
Due to the rarity of this subtype of hematological malignancy, limited data is available on the natural course or [[prognosis]].

*Apart from AMKL in [[Down syndrome]] patients, the prognosis of AMKL is poor. The efficacy profile of AMKL in Down syndrome patients is favorable, but it comes with a lot of treatment-related toxicity.

*According to the Children’s Oncology Group (COG) AML0431 trial results, the 5-year event-free survival and [[overall survival]] rates were 90% and 93% in 204 eligible Down syndrome with AMKL patients.

*Similarly, the reported 3-year overall survival rate was 100% among 3 AMKL with Down syndrome patients while (47±12%) in non-Down syndrome patients.

*The 5-year overall survival rate in AMKL was 10.6% versus 17.5% in non-M7 [[Acute Myeloid leukemia|Acute myeloid leukemia]] subtypes. Currently, [[chemotherapy]] and [[Allo-BMT|allogenic bone marrow transplant]] (Allo-BMT) are main therapy. Treatment-related toxicity is a big challenge. To address this issue, elaborated large future clinical studies are required.

==Diagnosis==
===Diagnostic Study of Choice===

* [[Bone marrow biopsy]] showing 30% or more leukemic cells of megakaryocytic progenitors.

===History and Symptoms===

*[[Acute megakaryoblastic leukemia]] (AMKL) has a wide array of presentations. The onset is either acute or insidious. The degree of [[pancytopenia]] varies among patients. Other features include [[fever]], irritability, [[headache]], fatigue, bone pain, [[hepatosplenomegaly]] (HSM), and [[lymphadenopathy]], pallor, generalized pain, temporal swelling, [[bruising]], and difficulty walking.

*Greater than 50% of [[leukemia]] patients demonstrate skeletal features and are mostly related to the AMKL subtype.

===Physical Examination===

*Physical exam findings include:

[[Down syndrome]] features are present in patients with Down syndrome associated AMKL.

===Laboratory Findings===

The diagnosis of AMKL (M7) is based on the following:

#[[Bone marrow]] [[biopsy]] demonstrating 30% or more leukemic cells of megakaryocytic lineage
#Conducting tests that detect [[platelet-specific antibodies]] which could be [[monoclonal]] or [[polyclonal]].
#Bone marrow biopsy is recommended in patients who developed [[myelofibrosis]]. Visualization of blasts and mature megakaryocytes on biopsy sections is diagnostic.

===Other Diagnostic Studies===

*In adults, the features include
**[[Pancytopenia]] with low [[blast]] counts in the blood
**[[Myelofibrosis]]
**An absence of [[lymphadenopathy]] and [[hepatosplenomegaly]]
**Poor response to [[chemotherapy]],and short clinical course.

*In children, the same clinical presentation but with variable course especially in very young children; both [[leukocytosis]] and [[organomegaly]] may be present in children with M7. Complete remission and long term survival are more common in children than adults.

*The morphology of cells was observed by means of Bone marrow smear
*The [[immunophenotype]] was detected by [[flow cytometry]] and [[immunohistochemistry]] assay.

*In blood and bone marrow smears megakaryoblasts are usually medium sized to large cells with a high nuclear- cytoplasmic ratio. Nuclear [[chromatin]] is dense and homogeneous. There is scanty, variable basophilic cytoplasm which may be vacuolated. An irregular cytoplasmic border is often noted in some of the [[megakaryoblasts]] and occasionally projections resembling budding atypical platelets are present. The megakaryoblasts lack [[myeloperoxidase]] activity and stain negatively with [[Sudan black B]] (SBB).

*They are alpha [[naphthyl butyrate esterase]] negative and manifest variable alpha naphthyl acetate esterase activity usually in scattered clumps or granules in the cytoplasm. [[PAS]] staining also varies from negative to focal or granular positivity, to strongly positive staining.

*A marrow aspirate is difficult to obtain in many cases because of variable degree of [[myelofibrosis]].

*More precise identification by immunophenotyping or with [[electron microscopy]] (EM). [[Immunophenotyping]] using MoAb to megakaryocyte restricted antigen (CD41 and CD61) may be diagnostic.

===Karyotype analysis:===

*It is essential owing to the fact that AMKL has complex [[karyotype]] with peculiar presentation ([[t(1;22)(p13;q13]]).

===Radiographic features:===

*Using [[Chest X-ray]] ('''CXR'''), '''[[skeletal survey]]''', '''[[CT scan]]''', and '''[[bone scan]]''' are:
*Showing osteolytic lesions in the ribs, diffuse [[metaphysical lucency]], [[periostitis]] with periosteal reaction, and pathologic fractures involving long bones, such as femoral bones, and increase uptake in the involved bones.

==Treatment==
===Medical Therapy===

*According to the AML-BFM (Berlin–Frankfurt–Münster) 98 and AML-BFM ((Berlin–Frankfurt–Münster) 93 clinical studies, intensive AML targeted [[chemotherapy]] in Down syndrome-associated AMKL results in high event-free survival rates versus non-Down syndrome patients. However, they are also prone to develop treatment-related toxicity at standard doses due to chemo sensitivity.

The treatment is divided into [[induction therapy]] and [[consolidation]] therapy.

*'''Induction therapy''' — involves two cycles (four weeks apart ) of [[Cytarabine|Ara-Cytarabine]] (Ara-C) at 100 mg/m2 /day continuous infusion for 7 days, [[vincristine]] at 0.7 mg/m2 on day 7, and [[pirarubicin]] at 25 mg/m2 by 60 min infusion on days 2, and 4 (AVC1).
*'''Consolidation therapy''' — follows once complete remission is achieved with the following regimen; [[etoposide]] & high-dose Ara-C (EC), [[mitoxantrone]] and continuous-dose Ara-C (MC), and pirarubicin, vincristine, and continuous-dose Ara-C (AVC2).

The doses are given below:

'''''MC regimen:'''''

*Ara-C at 100 mg/m2 /day continuous infusion for 5 days and
*Mitoxantrone at 3.5 mg/m2 by 60 min infusion on days 2–4

'''''EC regimen'''''

*High-dose Ara-C 1 g/m2 every 12 hrs on days 1–5,
*Etoposide 66 mg/m2 by 2 h infusion on days 2–4), and

'''''AVC2 regimen'''''

*Ara-C at 100 mg/m2 /day on days 1–5,
*Pirarubicin 35 mg/m2 by 60 min infusion on day 2, and
*Vincristine at 0.7 mg/m2 on day 5

In relapsed state, re-induction with [[fludarabine]] and Ara-C combination or same AVC regimen can be utilized. Allogenic bone marrow transplant (Allo-BMT) from a suitable donor is justified if the patients achieved second complete remission. Currently, there is no recommended definitive therapy for non-Down syndrome with AMKL cohort. Novel therapeutic interventions are undertaken.

*Some study groups proposed that non-[[Down syndrome]] with AMKL is a high-risk condition; therefore, allogeneic [[hematopoietic stem cell]] transplantation (Allo-HSCT) during first complete remission is recommended to benefit the patients. In contrast, no benefit of Allo-HSCT is evident over chemotherapy without remission.

*In AML-BFM 04 trial, patients were randomized to receive induction therapy with either (Ara-C), [[liposomal daunorubicin]], and etoposide (ADxE) or Ara-C, [[idarubicin]], and etoposide (AIE) regimen. Consolidation therapy with [[2-chloro-2-deoxyadenosine]] (2-CDA) and Ara-C and idarubicin was preceded by second induction therapy with HAM (high-dose Ara-C, mitoxantrone, cytarabine i.th). However, no significant results were obtained regarding event-free survival (EFS) and overall survival (OS).

===Surgery===
There is no established surgical [[intervention]] for acute megakaryoblastic [[leukemia]].

===Prevention===
There is no established method for [[prevention]] of acute megakaryoblastic [[leukemia]].

==References==

[[Category:Hematology]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
<references />

Acute megakaryoblastic leukemia

2021-05-04T15:11:02Z

Roukoz Abou Karam:

__NOTOC__
{{SI}}

Acute megakaryoblastic leukemia
{{CMG}}; {{AE}} {{Israrkhan}}

{{SK}} Leukemia, megakaryoblastic, acute; megakaryoblastic leukemia, acute; AMKL; leukemia, myeloid, acute, M7; megakaryocytic leukemia; megakaryocytic leukemia, acute; myeloid leukemia, acute, M7

==Overview==
Acute megakaryoblastic leukemia is a rare type of [[hematological malignancy]] that results from the clonal proliferation of [[Megakaryoblast|megakaryoblasts]] in the [[bone marrow]]. Prof. Dr. Von Boros first described it in 1931. In 1985, the [[French-British-American classification]] of [[Acute myeloid leukemia]] (AML) included it as (M7 subtype). Later in 2008, acute megakaryoblastic leukemia was classified under AML otherwise not specified category by [[World Health Organization]]. It results from a mutation involving several genes, particularly the [[GATA1]] gene, and [[transforming growth factor-β]] (TG-β). AMKL has commonly associated with [[Down syndrome]]. It has a bimodal distribution and is more common in children (<4) 15% than adults 0.6%. AMKL has a wide range of presentations which has either acute or insidious onset. It is characterized by fever, irritability, headache, fatigue, bone pain, generalized body aches, bruises, and difficulty walking. Physical exam findings include pallor, [[Hepatosplenomegaly]] (HSM), and [[lymphadenopathy]], bruises and [[purpura]], and sometimes temporal or orbital swelling. It is diagnosed by bone marrow biopsy showing 30% or more leukemic cells of megakaryocytic lineage and detection of platelet-specific [[peroxidase antibodies]]. Other lab findings include pancytopenia and megakaryocytic progenitors in the [[peripheral smear]]. Other diagnostic studies include; [[Immunophenotyping]] using MoAb to megakaryocyte restricted antigen (CD41 and CD61), complex karyotypic ([[t(1;22)(p13;q13]]) involvement, radiologic features of the osteolytic lesion, metaphyseal lucency, pathologic fractures using [[Chest X-ray|CXR]], [[CT scan]], [[bone scan]], and [[MRI]] modalities. Currently, [[chemotherapy]] and [[Allo-BMT|allogeneic bone marrow transplant]] (Allo-BMT) are mainstay therapy. However, treatment-related toxicity is a big challenge. Different drug combination regimens are available for AMKL. The commonly used drugs are [[Ara-Cytarabine|Cytarabine]], [[mitoxantrone]], [[etoposide]], [[vincristine]], [[fludarabine]], and [[Piraubicin|pirarubicin]]. The prognosis of AMKL in Down syndrome patients is favorable as compared with non-Down syndrome patients.

The following complications can be observed in patients with AMKL; [[periosteal elevation]], [[osteolytic lesions]], especially in long bones, e.g., [[femur]], [[osteoporosis]] with pathologic fractures, [[Sweet syndrome]] (SS), [[leukemia cutis]], and [[hypercalcemia]].
 
==Historical Perspective==

J. Von Boros first described acute megakaryoblastic leukemia in 1931.
==Classification==

For established [[French-British-American]] (FAB) classification, refer to [[Acute myeloid leukemia classification|acute myeloid leukemia classification.]]
==Pathophysiology==

*It is associated with [[GATA1]], and risks are increased in individuals with [[Down syndrome]]. However, not all cases are associated with Down syndrome, and other [[genes]] can also be associated with AMKL.

*According to the report of the [[French-American-British]] Cooperative Group, this category of AML (M7 subtype) is associated with 30% or more blasts in the bone marrow. Blasts are identified as being of megakaryocyte lineage by; expression of [[megakaryocyte]] specific [[antigen]]s and platelet [[peroxidase]] reaction on [[electron microscopy]].

*[[Myelofibrosis]] is usually associated with AMKL; however, the exact underlying pathophysiology is controversial. The investigators did not find any direct correlation between acute myelofibrosis and the [[fibroblasts]] obtained from the bone marrow of patients with AMKL. Nevertheless, it was proposed that some humoral factors may play a key role in developing bone marrow fibrosis.

*[[Transforming Growth Factor-β]] (TG-β) was identified to be the significant contributor in AMKL associated myelofibrosis in addition to some other unknown factors due to the strong stimulatory effects on [[collagen]].

==Causes==
Mutations involving

*GATA1 [[gene]]

*Transforming [[Growth Factor]]-β (TG-β)
*[[Karyotype]] (t(1;22)(p13;q13)

 
==Differentiating AMKL from other Diseases==

Distinguishing features from other subtypes of AML are following:

*[[Thrombocytopenia]] is more common and severe in AMKL compared with [[myelodysplastic syndrome]] (MDS). Blast cells in the bone marrow are <30% in MDS versus >30% in AMKL.
*Presence of megakaryocytic specific antigens ([[CD41,]] [[CD61]]) and markers ([[glycoprotein 1b]]) and platelets [[peroxidase]] activity. [[Karyotype]] analysis also helpful due to its complex and unusual karyotypic presentation (t(1;22)(p13;q13).

===Differential Diagnoses:===

====[[Acute myeloid leukemia]] otherwise not specified as per WHO classification:====

#''Acute myeloid leukemia with minimal differentiation''
#''Acute myeloid leukemia without maturation''
#''Acute myeloid leukemia with maturation''
#''Acute myelomonocytic leukemia''
#''Acute monoblastic/monocytic leukemia''
#'' Acute erythroid leukemia''
#''Pure erythroid leukemia''
#''Erythroleukemia, erythroid/myeloid''
#'' Acute basophilic leukemia''
#''Acute panmyelosis with myelofibrosis (a.k.a acute myelofibrosis)''

==Epidemiology and Demographics==

*AMKL is the most common subtype of AML reported in [[Down syndrome]] patients. It is more common in children compared with adults. The [[prevalence]] in children and adults is ~15% and 0.6%, respectively.

*Down syndrome patients carry a 200 fold increased risk of developing AMKL vs. non-Down syndrome patients. Similarly, another review proposed a 500 fold increased risk. It almost exclusively occurs in the first 3 years of life.
*[[Transient leukemia]] (TL) occurs in approximately 10% of Down syndrome infants, which is also attributed to transient [[myeloproliferative disorder]]. In most cases, TL spontaneously resolves; however, during the first four years of life, it progresses to acute megakaryoblastic leukemia in 13% to 33% of patients.

==Risk Factors==

*Risk of development of AMKL increases in patients with [[Down syndrome]] .

==Natural History==

*Clonal proliferation of early [[megakaryoblasts]] in the bone marrow results in acute megakaryoblastic leukemia (AMKL). It has a bimodal onset of presentation—occurs both in the pediatric age group (<4 years) and adults.
*In childhood, it is more prevalent in patients with Down syndrome. While it is rare in adults, approximately 0.6% (24/3603) reported in the [[GIMEMA trial]].
*Cases of AMKL secondary to [[chronic myelogenous leukemia]] and [[essential thrombocytosis]] have been reported in the medical literature.

==Complications==

#Periorbital swelling
#[[Periosteal elevation]]
#Osteolytic lesions, especially in long bones, e.g., femur
#[[Osteoporosis]] with pathologic fractures
#[[Sweet syndrome]] (SS)
#[[Leukemia cutis]]
#[[Hypercalcemia]]

==Prognosis==
Due to the rarity of this subtype of hematological malignancy, limited data is available on the natural course or [[prognosis]].

*Apart from AMKL in [[Down syndrome]] patients, the prognosis of AMKL is poor. The efficacy profile of AMKL in Down syndrome patients is favorable, but it comes with a lot of treatment-related toxicity.

*According to the Children’s Oncology Group (COG) AML0431 trial results, the 5-year event-free survival and [[overall survival]] rates were 90% and 93% in 204 eligible Down syndrome with AMKL patients.

*Similarly, the reported 3-year overall survival rate was 100% among 3 AMKL with Down syndrome patients while (47±12%) in non-Down syndrome patients.

*The 5-year overall survival rate in AMKL was 10.6% versus 17.5% in non-M7 [[Acute Myeloid leukemia|Acute myeloid leukemia]] subtypes. Currently, [[chemotherapy]] and [[Allo-BMT|allogenic bone marrow transplant]] (Allo-BMT) are main therapy. Treatment-related toxicity is a big challenge. To address this issue, elaborated large future clinical studies are required.

==Diagnosis==
===Diagnostic Study of Choice===

* [[Bone marrow biopsy]] showing 30% or more leukemic cells of megakaryocytic progenitors.

===History and Symptoms===

*[[Acute megakaryoblastic leukemia]] (AMKL) has a wide array of presentations. The onset is either acute or insidious. The degree of [[pancytopenia]] varies among patients. Other features include [[fever]], irritability, [[headache]], fatigue, bone pain, [[hepatosplenomegaly]] (HSM), and [[lymphadenopathy]], pallor, generalized pain, temporal swelling, [[bruising]], and difficulty walking.

*Greater than 50% of [[leukemia]] patients demonstrate skeletal features and are mostly related to the AMKL subtype.

===Physical Examination===

*Physical exam findings include:

[[Down syndrome]] features are present in patients with Down syndrome associated AMKL.

===Laboratory Findings===

The diagnosis of AMKL (M7) is based on the following:

#[[Bone marrow]] [[biopsy]] demonstrating 30% or more leukemic cells of megakaryocytic lineage
#Conducting tests that detect [[platelet-specific antibodies]] which could be [[monoclonal]] or [[polyclonal]].
#Bone marrow biopsy is recommended in patients who developed [[myelofibrosis]]. Visualization of blasts and mature megakaryocytes on biopsy sections is diagnostic.

===Other Diagnostic Studies===

*In adults, the features include
**[[Pancytopenia]] with low [[blast]] counts in the blood
**[[Myelofibrosis]]
**An absence of [[lymphadenopathy]] and [[hepatosplenomegaly]]
**Poor response to [[chemotherapy]],and short clinical course.

*In children, the same clinical presentation but with variable course especially in very young children; both [[leukocytosis]] and [[organomegaly]] may be present in children with M7. Complete remission and long term survival are more common in children than adults.

*The morphology of cells was observed by means of Bone marrow smear
*The [[immunophenotype]] was detected by [[flow cytometry]] and [[immunohistochemistry]] assay.

*In blood and bone marrow smears megakaryoblasts are usually medium sized to large cells with a high nuclear- cytoplasmic ratio. Nuclear [[chromatin]] is dense and homogeneous. There is scanty, variable basophilic cytoplasm which may be vacuolated. An irregular cytoplasmic border is often noted in some of the [[megakaryoblasts]] and occasionally projections resembling budding atypical platelets are present. The megakaryoblasts lack [[myeloperoxidase]] activity and stain negatively with [[Sudan black B]] (SBB).

*They are alpha [[naphthyl butyrate esterase]] negative and manifest variable alpha naphthyl acetate esterase activity usually in scattered clumps or granules in the cytoplasm. [[PAS]] staining also varies from negative to focal or granular positivity, to strongly positive staining.

*A marrow aspirate is difficult to obtain in many cases because of variable degree of [[myelofibrosis]].

*More precise identification by immunophenotyping or with [[electron microscopy]] (EM). [[Immunophenotyping]] using MoAb to megakaryocyte restricted antigen (CD41 and CD61) may be diagnostic.

===Karyotype analysis:===

*It is essential owing to the fact that AMKL has complex [[karyotype]] with peculiar presentation ([[t(1;22)(p13;q13]]).

===Radiographic features:===

*Using [[Chest X-ray]] ('''CXR'''), '''[[skeletal survey]]''', '''[[CT scan]]''', and '''[[bone scan]]''' are:
*Showing osteolytic lesions in the ribs, diffuse [[metaphysical lucency]], [[periostitis]] with periosteal reaction, and pathologic fractures involving long bones, such as femoral bones, and increase uptake in the involved bones.

==Treatment==
===Medical Therapy===

*According to the AML-BFM (Berlin–Frankfurt–Münster) 98 and AML-BFM ((Berlin–Frankfurt–Münster) 93 clinical studies, intensive AML targeted [[chemotherapy]] in Down syndrome-associated AMKL results in high event-free survival rates versus non-Down syndrome patients. However, they are also prone to develop treatment-related toxicity at standard doses due to chemo sensitivity.

The treatment is divided into [[induction therapy]] and [[consolidation]] therapy.

*'''Induction therapy''' — involves two cycles (four weeks apart ) of [[Cytarabine|Ara-Cytarabine]] (Ara-C) at 100 mg/m2 /day continuous infusion for 7 days, [[vincristine]] at 0.7 mg/m2 on day 7, and [[pirarubicin]] at 25 mg/m2 by 60 min infusion on days 2, and 4 (AVC1).
*'''Consolidation therapy''' — follows once complete remission is achieved with the following regimen; [[etoposide]] & high-dose Ara-C (EC), [[mitoxantrone]] and continuous-dose Ara-C (MC), and pirarubicin, vincristine, and continuous-dose Ara-C (AVC2).

The doses are given below:

'''''MC regimen:'''''

*Ara-C at 100 mg/m2 /day continuous infusion for 5 days and
*Mitoxantrone at 3.5 mg/m2 by 60 min infusion on days 2–4

'''''EC regimen'''''

*High-dose Ara-C 1 g/m2 every 12 hrs on days 1–5,
*Etoposide 66 mg/m2 by 2 h infusion on days 2–4), and

'''''AVC2 regimen'''''

*Ara-C at 100 mg/m2 /day on days 1–5,
*Pirarubicin 35 mg/m2 by 60 min infusion on day 2, and
*Vincristine at 0.7 mg/m2 on day 5

In relapsed state, re-induction with [[fludarabine]] and Ara-C combination or same AVC regimen can be utilized. Allogenic bone marrow transplant (Allo-BMT) from a suitable donor is justified if the patients achieved second complete remission. Currently, there is no recommended definitive therapy for non-Down syndrome with AMKL cohort. Novel therapeutic interventions are undertaken.

*Some study groups proposed that non-[[Down syndrome]] with AMKL is a high-risk condition; therefore, allogeneic [[hematopoietic stem cell]] transplantation (Allo-HSCT) during first complete remission is recommended to benefit the patients. In contrast, no benefit of Allo-HSCT is evident over chemotherapy without remission.

*In AML-BFM 04 trial, patients were randomized to receive induction therapy with either (Ara-C), [[liposomal daunorubicin]], and etoposide (ADxE) or Ara-C, [[idarubicin]], and etoposide (AIE) regimen. Consolidation therapy with [[2-chloro-2-deoxyadenosine]] (2-CDA) and Ara-C and idarubicin was preceded by second induction therapy with HAM (high-dose Ara-C, mitoxantrone, cytarabine i.th). However, no significant results were obtained regarding event-free survival (EFS) and overall survival (OS).

===Surgery===
There is no established surgical [[intervention]] for acute megakaryoblastic [[leukemia]].

===Prevention===
There is no established method for [[prevention]] of acute megakaryoblastic [[leukemia]].

==References==

[[Category:Hematology]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
<references />

Acute megakaryoblastic leukemia

2021-05-04T15:10:52Z

Roukoz Abou Karam:

__NOTOC__
{{SI}}

Acute megakaryoblastic leukemia
{{CMG}}; {{AE}} {{Israr}}

{{SK}} Leukemia, megakaryoblastic, acute; megakaryoblastic leukemia, acute; AMKL; leukemia, myeloid, acute, M7; megakaryocytic leukemia; megakaryocytic leukemia, acute; myeloid leukemia, acute, M7

==Overview==
Acute megakaryoblastic leukemia is a rare type of [[hematological malignancy]] that results from the clonal proliferation of [[Megakaryoblast|megakaryoblasts]] in the [[bone marrow]]. Prof. Dr. Von Boros first described it in 1931. In 1985, the [[French-British-American classification]] of [[Acute myeloid leukemia]] (AML) included it as (M7 subtype). Later in 2008, acute megakaryoblastic leukemia was classified under AML otherwise not specified category by [[World Health Organization]]. It results from a mutation involving several genes, particularly the [[GATA1]] gene, and [[transforming growth factor-β]] (TG-β). AMKL has commonly associated with [[Down syndrome]]. It has a bimodal distribution and is more common in children (<4) 15% than adults 0.6%. AMKL has a wide range of presentations which has either acute or insidious onset. It is characterized by fever, irritability, headache, fatigue, bone pain, generalized body aches, bruises, and difficulty walking. Physical exam findings include pallor, [[Hepatosplenomegaly]] (HSM), and [[lymphadenopathy]], bruises and [[purpura]], and sometimes temporal or orbital swelling. It is diagnosed by bone marrow biopsy showing 30% or more leukemic cells of megakaryocytic lineage and detection of platelet-specific [[peroxidase antibodies]]. Other lab findings include pancytopenia and megakaryocytic progenitors in the [[peripheral smear]]. Other diagnostic studies include; [[Immunophenotyping]] using MoAb to megakaryocyte restricted antigen (CD41 and CD61), complex karyotypic ([[t(1;22)(p13;q13]]) involvement, radiologic features of the osteolytic lesion, metaphyseal lucency, pathologic fractures using [[Chest X-ray|CXR]], [[CT scan]], [[bone scan]], and [[MRI]] modalities. Currently, [[chemotherapy]] and [[Allo-BMT|allogeneic bone marrow transplant]] (Allo-BMT) are mainstay therapy. However, treatment-related toxicity is a big challenge. Different drug combination regimens are available for AMKL. The commonly used drugs are [[Ara-Cytarabine|Cytarabine]], [[mitoxantrone]], [[etoposide]], [[vincristine]], [[fludarabine]], and [[Piraubicin|pirarubicin]]. The prognosis of AMKL in Down syndrome patients is favorable as compared with non-Down syndrome patients.

The following complications can be observed in patients with AMKL; [[periosteal elevation]], [[osteolytic lesions]], especially in long bones, e.g., [[femur]], [[osteoporosis]] with pathologic fractures, [[Sweet syndrome]] (SS), [[leukemia cutis]], and [[hypercalcemia]].
 
==Historical Perspective==

J. Von Boros first described acute megakaryoblastic leukemia in 1931.
==Classification==

For established [[French-British-American]] (FAB) classification, refer to [[Acute myeloid leukemia classification|acute myeloid leukemia classification.]]
==Pathophysiology==

*It is associated with [[GATA1]], and risks are increased in individuals with [[Down syndrome]]. However, not all cases are associated with Down syndrome, and other [[genes]] can also be associated with AMKL.

*According to the report of the [[French-American-British]] Cooperative Group, this category of AML (M7 subtype) is associated with 30% or more blasts in the bone marrow. Blasts are identified as being of megakaryocyte lineage by; expression of [[megakaryocyte]] specific [[antigen]]s and platelet [[peroxidase]] reaction on [[electron microscopy]].

*[[Myelofibrosis]] is usually associated with AMKL; however, the exact underlying pathophysiology is controversial. The investigators did not find any direct correlation between acute myelofibrosis and the [[fibroblasts]] obtained from the bone marrow of patients with AMKL. Nevertheless, it was proposed that some humoral factors may play a key role in developing bone marrow fibrosis.

*[[Transforming Growth Factor-β]] (TG-β) was identified to be the significant contributor in AMKL associated myelofibrosis in addition to some other unknown factors due to the strong stimulatory effects on [[collagen]].

==Causes==
Mutations involving

*GATA1 [[gene]]

*Transforming [[Growth Factor]]-β (TG-β)
*[[Karyotype]] (t(1;22)(p13;q13)

 
==Differentiating AMKL from other Diseases==

Distinguishing features from other subtypes of AML are following:

*[[Thrombocytopenia]] is more common and severe in AMKL compared with [[myelodysplastic syndrome]] (MDS). Blast cells in the bone marrow are <30% in MDS versus >30% in AMKL.
*Presence of megakaryocytic specific antigens ([[CD41,]] [[CD61]]) and markers ([[glycoprotein 1b]]) and platelets [[peroxidase]] activity. [[Karyotype]] analysis also helpful due to its complex and unusual karyotypic presentation (t(1;22)(p13;q13).

===Differential Diagnoses:===

====[[Acute myeloid leukemia]] otherwise not specified as per WHO classification:====

#''Acute myeloid leukemia with minimal differentiation''
#''Acute myeloid leukemia without maturation''
#''Acute myeloid leukemia with maturation''
#''Acute myelomonocytic leukemia''
#''Acute monoblastic/monocytic leukemia''
#'' Acute erythroid leukemia''
#''Pure erythroid leukemia''
#''Erythroleukemia, erythroid/myeloid''
#'' Acute basophilic leukemia''
#''Acute panmyelosis with myelofibrosis (a.k.a acute myelofibrosis)''

==Epidemiology and Demographics==

*AMKL is the most common subtype of AML reported in [[Down syndrome]] patients. It is more common in children compared with adults. The [[prevalence]] in children and adults is ~15% and 0.6%, respectively.

*Down syndrome patients carry a 200 fold increased risk of developing AMKL vs. non-Down syndrome patients. Similarly, another review proposed a 500 fold increased risk. It almost exclusively occurs in the first 3 years of life.
*[[Transient leukemia]] (TL) occurs in approximately 10% of Down syndrome infants, which is also attributed to transient [[myeloproliferative disorder]]. In most cases, TL spontaneously resolves; however, during the first four years of life, it progresses to acute megakaryoblastic leukemia in 13% to 33% of patients.

==Risk Factors==

*Risk of development of AMKL increases in patients with [[Down syndrome]] .

==Natural History==

*Clonal proliferation of early [[megakaryoblasts]] in the bone marrow results in acute megakaryoblastic leukemia (AMKL). It has a bimodal onset of presentation—occurs both in the pediatric age group (<4 years) and adults.
*In childhood, it is more prevalent in patients with Down syndrome. While it is rare in adults, approximately 0.6% (24/3603) reported in the [[GIMEMA trial]].
*Cases of AMKL secondary to [[chronic myelogenous leukemia]] and [[essential thrombocytosis]] have been reported in the medical literature.

==Complications==

#Periorbital swelling
#[[Periosteal elevation]]
#Osteolytic lesions, especially in long bones, e.g., femur
#[[Osteoporosis]] with pathologic fractures
#[[Sweet syndrome]] (SS)
#[[Leukemia cutis]]
#[[Hypercalcemia]]

==Prognosis==
Due to the rarity of this subtype of hematological malignancy, limited data is available on the natural course or [[prognosis]].

*Apart from AMKL in [[Down syndrome]] patients, the prognosis of AMKL is poor. The efficacy profile of AMKL in Down syndrome patients is favorable, but it comes with a lot of treatment-related toxicity.

*According to the Children’s Oncology Group (COG) AML0431 trial results, the 5-year event-free survival and [[overall survival]] rates were 90% and 93% in 204 eligible Down syndrome with AMKL patients.

*Similarly, the reported 3-year overall survival rate was 100% among 3 AMKL with Down syndrome patients while (47±12%) in non-Down syndrome patients.

*The 5-year overall survival rate in AMKL was 10.6% versus 17.5% in non-M7 [[Acute Myeloid leukemia|Acute myeloid leukemia]] subtypes. Currently, [[chemotherapy]] and [[Allo-BMT|allogenic bone marrow transplant]] (Allo-BMT) are main therapy. Treatment-related toxicity is a big challenge. To address this issue, elaborated large future clinical studies are required.

==Diagnosis==
===Diagnostic Study of Choice===

* [[Bone marrow biopsy]] showing 30% or more leukemic cells of megakaryocytic progenitors.

===History and Symptoms===

*[[Acute megakaryoblastic leukemia]] (AMKL) has a wide array of presentations. The onset is either acute or insidious. The degree of [[pancytopenia]] varies among patients. Other features include [[fever]], irritability, [[headache]], fatigue, bone pain, [[hepatosplenomegaly]] (HSM), and [[lymphadenopathy]], pallor, generalized pain, temporal swelling, [[bruising]], and difficulty walking.

*Greater than 50% of [[leukemia]] patients demonstrate skeletal features and are mostly related to the AMKL subtype.

===Physical Examination===

*Physical exam findings include:

[[Down syndrome]] features are present in patients with Down syndrome associated AMKL.

===Laboratory Findings===

The diagnosis of AMKL (M7) is based on the following:

#[[Bone marrow]] [[biopsy]] demonstrating 30% or more leukemic cells of megakaryocytic lineage
#Conducting tests that detect [[platelet-specific antibodies]] which could be [[monoclonal]] or [[polyclonal]].
#Bone marrow biopsy is recommended in patients who developed [[myelofibrosis]]. Visualization of blasts and mature megakaryocytes on biopsy sections is diagnostic.

===Other Diagnostic Studies===

*In adults, the features include
**[[Pancytopenia]] with low [[blast]] counts in the blood
**[[Myelofibrosis]]
**An absence of [[lymphadenopathy]] and [[hepatosplenomegaly]]
**Poor response to [[chemotherapy]],and short clinical course.

*In children, the same clinical presentation but with variable course especially in very young children; both [[leukocytosis]] and [[organomegaly]] may be present in children with M7. Complete remission and long term survival are more common in children than adults.

*The morphology of cells was observed by means of Bone marrow smear
*The [[immunophenotype]] was detected by [[flow cytometry]] and [[immunohistochemistry]] assay.

*In blood and bone marrow smears megakaryoblasts are usually medium sized to large cells with a high nuclear- cytoplasmic ratio. Nuclear [[chromatin]] is dense and homogeneous. There is scanty, variable basophilic cytoplasm which may be vacuolated. An irregular cytoplasmic border is often noted in some of the [[megakaryoblasts]] and occasionally projections resembling budding atypical platelets are present. The megakaryoblasts lack [[myeloperoxidase]] activity and stain negatively with [[Sudan black B]] (SBB).

*They are alpha [[naphthyl butyrate esterase]] negative and manifest variable alpha naphthyl acetate esterase activity usually in scattered clumps or granules in the cytoplasm. [[PAS]] staining also varies from negative to focal or granular positivity, to strongly positive staining.

*A marrow aspirate is difficult to obtain in many cases because of variable degree of [[myelofibrosis]].

*More precise identification by immunophenotyping or with [[electron microscopy]] (EM). [[Immunophenotyping]] using MoAb to megakaryocyte restricted antigen (CD41 and CD61) may be diagnostic.

===Karyotype analysis:===

*It is essential owing to the fact that AMKL has complex [[karyotype]] with peculiar presentation ([[t(1;22)(p13;q13]]).

===Radiographic features:===

*Using [[Chest X-ray]] ('''CXR'''), '''[[skeletal survey]]''', '''[[CT scan]]''', and '''[[bone scan]]''' are:
*Showing osteolytic lesions in the ribs, diffuse [[metaphysical lucency]], [[periostitis]] with periosteal reaction, and pathologic fractures involving long bones, such as femoral bones, and increase uptake in the involved bones.

==Treatment==
===Medical Therapy===

*According to the AML-BFM (Berlin–Frankfurt–Münster) 98 and AML-BFM ((Berlin–Frankfurt–Münster) 93 clinical studies, intensive AML targeted [[chemotherapy]] in Down syndrome-associated AMKL results in high event-free survival rates versus non-Down syndrome patients. However, they are also prone to develop treatment-related toxicity at standard doses due to chemo sensitivity.

The treatment is divided into [[induction therapy]] and [[consolidation]] therapy.

*'''Induction therapy''' — involves two cycles (four weeks apart ) of [[Cytarabine|Ara-Cytarabine]] (Ara-C) at 100 mg/m2 /day continuous infusion for 7 days, [[vincristine]] at 0.7 mg/m2 on day 7, and [[pirarubicin]] at 25 mg/m2 by 60 min infusion on days 2, and 4 (AVC1).
*'''Consolidation therapy''' — follows once complete remission is achieved with the following regimen; [[etoposide]] & high-dose Ara-C (EC), [[mitoxantrone]] and continuous-dose Ara-C (MC), and pirarubicin, vincristine, and continuous-dose Ara-C (AVC2).

The doses are given below:

'''''MC regimen:'''''

*Ara-C at 100 mg/m2 /day continuous infusion for 5 days and
*Mitoxantrone at 3.5 mg/m2 by 60 min infusion on days 2–4

'''''EC regimen'''''

*High-dose Ara-C 1 g/m2 every 12 hrs on days 1–5,
*Etoposide 66 mg/m2 by 2 h infusion on days 2–4), and

'''''AVC2 regimen'''''

*Ara-C at 100 mg/m2 /day on days 1–5,
*Pirarubicin 35 mg/m2 by 60 min infusion on day 2, and
*Vincristine at 0.7 mg/m2 on day 5

In relapsed state, re-induction with [[fludarabine]] and Ara-C combination or same AVC regimen can be utilized. Allogenic bone marrow transplant (Allo-BMT) from a suitable donor is justified if the patients achieved second complete remission. Currently, there is no recommended definitive therapy for non-Down syndrome with AMKL cohort. Novel therapeutic interventions are undertaken.

*Some study groups proposed that non-[[Down syndrome]] with AMKL is a high-risk condition; therefore, allogeneic [[hematopoietic stem cell]] transplantation (Allo-HSCT) during first complete remission is recommended to benefit the patients. In contrast, no benefit of Allo-HSCT is evident over chemotherapy without remission.

*In AML-BFM 04 trial, patients were randomized to receive induction therapy with either (Ara-C), [[liposomal daunorubicin]], and etoposide (ADxE) or Ara-C, [[idarubicin]], and etoposide (AIE) regimen. Consolidation therapy with [[2-chloro-2-deoxyadenosine]] (2-CDA) and Ara-C and idarubicin was preceded by second induction therapy with HAM (high-dose Ara-C, mitoxantrone, cytarabine i.th). However, no significant results were obtained regarding event-free survival (EFS) and overall survival (OS).

===Surgery===
There is no established surgical [[intervention]] for acute megakaryoblastic [[leukemia]].

===Prevention===
There is no established method for [[prevention]] of acute megakaryoblastic [[leukemia]].

==References==

[[Category:Hematology]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
<references />

Acute megakaryoblastic leukemia

2021-05-04T15:07:36Z

Roukoz Abou Karam: /* Causes */

Pulmonology status update

2021-05-04T15:06:03Z

Roukoz Abou Karam: /* In progress chapters */

__NOTOC__

{{CMG}}; {{AE}} {{Hudakarman}}
{{Organ System Project}}
System leader: '''[[User:Roukoz Abou Karam|Roukoz Abou Karam, M.D.]]'''
==Status Updates==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Resident survival guide Progress
|-
|Completed
|9
|-
|In progress
|1
|-
|Remaining
|2
|-
! colspan="2" style="background:#efefef;" |Primary care chapter Progress
|-
|Completed
|6
|-
|In progress
|5
|-
|Remaining
|0
|}

==Primary Care Topics==

{| class="wikitable sortable"
! colspan="4" |Primary care chapters
! colspan="3" |Primary care resident survival guides
|-
!Specialty
!Topic
!Author
!Status
!Resident Survival Guide Page
!Author
!Status
|-
|Pulmonary||[[Asthma|Asthma exacerbation]]
|
|Complete||[[Asthma exacerbation resident survival guide]]||Abdurahman, Vidit||Complete
|-
|Pulmonary||[[Chronic obstructive pulmonary disease|COPD exacerbation]]
|Roukoz Abou Karam
|Complete||[[COPD exacerbation resident survival guide]]|| ||Complete
|-
|Pulmonary
|[[Cough]]
|Abiodun Akanmode
|Complete
|[[Cough resident survival guide]]
|Sara Haddadi
|In progress
|-
|Pulmonary
|[[Dyspnea]]
|Roukoz Abou Karam
|In progress
|[[Dyspnea resident survival guide]]
|Eiman
|Needs review
|-
|Pulmonary
|[[Chest pain]]
|Aisha Adigun
|Complete
|[[Chest pain resident survival guide]]
|
|Complete
|-
|Pulmonary
|[[Hemoptysis]]
|
|Complete
|[[Hemoptysis resident survival guide]]
|Teresa
|Complete
|-
|Pulmonary||[[Anaphylaxis]]
|Dushka Riaz
|Complete||[[Anaphylaxis resident survival guide]]||Vidit||Complete
|-
|Pulmonary||[[Acute respiratory distress syndrome]]
|Roukoz Abou Karam
|Complete||[[Acute respiratory distress syndrome resident survival guide]]||Ayokunle||Complete
|-
|Pulmonary||[[Pleural effusion]]
|Dushka Riaz
|Complete||[[Pleural effusion resident survival guide]]||Twinkle||Complete
|-
|Pulmonary||[[Pulmonary embolism]]
|
|Complete||[[Pulmonary embolism resident survival guide]]|| ||Complete
|-
|Pulmonary
|[[Lung mass]]
|
|Complete
|[[Lung mass resident survival guide]]
|Akshun Kalia
|Complete
|} 

==Status Update==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Progress
|-
|Completed
|41
|-
|In progress
|9
|-
|Remaining
|20
|}
==List of Chapters Requiring Content==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="21" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonolgy
| style="padding: 5px 5px; background: #F5F5F5;" |[[Amniotic fluid embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchoscopy]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hepatopulmonary syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hydrothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |in progress
| style="padding: 5px 5px; background: #F5F5F5;" |Kunwardeep
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hypoxemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Mediastinal disorders
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mediastinal mass|Mediastinal masses]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Pleural disorders
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pleural plaque]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pleurodynia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Pressure associated lung diseases
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Altitude sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Barotrauma]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Nitrogen narcosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary function tests]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary nodule]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Idiopathic pulmonary hemosiderosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary lymphangioleiomyomatosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|}

==In progress chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="22" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonology
| style="padding: 5px 5px; background: #F5F5F5;" |[[Decompression sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Hazem
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Air embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mounika Lakumalla
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmed Elsaiey
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hepatopulmonary syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Soroush
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Tracheitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dushka
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumoconiosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dushka
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Berylliosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Omid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Farmer's lung]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Aisha
| style="padding: 5px 5px; background: #F5F5F5;" |Ali Musadiq
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Decompression sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Jaspinder Kaur
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmed Elsaiey
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Chylothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Joanna Ekabua
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz Abou Karam
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Thoracentesis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ayeesha
| style="padding: 5px 5px; background: #F5F5F5;" |Ali Musadiq
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Flock worker's lung]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usman Shah
| style="padding: 5px 5px; background: #F5F5F5;" |Sara Mohsin
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-

|}

==Completed chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="45" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonology
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cystic fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Shamila
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary hypertension]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ajay
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory failure]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Khurram/Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary edema]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Famaz/Manpreet
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Neurogenic pulmonary edema]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Shamila
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchiectasis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hemoptysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Occupational lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Restrictive lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Obstructive lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Interstitial lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf/Anmol
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Idiopathic pulmonary fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmad E
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary alveolar proteinosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mahda
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cryptogenic organizing pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Manpreet
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Interstitial pneumonitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Chandra
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Small cell lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mesothelioma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mazia/feham/fatima
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid/Fehman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hypersensitivity pneumonitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sargun
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Non small cell lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mohsin
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Adenocarcinoma of the lung|Adenocarcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sudarshana
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Large cell carcinoma of the lung|Large cell carcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Aditiya
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Squamous cell carcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lung mass]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Akshun
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cyanosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Chandra/Medhat/Amandeep
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory acidosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Krishna
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory alkalosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Madhu
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Diaphragmatic paralysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mahda
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchogenic cyst]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Joanna Ekabua
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Eosinophilic pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Medhat
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Fat embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Fehman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mechanical ventilation]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ajay
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Atelectasis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sudarshana
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pancoast tumor]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mazia
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Blood gas analysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Medhat
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[CO poisoning]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Fatima
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Aspiration pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory patterns]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Eiman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hyperventilation]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Amresh/Akshun/Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|}

Acute megakaryoblastic leukemia

2021-04-27T15:23:36Z

Roukoz Abou Karam: /* Diagnosis */

Acute megakaryoblastic leukemia

2021-04-27T15:22:49Z

Roukoz Abou Karam:

__NOTOC__
{{SI}}

Acute megakaryoblastic leukemia
{{CMG}}; {{AE}}

{{SK}} Leukemia, megakaryoblastic, acute; megakaryoblastic leukemia, acute; AMKL; leukemia, myeloid, acute, M7; megakaryocytic leukemia; megakaryocytic leukemia, acute; myeloid leukemia, acute, M7

==Overview==

==Historical Perspective==

==Classification==

==Pathophysiology==
*It is associated with [[GATA1]], and risks are increased in individuals with [[Down syndrome]].<ref name="pmid12586620">{{cite journal |author=Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A |title=GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome |journal=Blood |volume=101 |issue=11 |pages=4301–4 |year=2003 |pmid=12586620 |doi=10.1182/blood-2003-01-0013 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=12586620}}</ref> However, not all cases are associated with Down syndrome,<ref name="pmid18275433">{{cite journal |author=Hama A, Yagasaki H, Takahashi Y, ''et al'' |title=Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome |journal=Br. J. Haematol. |volume=140 |issue=5 |pages=552–61 |year=2008 |pmid=18275433 |doi=10.1111/j.1365-2141.2007.06971.x |url=http://dx.doi.org/10.1111/j.1365-2141.2007.06971.x}}</ref> and other [[genes]] can also be associated with AMKL.<ref name="pmid17360941">{{cite journal |author=Gu TL, Mercher T, Tyner JW, ''et al'' |title=A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia |journal=Blood |volume=110 |issue=1 |pages=323–33 |year=2007 |pmid=17360941 |doi=10.1182/blood-2006-10-052282 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=17360941}}</ref>

*According to the report of the [[French-American-British]] Cooperative Group, this category of AML (M7 subtype) is associated with 30% or more blasts in the bone marrow. Blasts are identified as being of megakaryocyte lineage by; expression of [[megakaryocyte]] specific [[antigen]]s and platelet [[peroxidase]] reaction on [[electron microscopy]].<ref name="Bennett19852">{{cite journal|last1=Bennett|first1=John M.|title=Criteria for the Diagnosis of Acute Leukemia of Megakaryocyte Lineage (M7)|journal=Annals of Internal Medicine|volume=103|issue=3|year=1985|pages=460|issn=0003-4819|doi=10.7326/0003-4819-103-3-460}}</ref>

*[[Myelofibrosis]] is usually associated with AMKL; however, the exact underlying pathophysiology is controversial. The investigators did not find any direct correlation between acute myelofibrosis and the [[fibroblasts]] obtained from the bone marrow of patients with AMKL. Nevertheless, it was proposed that some humoral factors may play a key role in developing bone marrow fibrosis.<ref name="ClareElson1982">{{cite journal|last1=Clare|first1=Nanette|last2=Elson|first2=David|last3=Manhoff|first3=Louis|title=Cytogenetic Studies of Peripheral Myeloblasts and Bone Marrow Fibroblasts in Acute Myelofibrosis|journal=American Journal of Clinical Pathology|volume=77|issue=6|year=1982|pages=762–766|issn=0002-9173|doi=10.1093/ajcp/77.6.762}}</ref>

*[[Transforming Growth Factor-β]] (TG-β) was identified to be the significant contributor in AMKL associated myelofibrosis in addition to some other unknown factors due to the strong stimulatory effects on [[collagen]].<ref name="TeruiNiitsu1990">{{cite journal|last1=Terui|first1=T|last2=Niitsu|first2=Y|last3=Mahara|first3=K|last4=Fujisaki|first4=Y|last5=Urushizaki|first5=Y|last6=Mogi|first6=Y|last7=Kohgo|first7=Y|last8=Watanabe|first8=N|last9=Ogura|first9=M|last10=Saito|first10=H|title=The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis|journal=Blood|volume=75|issue=7|year=1990|pages=1540–1548|issn=0006-4971|doi=10.1182/blood.V75.7.1540.1540}}</ref>

==Causes==

==Differentiating [disease name] from other Diseases==

Distinguishing features from other subtypes of AML are following:

*[[Thrombocytopenia]] is more common and severe in AMKL compared with [[myelodysplastic syndrome]] (MDS). Blast cells in the bone marrow are <30% in MDS versus >30% in AMKL.<ref name="ZipurskyThorner1994">{{cite journal|last1=Zipursky|first1=A.|last2=Thorner|first2=P.|last3=De Harven|first3=E.|last4=Christensen|first4=H.|last5=Doyle|first5=J.|title=Myelodysplasia and acute megakaryoblastic leukemia in down's syndrome|journal=Leukemia Research|volume=18|issue=3|year=1994|pages=163–171|issn=01452126|doi=10.1016/0145-2126(94)90111-2}}</ref>
*Presence of megakaryocytic specific antigens ([[CD41,]] [[CD61]])<ref name="O Olatunji2018">{{cite journal|last1=O Olatunji|first1=Philip|title=A case of acute megakaryoblastic leukaemia (FAB M7), a rare type of acute myeloid leukemia (AML), in a teenager|journal=Malawi Medical Journal|volume=30|issue=4|year=2018|pages=298|issn=1995-7262|doi=10.4314/mmj.v30i4.15}}</ref> and markers ([[glycoprotein 1b]]) and platelets [[peroxidase]] activity. [[Karyotype]] analysis also helpful due to its complex and unusual karyotypic presentation (t(1;22)(p13;q13).<ref name="DöhnerEstey2010">{{cite journal|last1=Döhner|first1=Hartmut|last2=Estey|first2=Elihu H.|last3=Amadori|first3=Sergio|last4=Appelbaum|first4=Frederick R.|last5=Büchner|first5=Thomas|last6=Burnett|first6=Alan K.|last7=Dombret|first7=Hervé|last8=Fenaux|first8=Pierre|last9=Grimwade|first9=David|last10=Larson|first10=Richard A.|last11=Lo-Coco|first11=Francesco|last12=Naoe|first12=Tomoki|last13=Niederwieser|first13=Dietger|last14=Ossenkoppele|first14=Gert J.|last15=Sanz|first15=Miguel A.|last16=Sierra|first16=Jorge|last17=Tallman|first17=Martin S.|last18=Löwenberg|first18=Bob|last19=Bloomfield|first19=Clara D.|title=Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet|journal=Blood|volume=115|issue=3|year=2010|pages=453–474|issn=0006-4971|doi=10.1182/blood-2009-07-235358}}</ref><ref name="De MarchiAraki2019">{{cite journal|last1=De Marchi|first1=Federico|last2=Araki|first2=Marito|last3=Komatsu|first3=Norio|title=Molecular features, prognosis, and novel treatment options for pediatric acute megakaryoblastic leukemia|journal=Expert Review of Hematology|volume=12|issue=5|year=2019|pages=285–293|issn=1747-4086|doi=10.1080/17474086.2019.1609351}}</ref>

===Differential Diagnoses:<ref name="DöhnerEstey20105">{{cite journal|last1=Döhner|first1=Hartmut|last2=Estey|first2=Elihu H.|last3=Amadori|first3=Sergio|last4=Appelbaum|first4=Frederick R.|last5=Büchner|first5=Thomas|last6=Burnett|first6=Alan K.|last7=Dombret|first7=Hervé|last8=Fenaux|first8=Pierre|last9=Grimwade|first9=David|last10=Larson|first10=Richard A.|last11=Lo-Coco|first11=Francesco|last12=Naoe|first12=Tomoki|last13=Niederwieser|first13=Dietger|last14=Ossenkoppele|first14=Gert J.|last15=Sanz|first15=Miguel A.|last16=Sierra|first16=Jorge|last17=Tallman|first17=Martin S.|last18=Löwenberg|first18=Bob|last19=Bloomfield|first19=Clara D.|title=Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet|journal=Blood|volume=115|issue=3|year=2010|pages=453–474|issn=0006-4971|doi=10.1182/blood-2009-07-235358}}</ref>===

====[[Acute myeloid leukemia]] otherwise not specified as per WHO classification:====

#''Acute myeloid leukemia with minimal differentiation''
#''Acute myeloid leukemia without maturation''
#''Acute myeloid leukemia with maturation''
#''Acute myelomonocytic leukemia''
#''Acute monoblastic/monocytic leukemia''
#'' Acute erythroid leukemia''
#''Pure erythroid leukemia''
#''Erythroleukemia, erythroid/myeloid''
#'' Acute basophilic leukemia''
#''Acute panmyelosis with myelofibrosis (a.k.a acute myelofibrosis)''

==Epidemiology and Demographics==

* AMKL is the most common subtype of AML reported in [[Down syndrome]] patients.<ref name="XavierGe2009">{{cite journal|last1=Xavier|first1=Ana C.|last2=Ge|first2=Yubin|last3=Taub|first3=Jeffrey W.|title=Down Syndrome and Malignancies: A Unique Clinical Relationship|journal=The Journal of Molecular Diagnostics|volume=11|issue=5|year=2009|pages=371–380|issn=15251578|doi=10.2353/jmoldx.2009.080132}}</ref> It is more common in children compared with adults. The [[prevalence]] in children and adults is ~15% and 0.6%, respectively.<ref name="XavierGe20092">{{cite journal|last1=Xavier|first1=Ana C.|last2=Ge|first2=Yubin|last3=Taub|first3=Jeffrey W.|title=Down Syndrome and Malignancies: A Unique Clinical Relationship|journal=The Journal of Molecular Diagnostics|volume=11|issue=5|year=2009|pages=371–380|issn=15251578|doi=10.2353/jmoldx.2009.080132}}</ref><ref name="PaganoPulsoni2002">{{cite journal|last1=Pagano|first1=L|last2=Pulsoni|first2=A|last3=Vignetti|first3=M|last4=Mele|first4=L|last5=Fianchi|first5=L|last6=Petti|first6=MC|last7=Mirto|first7=S|last8=Falcucci|first8=P|last9=Fazi|first9=P|last10=Broccia|first10=G|last11=Specchia|first11=G|last12=Di Raimondo|first12=F|last13=Pacilli|first13=L|last14=Leoni|first14=P|last15=Ladogana|first15=S|last16=Gallo|first16=E|last17=Venditti|first17=A|last18=Avanzi|first18=G|last19=Camera|first19=A|last20=Liso|first20=V|last21=Leone|first21=G|last22=Mandelli|first22=F|title=Acute megakaryoblastic leukemia: experience of GIMEMA trials|journal=Leukemia|volume=16|issue=9|year=2002|pages=1622–1626|issn=0887-6924|doi=10.1038/sj.leu.2402618}}</ref>

*Down syndrome patients carry a 200 fold increased risk of developing AMKL vs. non-Down syndrome patients.<ref name="ZipurskyPeeters20092">{{cite journal|last1=Zipursky|first1=Alvin|last2=Peeters|first2=Marie|last3=Poon|first3=Annette|title=Megakaryoblastic Leukemia and Down's Syndrome: A Review|journal=Pediatric Hematology and Oncology|volume=4|issue=3|year=2009|pages=211–230|issn=0888-0018|doi=10.3109/08880018709141272}}</ref> Similarly, another review proposed a 500 fold increased risk.<ref name="AthaleRazzouk2001">{{cite journal|last1=Athale|first1=Uma H.|last2=Razzouk|first2=Bassem I.|last3=Raimondi|first3=Susana C.|last4=Tong|first4=Xin|last5=Behm|first5=Frederick G.|last6=Head|first6=David R.|last7=Srivastava|first7=Deo K.|last8=Rubnitz|first8=Jeffrey E.|last9=Bowman|first9=Laura|last10=Pui|first10=Ching-Hon|last11=Ribeiro|first11=Raul C.|title=Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience|journal=Blood|volume=97|issue=12|year=2001|pages=3727–3732|issn=1528-0020|doi=10.1182/blood.V97.12.3727}}</ref> It almost exclusively occurs in the first 3 years of life.<ref name="XavierGe20094">{{cite journal|last1=Xavier|first1=Ana C.|last2=Ge|first2=Yubin|last3=Taub|first3=Jeffrey W.|title=Down Syndrome and Malignancies: A Unique Clinical Relationship|journal=The Journal of Molecular Diagnostics|volume=11|issue=5|year=2009|pages=371–380|issn=15251578|doi=10.2353/jmoldx.2009.080132}}</ref><ref name="ZipurskyPeeters20094">{{cite journal|last1=Zipursky|first1=Alvin|last2=Peeters|first2=Marie|last3=Poon|first3=Annette|title=Megakaryoblastic Leukemia and Down's Syndrome: A Review|journal=Pediatric Hematology and Oncology|volume=4|issue=3|year=2009|pages=211–230|issn=0888-0018|doi=10.3109/08880018709141272}}</ref>
*[[Transient leukemia]] (TL) occurs in approximately 10% of Down syndrome infants, which is also attributed to transient [[myeloproliferative disorder]].<ref name="Zipursky2003">{{cite journal|last1=Zipursky|first1=Alvin|title=Transient leukaemia - a benign form of leukaemia in newborn infants with trisomy 21|journal=British Journal of Haematology|volume=120|issue=6|year=2003|pages=930–938|issn=00071048|doi=10.1046/j.1365-2141.2003.04229.x}}</ref><ref name="PineGuo2007">{{cite journal|last1=Pine|first1=Sharon R.|last2=Guo|first2=Qianxu|last3=Yin|first3=Changhong|last4=Jayabose|first4=Somasundaram|last5=Druschel|first5=Charlotte M.|last6=Sandoval|first6=Claudio|title=Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome|journal=Blood|volume=110|issue=6|year=2007|pages=2128–2131|issn=0006-4971|doi=10.1182/blood-2007-01-069542}}</ref> In most cases, TL spontaneously resolves; however, during the first four years of life, it progresses to acute megakaryoblastic leukemia in 13% to 33% of patients.<ref name="KlusmannCreutzig2008">{{cite journal|last1=Klusmann|first1=Jan-Henning|last2=Creutzig|first2=Ursula|last3=Zimmermann|first3=Martin|last4=Dworzak|first4=Michael|last5=Jorch|first5=Norbert|last6=Langebrake|first6=Claudia|last7=Pekrun|first7=Arnulf|last8=Macakova-Reinhardt|first8=Katarina|last9=Reinhardt|first9=Dirk|title=Treatment and prognostic impact of transient leukemia in neonates with Down syndrome|journal=Blood|volume=111|issue=6|year=2008|pages=2991–2998|issn=0006-4971|doi=10.1182/blood-2007-10-118810}}</ref>

==Risk Factors==
*Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

== Natural History, Complications and Prognosis==
Due to the rarity of this subtype of hematological malignancy, limited data is available on the natural course or [[prognosis]].

*Clonal proliferation of early [[megakaryoblasts]] in the bone marrow results in acute megakaryoblastic leukemia (AMKL).<ref name="pmid11001891">{{cite journal| author=Tallman MS, Neuberg D, Bennett JM, Francois CJ, Paietta E, Wiernik PH | display-authors=etal| title=Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. | journal=Blood | year= 2000 | volume= 96 | issue= 7 | pages= 2405-11 | pmid=11001891 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11001891 }}</ref> It has a bimodal onset of presentation—occurs both in the pediatric age group (<4 years) and adults.<ref name="GassmannLöffler2009">{{cite journal|last1=Gassmann|first1=Winfried|last2=Löffler|first2=Helmut|title=Acute Megakaryoblastic Leukemia|journal=Leukemia & Lymphoma|volume=18|issue=sup1|year=2009|pages=69–73|issn=1042-8194|doi=10.3109/10428199509075307}}</ref>
*In childhood, it is more prevalent in patients with Down syndrome. While it is rare in adults, approximately 0.6% (24/3603) reported in the [[GIMEMA trial]].<ref name="PaganoPulsoni2002">{{cite journal|last1=Pagano|first1=L|last2=Pulsoni|first2=A|last3=Vignetti|first3=M|last4=Mele|first4=L|last5=Fianchi|first5=L|last6=Petti|first6=MC|last7=Mirto|first7=S|last8=Falcucci|first8=P|last9=Fazi|first9=P|last10=Broccia|first10=G|last11=Specchia|first11=G|last12=Di Raimondo|first12=F|last13=Pacilli|first13=L|last14=Leoni|first14=P|last15=Ladogana|first15=S|last16=Gallo|first16=E|last17=Venditti|first17=A|last18=Avanzi|first18=G|last19=Camera|first19=A|last20=Liso|first20=V|last21=Leone|first21=G|last22=Mandelli|first22=F|title=Acute megakaryoblastic leukemia: experience of GIMEMA trials|journal=Leukemia|volume=16|issue=9|year=2002|pages=1622–1626|issn=0887-6924|doi=10.1038/sj.leu.2402618}}</ref>
*Cases of AMKL secondary to [[chronic myelogenous leukemia]] and [[essential thrombocytosis]] have been reported in the medical literature.<ref>{{cite journal|journal=ecancermedicalscience|issn=17546605|doi=10.3332/ecancer.2013.375}}</ref><ref name="RadaelliMazza2002">{{cite journal|last1=Radaelli|first1=Franca|last2=Mazza|first2=Rita|last3=Curioni|first3=Elisabetta|last4=Ciani|first4=Alberto|last5=Pomati|first5=Mauro|last6=Maiolo|first6=Anna-Teresa|title=Acute megakaryocytic leukemia in essential thrombocythemia: an unusual evolution?|journal=European Journal of Haematology|volume=69|issue=2|year=2002|pages=108–111|issn=09024441|doi=10.1034/j.1600-0609.2002.02734.x}}</ref>

==Complications==

#Periorbital swelling
#[[Periosteal elevation]]
#Osteolytic lesions, especially in long bones, e.g., femur<ref name="AthaleKaste2002">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref>
#[[Osteoporosis]] with pathologic fractures<ref name="AthaleKaste20022">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref><ref name="KushnerWeinstein1980">{{cite journal|last1=Kushner|first1=David C.|last2=Weinstein|first2=Howard J.|last3=Kirkpatrick|first3=John A.|title=The radiologic diagnosis of leukemia and lymphoma in children|journal=Seminars in Roentgenology|volume=15|issue=4|year=1980|pages=316–334|issn=0037198X|doi=10.1016/0037-198X(80)90027-9}}</ref>
#[[Sweet syndrome]] (SS)<ref name="pmid8479086">{{cite journal| author=Yokoyama K, Kojima M, Komatsumoto S, Nara M, Ohyashiki K, Ikeda Y | display-authors=etal| title=[Acute megakaryoblastic leukemia associated with Sweet's syndrome, including review of the literature]. | journal=Rinsho Ketsueki | year= 1993 | volume= 34 | issue= 3 | pages= 341-7 | pmid=8479086 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8479086 }}</ref>
#[[Leukemia cutis]]<ref name="pmid1758056">{{cite journal| author=Tsurumi H, Takahashi T, Koshino Y, Oyama M, Matsutomo K, Yasuda M | display-authors=etal| title=[Acute megakaryoblastic leukemia with leukemia cutis, meningeal leukemia, and myelofibrosis]. | journal=Rinsho Ketsueki | year= 1991 | volume= 32 | issue= 11 | pages= 1475-80 | pmid=1758056 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1758056 }}</ref>
#[[Hypercalcemia]]<ref name="pmid19415024">{{cite journal| author=Qayed M, Ahmed I, Valentini RP, Cushing B, Rajpurkar M| title=Hypercalcemia in pediatric acute megakaryocytic leukemia: case report and review of the literature. | journal=J Pediatr Hematol Oncol | year= 2009 | volume= 31 | issue= 5 | pages= 373-6 | pmid=19415024 | doi=10.1097/MPH.0b013e31819a5d29 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19415024 }}</ref>

==Prognosis==
Apart from AMKL in [[Down syndrome]] patients, the prognosis of AMKL is poor. The efficacy profile of AMKL in Down syndrome patients is favorable, but it comes with a lot of treatment-related toxicity.

*According to the Children’s Oncology Group (COG) AML0431 trial results, the 5-year event-free survival and [[overall survival]] rates were 90% and 93% in 204 eligible Down syndrome with AMKL patients.<ref name="TaubBerman2017">{{cite journal|last1=Taub|first1=Jeffrey W.|last2=Berman|first2=Jason N.|last3=Hitzler|first3=Johann K.|last4=Sorrell|first4=April D.|last5=Lacayo|first5=Norman J.|last6=Mast|first6=Kelley|last7=Head|first7=David|last8=Raimondi|first8=Susana|last9=Hirsch|first9=Betsy|last10=Ge|first10=Yubin|last11=Gerbing|first11=Robert B.|last12=Wang|first12=Yi-Cheng|last13=Alonzo|first13=Todd A.|last14=Campana|first14=Dario|last15=Coustan-Smith|first15=Elaine|last16=Mathew|first16=Prasad|last17=Gamis|first17=Alan S.|title=Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial|journal=Blood|volume=129|issue=25|year=2017|pages=3304–3313|issn=0006-4971|doi=10.1182/blood-2017-01-764324}}</ref>

*Similarly, the reported 3-year overall survival rate was 100% among 3 AMKL with Down syndrome patients while (47±12%) in non-Down syndrome patients.<ref name="QiMao2020">{{cite journal|last1=Qi|first1=Haixiao|last2=Mao|first2=Yan|last3=Cao|first3=Qian|last4=Sun|first4=Xingzhen|last5=Kuai|first5=Wenxia|last6=Song|first6=Junhong|last7=Ma|first7=Li|last8=Hong|first8=Ze|last9=Hu|first9=Jian|last10=Zhou|first10=Guoping|title=Clinical Characteristics and Prognosis of 27 Patients with Childhood Acute Megakaryoblastic Leukemia|journal=Medical Science Monitor|volume=26|year=2020|issn=1643-3750|doi=10.12659/MSM.922662}}</ref>

*The 5-year overall survival rate in AMKL was 10.6% versus 17.5% in non-M7 [[Acute Myeloid leukemia|Acute myeloid leukemia]] subtypes.<ref name="GiriPathak2014">{{cite journal|last1=Giri|first1=Smith|last2=Pathak|first2=Ranjan|last3=Prouet|first3=Philippe|last4=Li|first4=Bojia|last5=Martin|first5=Mike G.|title=Acute megakaryocytic leukemia is associated with worse outcomes than other types of acute myeloid leukemia|journal=Blood|volume=124|issue=25|year=2014|pages=3833–3834|issn=0006-4971|doi=10.1182/blood-2014-09-603415}}</ref> Currently, [[chemotherapy]] and [[Allo-BMT|allogenic bone marrow transplant]] (Allo-BMT) are main therapy. Treatment-related toxicity is a big challenge. To address this issue, elaborated large future clinical studies are required.

== Diagnosis ==
===Diagnostic Criteria===

=== History and Symptoms ===

*[[Acute megakaryoblastic leukemia]] (AMKL) has a wide array of presentations. The onset is either acute or insidious. The degree of [[pancytopenia]] varies among patients.<ref name="pmid2978961">{{cite journal| author=Zipursky A, Peeters M, Poon A| title=Megakaryoblastic leukemia and Down's syndrome: a review. | journal=Pediatr Hematol Oncol | year= 1987 | volume= 4 | issue= 3 | pages= 211-30 | pmid=2978961 | doi=10.3109/08880018709141272 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2978961 }}</ref> Other features include [[fever]], irritability, [[headache]], fatigue, bone pain,<ref name="pmid12749007">{{cite journal| author=Paredes-Aguilera R, Romero-Guzman L, Lopez-Santiago N, Trejo RA| title=Biology, clinical, and hematologic features of acute megakaryoblastic leukemia in children. | journal=Am J Hematol | year= 2003 | volume= 73 | issue= 2 | pages= 71-80 | pmid=12749007 | doi=10.1002/ajh.10320 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12749007 }}</ref> [[hepatosplenomegaly]] (HSM), and [[lymphadenopathy]],<ref name="JayasudhaNair2014">{{cite journal|last1=Jayasudha|first1=A. V.|last2=Nair|first2=Rekha A.|last3=Jacob|first3=Priya Mary|last4=Renu|first4=S.|last5=Anila|first5=K. R.|last6=Sindhu Nair|first6=P.|last7=Priya Kumari|first7=T.|last8=Kusuma Kumary|first8=P.|title=Clinical and Hematological Profile of Acute Megakaryoblastic Leukemia: A 2 Year Study|journal=Indian Journal of Hematology and Blood Transfusion|volume=31|issue=2|year=2014|pages=169–173|issn=0971-4502|doi=10.1007/s12288-014-0413-1}}</ref><ref name="AthaleKaste2002">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref> pallor, generalized pain, temporal swelling, [[bruising]], and difficulty walking.<ref name="AthaleKaste20023">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref>

*Greater than 50% of [[leukemia]] patients demonstrate skeletal features and are mostly related to the AMKL subtype.<ref name="AthaleKaste20024">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref>

=== Physical Examination ===

*Physical exam findings include:<ref name="AthaleKaste2002">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref><ref name="Paredes-AguileraRomero-Guzman2003">{{cite journal|last1=Paredes-Aguilera|first1=Rogelio|last2=Romero-Guzman|first2=Lina|last3=Lopez-Santiago|first3=Norma|last4=Trejo|first4=Rosa Arana|title=Biology, clinical, and hematologic features of acute megakaryoblastic leukemia in children|journal=American Journal of Hematology|volume=73|issue=2|year=2003|pages=71–80|issn=0361-8609|doi=10.1002/ajh.10320}}</ref>

[[Down syndrome]] features are present in patients with Down syndrome associated AMKL.

=== Laboratory Findings ===

The diagnosis of AMKL (M7) is based on the following:

#[[Bone marrow]] [[biopsy]] demonstrating 30% or more leukemic cells of megakaryocytic lineage
#Conducting tests that detect [[platelet-specific antibodies]] which could be [[monoclonal]] or [[polyclonal]].
#Bone marrow biopsy is recommended in patients who developed [[myelofibrosis]]. Visualization of blasts and mature megakaryocytes on biopsy sections is diagnostic.

===Electrocardiogram===
There are no ECG findings associated with

===X-ray===

===Echocardiography or Ultrasound===

===CT scan===

===MRI===

===Other Imaging Findings===

===Other Diagnostic Studies===
*In adults, the features include
**[[Pancytopenia]] with low [[blast]] counts in the blood
**[[Myelofibrosis]]
**An absence of [[lymphadenopathy]] and [[hepatosplenomegaly]]
**Poor response to [[chemotherapy]],and short clinical course.

*In children, the same clinical presentation but with variable course especially in very young children; both [[leukocytosis]] and [[organomegaly]] may be present in children with M7. Complete remission and long term survival are more common in children than adults.

*The morphology of cells was observed by means of Bone marrow smear
*The [[immunophenotype]] was detected by [[flow cytometry]] and [[immunohistochemistry]] assay.<ref name="pmid17605859">{{cite journal |author=Lei Q, Liu Y, Tang SQ |title=[Childhood acute megakaryoblastic leukemia] |language=Chinese |journal=Zhongguo Shi Yan Xue Ye Xue Za Zhi |volume=15 |issue=3 |pages=528-32 |year=2007 |pmid=17605859 |doi=}}</ref>

*In blood and bone marrow smears megakaryoblasts are usually medium sized to large cells with a high nuclear- cytoplasmic ratio. Nuclear [[chromatin]] is dense and homogeneous. There is scanty, variable basophilic cytoplasm which may be vacuolated. An irregular cytoplasmic border is often noted in some of the [[megakaryoblasts]] and occasionally projections resembling budding atypical platelets are present. The megakaryoblasts lack [[myeloperoxidase]] activity and stain negatively with [[Sudan black B]] (SBB).

*They are alpha [[naphthyl butyrate esterase]] negative and manifest variable alpha naphthyl acetate esterase activity usually in scattered clumps or granules in the cytoplasm. [[PAS]] staining also varies from negative to focal or granular positivity, to strongly positive staining.

*A marrow aspirate is difficult to obtain in many cases because of variable degree of [[myelofibrosis]].

*More precise identification by immunophenotyping or with [[electron microscopy]] (EM). [[Immunophenotyping]] using MoAb to megakaryocyte restricted antigen (CD41 and CD61) may be diagnostic.<ref name="pmid12239137">{{cite journal |author=Vardiman JW, Harris NL, Brunning RD |title=The World Health Organization (WHO) classification of the myeloid neoplasms |journal=[[Blood]] |volume=100 |issue=7 |pages=2292-302 |year=2002 |pmid=12239137 |doi=10.1182/blood-2002-04-1199 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=12239137}}</ref>

===Karyotype analysis:===

*It is essential owing to the fact that AMKL has complex [[karyotype]] with peculiar presentation (t(1;22)(p13;q13).<ref name="DöhnerEstey2010">{{cite journal|last1=Döhner|first1=Hartmut|last2=Estey|first2=Elihu H.|last3=Amadori|first3=Sergio|last4=Appelbaum|first4=Frederick R.|last5=Büchner|first5=Thomas|last6=Burnett|first6=Alan K.|last7=Dombret|first7=Hervé|last8=Fenaux|first8=Pierre|last9=Grimwade|first9=David|last10=Larson|first10=Richard A.|last11=Lo-Coco|first11=Francesco|last12=Naoe|first12=Tomoki|last13=Niederwieser|first13=Dietger|last14=Ossenkoppele|first14=Gert J.|last15=Sanz|first15=Miguel A.|last16=Sierra|first16=Jorge|last17=Tallman|first17=Martin S.|last18=Löwenberg|first18=Bob|last19=Bloomfield|first19=Clara D.|title=Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet|journal=Blood|volume=115|issue=3|year=2010|pages=453–474|issn=0006-4971|doi=10.1182/blood-2009-07-235358}}</ref><ref name="De MarchiAraki2019">{{cite journal|last1=De Marchi|first1=Federico|last2=Araki|first2=Marito|last3=Komatsu|first3=Norio|title=Molecular features, prognosis, and novel treatment options for pediatric acute megakaryoblastic leukemia|journal=Expert Review of Hematology|volume=12|issue=5|year=2019|pages=285–293|issn=1747-4086|doi=10.1080/17474086.2019.1609351}}</ref>

===Radiographic features:===

*Using [[Chest X-ray]] ('''CXR'''), '''[[skeletal survey]]''', '''[[CT scan]]''', and '''[[bone scan]]''' are:
*Osteolytic lesions in the ribs, diffuse [[metaphysical lucency]], [[periostitis]] with periosteal reaction, and pathologic fractures involving long bones, such as femoral bones, and increase uptake in the involved bones.<ref name="AthaleKaste2002">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref>

== Treatment ==
=== Medical Therapy ===
*According to the AML-BFM (Berlin–Frankfurt–Münster) 98 and AML-BFM ((Berlin–Frankfurt–Münster) 93 clinical studies, intensive AML targeted [[chemotherapy]] in Down syndrome-associated AMKL results in high event-free survival rates versus non-Down syndrome patients. However, they are also prone to develop treatment-related toxicity at standard doses due to chemo sensitivity.<ref name="CreutzigReinhardt2005">{{cite journal|last1=Creutzig|first1=U|last2=Reinhardt|first2=D|last3=Diekamp|first3=S|last4=Dworzak|first4=M|last5=Stary|first5=J|last6=Zimmermann|first6=M|title=AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity|journal=Leukemia|volume=19|issue=8|year=2005|pages=1355–1360|issn=0887-6924|doi=10.1038/sj.leu.2403814}}</ref>

The treatment is divided into [[induction therapy]] and [[consolidation]] therapy.

*'''Induction therapy''' — involves two cycles (four weeks apart ) of [[Cytarabine|Ara-Cytarabine]] (Ara-C) at 100 mg/m2 /day continuous infusion for 7 days, [[vincristine]] at 0.7 mg/m2 on day 7, and [[pirarubicin]] at 25 mg/m2 by 60 min infusion on days 2, and 4 (AVC1).<ref name="TagaShimomura2011">{{cite journal|last1=Taga|first1=Takashi|last2=Shimomura|first2=Yasuto|last3=Horikoshi|first3=Yasuo|last4=Ogawa|first4=Atsushi|last5=Itoh|first5=Masaki|last6=Okada|first6=Masahiko|last7=Ueyama|first7=Junichi|last8=Higa|first8=Takeshi|last9=Watanabe|first9=Arata|last10=Kanegane|first10=Hirokazu|last11=Iwai|first11=Asayuki|last12=Saiwakawa|first12=Yutaka|last13=Kogawa|first13=Kazuhiro|last14=Yamanaka|first14=Junko|last15=Tsurusawa|first15=Masahito|title=Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study|journal=Pediatric Blood & Cancer|volume=57|issue=1|year=2011|pages=36–40|issn=15455009|doi=10.1002/pbc.22943}}</ref>
*'''Consolidation therapy''' — follows once complete remission is achieved with the following regimen; [[etoposide]] & high-dose Ara-C (EC), [[mitoxantrone]] and continuous-dose Ara-C (MC), and pirarubicin, vincristine, and continuous-dose Ara-C (AVC2).<ref name="TagaShimomura20112">{{cite journal|last1=Taga|first1=Takashi|last2=Shimomura|first2=Yasuto|last3=Horikoshi|first3=Yasuo|last4=Ogawa|first4=Atsushi|last5=Itoh|first5=Masaki|last6=Okada|first6=Masahiko|last7=Ueyama|first7=Junichi|last8=Higa|first8=Takeshi|last9=Watanabe|first9=Arata|last10=Kanegane|first10=Hirokazu|last11=Iwai|first11=Asayuki|last12=Saiwakawa|first12=Yutaka|last13=Kogawa|first13=Kazuhiro|last14=Yamanaka|first14=Junko|last15=Tsurusawa|first15=Masahito|title=Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study|journal=Pediatric Blood & Cancer|volume=57|issue=1|year=2011|pages=36–40|issn=15455009|doi=10.1002/pbc.22943}}</ref>

The doses are given below:<ref name="TagaShimomura20113">{{cite journal|last1=Taga|first1=Takashi|last2=Shimomura|first2=Yasuto|last3=Horikoshi|first3=Yasuo|last4=Ogawa|first4=Atsushi|last5=Itoh|first5=Masaki|last6=Okada|first6=Masahiko|last7=Ueyama|first7=Junichi|last8=Higa|first8=Takeshi|last9=Watanabe|first9=Arata|last10=Kanegane|first10=Hirokazu|last11=Iwai|first11=Asayuki|last12=Saiwakawa|first12=Yutaka|last13=Kogawa|first13=Kazuhiro|last14=Yamanaka|first14=Junko|last15=Tsurusawa|first15=Masahito|title=Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study|journal=Pediatric Blood & Cancer|volume=57|issue=1|year=2011|pages=36–40|issn=15455009|doi=10.1002/pbc.22943}}</ref>

'''''MC regimen:'''''

*Ara-C at 100 mg/m2 /day continuous infusion for 5 days and
*Mitoxantrone at 3.5 mg/m2 by 60 min infusion on days 2–4

'''''EC regimen'''''

*High-dose Ara-C 1 g/m2 every 12 hrs on days 1–5,
*Etoposide 66 mg/m2 by 2 h infusion on days 2–4), and

'''''AVC2 regimen'''''

*Ara-C at 100 mg/m2 /day on days 1–5,
*Pirarubicin 35 mg/m2 by 60 min infusion on day 2, and
*Vincristine at 0.7 mg/m2 on day 5

In relapsed state, re-induction with [[fludarabine]] and Ara-C combination or same AVC regimen can be utilized. Allogenic bone marrow transplant (Allo-BMT) from a suitable donor is justified if the patients achieved second complete remission. Currently, there is no recommended definitive therapy for non-Down syndrome with AMKL cohort. Novel therapeutic interventions are undertaken.<ref name="De MarchiAraki20192">{{cite journal|last1=De Marchi|first1=Federico|last2=Araki|first2=Marito|last3=Komatsu|first3=Norio|title=Molecular features, prognosis, and novel treatment options for pediatric acute megakaryoblastic leukemia|journal=Expert Review of Hematology|volume=12|issue=5|year=2019|pages=285–293|issn=1747-4086|doi=10.1080/17474086.2019.1609351}}</ref>

*Some study groups proposed that non-[[Down syndrome]] with AMKL is a high-risk condition; therefore, allogeneic [[hematopoietic stem cell]] transplantation (Allo-HSCT) during first complete remission is recommended to benefit the patients. In contrast, no benefit of Allo-HSCT is evident over chemotherapy without remission.<ref name="AthaleRazzouk2001">{{cite journal|last1=Athale|first1=Uma H.|last2=Razzouk|first2=Bassem I.|last3=Raimondi|first3=Susana C.|last4=Tong|first4=Xin|last5=Behm|first5=Frederick G.|last6=Head|first6=David R.|last7=Srivastava|first7=Deo K.|last8=Rubnitz|first8=Jeffrey E.|last9=Bowman|first9=Laura|last10=Pui|first10=Ching-Hon|last11=Ribeiro|first11=Raul C.|title=Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience|journal=Blood|volume=97|issue=12|year=2001|pages=3727–3732|issn=1528-0020|doi=10.1182/blood.V97.12.3727}}</ref>

*In AML-BFM 04 trial, patients were randomized to receive induction therapy with either (Ara-C), [[liposomal daunorubicin]], and etoposide (ADxE) or Ara-C, [[idarubicin]], and etoposide (AIE) regimen. Consolidation therapy with [[2-chloro-2-deoxyadenosine]] (2-CDA) and Ara-C and idarubicin was preceded by second induction therapy with HAM (high-dose Ara-C, mitoxantrone, cytarabine i.th). However, no significant results were obtained regarding event-free survival (EFS) and overall survival (OS).<ref name="SchweitzerZimmermann2015">{{cite journal|last1=Schweitzer|first1=Jana|last2=Zimmermann|first2=Martin|last3=Rasche|first3=Mareike|last4=von Neuhoff|first4=Christine|last5=Creutzig|first5=Ursula|last6=Dworzak|first6=Michael|last7=Reinhardt|first7=Dirk|last8=Klusmann|first8=Jan-Henning|title=Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial|journal=Annals of Hematology|volume=94|issue=8|year=2015|pages=1327–1336|issn=0939-5555|doi=10.1007/s00277-015-2383-2}}</ref>

=== Surgery ===

=== Prevention ===

==References==

[[Category:Hematology]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Acute megakaryoblastic leukemia overview

2021-04-26T18:48:19Z

Roukoz Abou Karam:

__NOTOC__
{{Acute megakaryoblastic leukemia}}
{{CMG}}

==Overview==

'''Acute megakaryoblastic leukemia''' (AMKL) is a form of [[leukemia]] where a majority of the blasts are [[megakaryoblastic]].<ref name="titleFinal Diagnosis -- Case 439">{{cite web |url=http://path.upmc.edu/cases/case439/dx.html |title=Final Diagnosis -- Case 439 |accessdate=2008-03-08 |format= |work=}}</ref>

This rare subtype of [[acute myeloid leukemia]] (AML) was first reported in 1931 by Von Boros and his colleagues.<ref name="OkiKantarjian2006">{{cite journal|last1=Oki|first1=Yasuhiro|last2=Kantarjian|first2=Hagop M.|last3=Zhou|first3=Xian|last4=Cortes|first4=Jorge|last5=Faderl|first5=Stefan|last6=Verstovsek|first6=Srdan|last7=O'Brien|first7=Susan|last8=Koller|first8=Charles|last9=Beran|first9=Miloslav|last10=Bekele|first10=B. Nebiyou|last11=Pierce|first11=Sherry|last12=Thomas|first12=Deborah|last13=Ravandi|first13=Farhad|last14=Wierda|first14=William G.|last15=Giles|first15=Francis|last16=Ferrajoli|first16=Alessandra|last17=Jabbour|first17=Elias|last18=Keating|first18=Michael J.|last19=Bueso-Ramos|first19=Carlos E.|last20=Estey|first20=Elihu|last21=Garcia-Manero|first21=Guillermo|title=Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center|journal=Blood|volume=107|issue=3|year=2006|pages=880–884|issn=0006-4971|doi=10.1182/blood-2005-06-2450}}</ref>

It is classified under [[Acute_myelogenous_leukemia#French-American-British_classification|M7]] in the [[French-American-British classification]].<ref name="Bennett1985">{{cite journal|last1=Bennett|first1=John M.|title=Criteria for the Diagnosis of Acute Leukemia of Megakaryocyte Lineage (M7)|journal=Annals of Internal Medicine|volume=103|issue=3|year=1985|pages=460|issn=0003-4819|doi=10.7326/0003-4819-103-3-460}}</ref> Subsequently, it was introduced in the [[WHO]] 2008 classification of myeloid neoplasms and acute leukemia.<ref name="VardimanThiele2009">{{cite journal|last1=Vardiman|first1=James W.|last2=Thiele|first2=Jüergen|last3=Arber|first3=Daniel A.|last4=Brunning|first4=Richard D.|last5=Borowitz|first5=Michael J.|last6=Porwit|first6=Anna|last7=Harris|first7=Nancy Lee|last8=Le Beau|first8=Michelle M.|last9=Hellström-Lindberg|first9=Eva|last10=Tefferi|first10=Ayalew|last11=Bloomfield|first11=Clara D.|title=The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes|journal=Blood|volume=114|issue=5|year=2009|pages=937–951|issn=0006-4971|doi=10.1182/blood-2009-03-209262}}</ref>

In the first three years of life megakaryoblastic leukemia is the most common type of leukemia in patients with [[Down syndrome]].<ref>Hitzler JK. (2007) Acute megakaryoblastic leukemia in Down syndrome. Pediatr Blood Cancer. Dec;49(7 Suppl):1066-9. PMID: 17943965. </ref>

==Historical Perspective==

==Classification==

==Pathophysiology==

==Causes==

==Differentiating Xyz from Other Diseases==

==Epidemiology and Demographics==

==Risk Factors==

==Screening==

==Natural History, Complications, and Prognosis==

==Diagnosis==
===Diagnostic Study of Choice===

===History and Symptoms===

===Physical Examination===

===Laboratory Findings===

===Electrocardiogram===

===X-ray===

===Echocardiography and Ultrasound===

===CT scan===

===MRI===

===Other Imaging Findings===

===Other Diagnostic Studies===

==Treatment==
===Medical Therapy===

=== Interventions ===

===Surgery===

===Primary Prevention===

===Secondary Prevention===
==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]

Acute megakaryoblastic leukemia surgery

2021-04-26T18:47:13Z

Roukoz Abou Karam:

__NOTOC__
{{Acute megakaryoblastic leukemia}}
{{CMG}}; {{AE}}

==Overview==
Surgical intervention is not recommended for the management of acute megakaryoblastic leukemia.

==Surgery==
Surgical intervention is not recommended for the management of acute megakaryoblastic leukemia.

==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]

Acute megakaryoblastic leukemia medical therapy

2021-04-26T18:42:30Z

Roukoz Abou Karam:

__NOTOC__
{{Acute megakaryoblastic leukemia}}
{{CMG}}; {{AE}}

==Overview==

==Medical Therapy==

*According to the AML-BFM (Berlin–Frankfurt–Münster) 98 and AML-BFM ((Berlin–Frankfurt–Münster) 93 clinical studies, intensive AML targeted [[chemotherapy]] in Down syndrome-associated AMKL results in high event-free survival rates versus non-Down syndrome patients. However, they are also prone to develop treatment-related toxicity at standard doses due to chemo sensitivity.<ref name="CreutzigReinhardt2005">{{cite journal|last1=Creutzig|first1=U|last2=Reinhardt|first2=D|last3=Diekamp|first3=S|last4=Dworzak|first4=M|last5=Stary|first5=J|last6=Zimmermann|first6=M|title=AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity|journal=Leukemia|volume=19|issue=8|year=2005|pages=1355–1360|issn=0887-6924|doi=10.1038/sj.leu.2403814}}</ref>

The treatment is divided into [[induction therapy]] and [[consolidation]] therapy.

*'''Induction therapy''' — involves two cycles (four weeks apart ) of [[Cytarabine|Ara-Cytarabine]] (Ara-C) at 100 mg/m2 /day continuous infusion for 7 days, [[vincristine]] at 0.7 mg/m2 on day 7, and [[pirarubicin]] at 25 mg/m2 by 60 min infusion on days 2, and 4 (AVC1).<ref name="TagaShimomura2011">{{cite journal|last1=Taga|first1=Takashi|last2=Shimomura|first2=Yasuto|last3=Horikoshi|first3=Yasuo|last4=Ogawa|first4=Atsushi|last5=Itoh|first5=Masaki|last6=Okada|first6=Masahiko|last7=Ueyama|first7=Junichi|last8=Higa|first8=Takeshi|last9=Watanabe|first9=Arata|last10=Kanegane|first10=Hirokazu|last11=Iwai|first11=Asayuki|last12=Saiwakawa|first12=Yutaka|last13=Kogawa|first13=Kazuhiro|last14=Yamanaka|first14=Junko|last15=Tsurusawa|first15=Masahito|title=Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study|journal=Pediatric Blood & Cancer|volume=57|issue=1|year=2011|pages=36–40|issn=15455009|doi=10.1002/pbc.22943}}</ref>
*'''Consolidation therapy''' — follows once complete remission is achieved with the following regimen; [[etoposide]] & high-dose Ara-C (EC), [[mitoxantrone]] and continuous-dose Ara-C (MC), and pirarubicin, vincristine, and continuous-dose Ara-C (AVC2).<ref name="TagaShimomura20112">{{cite journal|last1=Taga|first1=Takashi|last2=Shimomura|first2=Yasuto|last3=Horikoshi|first3=Yasuo|last4=Ogawa|first4=Atsushi|last5=Itoh|first5=Masaki|last6=Okada|first6=Masahiko|last7=Ueyama|first7=Junichi|last8=Higa|first8=Takeshi|last9=Watanabe|first9=Arata|last10=Kanegane|first10=Hirokazu|last11=Iwai|first11=Asayuki|last12=Saiwakawa|first12=Yutaka|last13=Kogawa|first13=Kazuhiro|last14=Yamanaka|first14=Junko|last15=Tsurusawa|first15=Masahito|title=Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study|journal=Pediatric Blood & Cancer|volume=57|issue=1|year=2011|pages=36–40|issn=15455009|doi=10.1002/pbc.22943}}</ref>

The doses are given below:<ref name="TagaShimomura20113">{{cite journal|last1=Taga|first1=Takashi|last2=Shimomura|first2=Yasuto|last3=Horikoshi|first3=Yasuo|last4=Ogawa|first4=Atsushi|last5=Itoh|first5=Masaki|last6=Okada|first6=Masahiko|last7=Ueyama|first7=Junichi|last8=Higa|first8=Takeshi|last9=Watanabe|first9=Arata|last10=Kanegane|first10=Hirokazu|last11=Iwai|first11=Asayuki|last12=Saiwakawa|first12=Yutaka|last13=Kogawa|first13=Kazuhiro|last14=Yamanaka|first14=Junko|last15=Tsurusawa|first15=Masahito|title=Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study|journal=Pediatric Blood & Cancer|volume=57|issue=1|year=2011|pages=36–40|issn=15455009|doi=10.1002/pbc.22943}}</ref>

'''''MC regimen:'''''

*Ara-C at 100 mg/m2 /day continuous infusion for 5 days and
*Mitoxantrone at 3.5 mg/m2 by 60 min infusion on days 2–4

'''''EC regimen'''''

*High-dose Ara-C 1 g/m2 every 12 hrs on days 1–5,
*Etoposide 66 mg/m2 by 2 h infusion on days 2–4), and

'''''AVC2 regimen'''''

*Ara-C at 100 mg/m2 /day on days 1–5,
*Pirarubicin 35 mg/m2 by 60 min infusion on day 2, and
*Vincristine at 0.7 mg/m2 on day 5

In relapsed state, re-induction with [[fludarabine]] and Ara-C combination or same AVC regimen can be utilized. Allogenic bone marrow transplant (Allo-BMT) from a suitable donor is justified if the patients achieved second complete remission. Currently, there is no recommended definitive therapy for non-Down syndrome with AMKL cohort. Novel therapeutic interventions are undertaken.<ref name="De MarchiAraki20192">{{cite journal|last1=De Marchi|first1=Federico|last2=Araki|first2=Marito|last3=Komatsu|first3=Norio|title=Molecular features, prognosis, and novel treatment options for pediatric acute megakaryoblastic leukemia|journal=Expert Review of Hematology|volume=12|issue=5|year=2019|pages=285–293|issn=1747-4086|doi=10.1080/17474086.2019.1609351}}</ref>

*Some study groups proposed that non-[[Down syndrome]] with AMKL is a high-risk condition; therefore, allogeneic [[hematopoietic stem cell]] transplantation (Allo-HSCT) during first complete remission is recommended to benefit the patients. In contrast, no benefit of Allo-HSCT is evident over chemotherapy without remission.<ref name="AthaleRazzouk2001">{{cite journal|last1=Athale|first1=Uma H.|last2=Razzouk|first2=Bassem I.|last3=Raimondi|first3=Susana C.|last4=Tong|first4=Xin|last5=Behm|first5=Frederick G.|last6=Head|first6=David R.|last7=Srivastava|first7=Deo K.|last8=Rubnitz|first8=Jeffrey E.|last9=Bowman|first9=Laura|last10=Pui|first10=Ching-Hon|last11=Ribeiro|first11=Raul C.|title=Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience|journal=Blood|volume=97|issue=12|year=2001|pages=3727–3732|issn=1528-0020|doi=10.1182/blood.V97.12.3727}}</ref>

*In AML-BFM 04 trial, patients were randomized to receive induction therapy with either (Ara-C), [[liposomal daunorubicin]], and etoposide (ADxE) or Ara-C, [[idarubicin]], and etoposide (AIE) regimen. Consolidation therapy with [[2-chloro-2-deoxyadenosine]] (2-CDA) and Ara-C and idarubicin was preceded by second induction therapy with HAM (high-dose Ara-C, mitoxantrone, cytarabine i.th). However, no significant results were obtained regarding event-free survival (EFS) and overall survival (OS).<ref name="SchweitzerZimmermann2015">{{cite journal|last1=Schweitzer|first1=Jana|last2=Zimmermann|first2=Martin|last3=Rasche|first3=Mareike|last4=von Neuhoff|first4=Christine|last5=Creutzig|first5=Ursula|last6=Dworzak|first6=Michael|last7=Reinhardt|first7=Dirk|last8=Klusmann|first8=Jan-Henning|title=Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial|journal=Annals of Hematology|volume=94|issue=8|year=2015|pages=1327–1336|issn=0939-5555|doi=10.1007/s00277-015-2383-2}}</ref>

==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]
[[Category:Needs content]]

Acute megakaryoblastic leukemia medical therapy

2021-04-26T18:42:14Z

Roukoz Abou Karam:

__NOTOC__
{{Acute megakaryoblastic leukemia}}
{{CMG}}; {{AE}} {{israrkhan}}

==Overview==

==Medical Therapy==

*According to the AML-BFM (Berlin–Frankfurt–Münster) 98 and AML-BFM ((Berlin–Frankfurt–Münster) 93 clinical studies, intensive AML targeted [[chemotherapy]] in Down syndrome-associated AMKL results in high event-free survival rates versus non-Down syndrome patients. However, they are also prone to develop treatment-related toxicity at standard doses due to chemo sensitivity.<ref name="CreutzigReinhardt2005">{{cite journal|last1=Creutzig|first1=U|last2=Reinhardt|first2=D|last3=Diekamp|first3=S|last4=Dworzak|first4=M|last5=Stary|first5=J|last6=Zimmermann|first6=M|title=AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity|journal=Leukemia|volume=19|issue=8|year=2005|pages=1355–1360|issn=0887-6924|doi=10.1038/sj.leu.2403814}}</ref>

The treatment is divided into [[induction therapy]] and [[consolidation]] therapy.

*'''Induction therapy''' — involves two cycles (four weeks apart ) of [[Cytarabine|Ara-Cytarabine]] (Ara-C) at 100 mg/m2 /day continuous infusion for 7 days, [[vincristine]] at 0.7 mg/m2 on day 7, and [[pirarubicin]] at 25 mg/m2 by 60 min infusion on days 2, and 4 (AVC1).<ref name="TagaShimomura2011">{{cite journal|last1=Taga|first1=Takashi|last2=Shimomura|first2=Yasuto|last3=Horikoshi|first3=Yasuo|last4=Ogawa|first4=Atsushi|last5=Itoh|first5=Masaki|last6=Okada|first6=Masahiko|last7=Ueyama|first7=Junichi|last8=Higa|first8=Takeshi|last9=Watanabe|first9=Arata|last10=Kanegane|first10=Hirokazu|last11=Iwai|first11=Asayuki|last12=Saiwakawa|first12=Yutaka|last13=Kogawa|first13=Kazuhiro|last14=Yamanaka|first14=Junko|last15=Tsurusawa|first15=Masahito|title=Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study|journal=Pediatric Blood & Cancer|volume=57|issue=1|year=2011|pages=36–40|issn=15455009|doi=10.1002/pbc.22943}}</ref>
*'''Consolidation therapy''' — follows once complete remission is achieved with the following regimen; [[etoposide]] & high-dose Ara-C (EC), [[mitoxantrone]] and continuous-dose Ara-C (MC), and pirarubicin, vincristine, and continuous-dose Ara-C (AVC2).<ref name="TagaShimomura20112">{{cite journal|last1=Taga|first1=Takashi|last2=Shimomura|first2=Yasuto|last3=Horikoshi|first3=Yasuo|last4=Ogawa|first4=Atsushi|last5=Itoh|first5=Masaki|last6=Okada|first6=Masahiko|last7=Ueyama|first7=Junichi|last8=Higa|first8=Takeshi|last9=Watanabe|first9=Arata|last10=Kanegane|first10=Hirokazu|last11=Iwai|first11=Asayuki|last12=Saiwakawa|first12=Yutaka|last13=Kogawa|first13=Kazuhiro|last14=Yamanaka|first14=Junko|last15=Tsurusawa|first15=Masahito|title=Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study|journal=Pediatric Blood & Cancer|volume=57|issue=1|year=2011|pages=36–40|issn=15455009|doi=10.1002/pbc.22943}}</ref>

The doses are given below:<ref name="TagaShimomura20113">{{cite journal|last1=Taga|first1=Takashi|last2=Shimomura|first2=Yasuto|last3=Horikoshi|first3=Yasuo|last4=Ogawa|first4=Atsushi|last5=Itoh|first5=Masaki|last6=Okada|first6=Masahiko|last7=Ueyama|first7=Junichi|last8=Higa|first8=Takeshi|last9=Watanabe|first9=Arata|last10=Kanegane|first10=Hirokazu|last11=Iwai|first11=Asayuki|last12=Saiwakawa|first12=Yutaka|last13=Kogawa|first13=Kazuhiro|last14=Yamanaka|first14=Junko|last15=Tsurusawa|first15=Masahito|title=Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study|journal=Pediatric Blood & Cancer|volume=57|issue=1|year=2011|pages=36–40|issn=15455009|doi=10.1002/pbc.22943}}</ref>

'''''MC regimen:'''''

*Ara-C at 100 mg/m2 /day continuous infusion for 5 days and
*Mitoxantrone at 3.5 mg/m2 by 60 min infusion on days 2–4

'''''EC regimen'''''

*High-dose Ara-C 1 g/m2 every 12 hrs on days 1–5,
*Etoposide 66 mg/m2 by 2 h infusion on days 2–4), and

'''''AVC2 regimen'''''

*Ara-C at 100 mg/m2 /day on days 1–5,
*Pirarubicin 35 mg/m2 by 60 min infusion on day 2, and
*Vincristine at 0.7 mg/m2 on day 5

In relapsed state, re-induction with [[fludarabine]] and Ara-C combination or same AVC regimen can be utilized. Allogenic bone marrow transplant (Allo-BMT) from a suitable donor is justified if the patients achieved second complete remission. Currently, there is no recommended definitive therapy for non-Down syndrome with AMKL cohort. Novel therapeutic interventions are undertaken.<ref name="De MarchiAraki20192">{{cite journal|last1=De Marchi|first1=Federico|last2=Araki|first2=Marito|last3=Komatsu|first3=Norio|title=Molecular features, prognosis, and novel treatment options for pediatric acute megakaryoblastic leukemia|journal=Expert Review of Hematology|volume=12|issue=5|year=2019|pages=285–293|issn=1747-4086|doi=10.1080/17474086.2019.1609351}}</ref>

*Some study groups proposed that non-[[Down syndrome]] with AMKL is a high-risk condition; therefore, allogeneic [[hematopoietic stem cell]] transplantation (Allo-HSCT) during first complete remission is recommended to benefit the patients. In contrast, no benefit of Allo-HSCT is evident over chemotherapy without remission.<ref name="AthaleRazzouk2001">{{cite journal|last1=Athale|first1=Uma H.|last2=Razzouk|first2=Bassem I.|last3=Raimondi|first3=Susana C.|last4=Tong|first4=Xin|last5=Behm|first5=Frederick G.|last6=Head|first6=David R.|last7=Srivastava|first7=Deo K.|last8=Rubnitz|first8=Jeffrey E.|last9=Bowman|first9=Laura|last10=Pui|first10=Ching-Hon|last11=Ribeiro|first11=Raul C.|title=Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience|journal=Blood|volume=97|issue=12|year=2001|pages=3727–3732|issn=1528-0020|doi=10.1182/blood.V97.12.3727}}</ref>

*In AML-BFM 04 trial, patients were randomized to receive induction therapy with either (Ara-C), [[liposomal daunorubicin]], and etoposide (ADxE) or Ara-C, [[idarubicin]], and etoposide (AIE) regimen. Consolidation therapy with [[2-chloro-2-deoxyadenosine]] (2-CDA) and Ara-C and idarubicin was preceded by second induction therapy with HAM (high-dose Ara-C, mitoxantrone, cytarabine i.th). However, no significant results were obtained regarding event-free survival (EFS) and overall survival (OS).<ref name="SchweitzerZimmermann2015">{{cite journal|last1=Schweitzer|first1=Jana|last2=Zimmermann|first2=Martin|last3=Rasche|first3=Mareike|last4=von Neuhoff|first4=Christine|last5=Creutzig|first5=Ursula|last6=Dworzak|first6=Michael|last7=Reinhardt|first7=Dirk|last8=Klusmann|first8=Jan-Henning|title=Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial|journal=Annals of Hematology|volume=94|issue=8|year=2015|pages=1327–1336|issn=0939-5555|doi=10.1007/s00277-015-2383-2}}</ref>

==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]
[[Category:Needs content]]

Acute megakaryoblastic leukemia medical therapy

2021-04-26T18:40:10Z

Roukoz Abou Karam:

__NOTOC__
{{Acute megakaryoblastic leukemia}}
{{CMG}}; {{AE}} {{Israrkhan}}

==Overview==

==Medical Therapy==

*According to the AML-BFM (Berlin–Frankfurt–Münster) 98 and AML-BFM ((Berlin–Frankfurt–Münster) 93 clinical studies, intensive AML targeted [[chemotherapy]] in Down syndrome-associated AMKL results in high event-free survival rates versus non-Down syndrome patients. However, they are also prone to develop treatment-related toxicity at standard doses due to chemo sensitivity.<ref name="CreutzigReinhardt2005">{{cite journal|last1=Creutzig|first1=U|last2=Reinhardt|first2=D|last3=Diekamp|first3=S|last4=Dworzak|first4=M|last5=Stary|first5=J|last6=Zimmermann|first6=M|title=AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity|journal=Leukemia|volume=19|issue=8|year=2005|pages=1355–1360|issn=0887-6924|doi=10.1038/sj.leu.2403814}}</ref>

The treatment is divided into [[induction therapy]] and [[consolidation]] therapy.

*'''Induction therapy''' — involves two cycles (four weeks apart ) of [[Cytarabine|Ara-Cytarabine]] (Ara-C) at 100 mg/m2 /day continuous infusion for 7 days, [[vincristine]] at 0.7 mg/m2 on day 7, and [[pirarubicin]] at 25 mg/m2 by 60 min infusion on days 2, and 4 (AVC1).<ref name="TagaShimomura2011">{{cite journal|last1=Taga|first1=Takashi|last2=Shimomura|first2=Yasuto|last3=Horikoshi|first3=Yasuo|last4=Ogawa|first4=Atsushi|last5=Itoh|first5=Masaki|last6=Okada|first6=Masahiko|last7=Ueyama|first7=Junichi|last8=Higa|first8=Takeshi|last9=Watanabe|first9=Arata|last10=Kanegane|first10=Hirokazu|last11=Iwai|first11=Asayuki|last12=Saiwakawa|first12=Yutaka|last13=Kogawa|first13=Kazuhiro|last14=Yamanaka|first14=Junko|last15=Tsurusawa|first15=Masahito|title=Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study|journal=Pediatric Blood & Cancer|volume=57|issue=1|year=2011|pages=36–40|issn=15455009|doi=10.1002/pbc.22943}}</ref>
*'''Consolidation therapy''' — follows once complete remission is achieved with the following regimen; [[etoposide]] & high-dose Ara-C (EC), [[mitoxantrone]] and continuous-dose Ara-C (MC), and pirarubicin, vincristine, and continuous-dose Ara-C (AVC2).<ref name="TagaShimomura20112">{{cite journal|last1=Taga|first1=Takashi|last2=Shimomura|first2=Yasuto|last3=Horikoshi|first3=Yasuo|last4=Ogawa|first4=Atsushi|last5=Itoh|first5=Masaki|last6=Okada|first6=Masahiko|last7=Ueyama|first7=Junichi|last8=Higa|first8=Takeshi|last9=Watanabe|first9=Arata|last10=Kanegane|first10=Hirokazu|last11=Iwai|first11=Asayuki|last12=Saiwakawa|first12=Yutaka|last13=Kogawa|first13=Kazuhiro|last14=Yamanaka|first14=Junko|last15=Tsurusawa|first15=Masahito|title=Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study|journal=Pediatric Blood & Cancer|volume=57|issue=1|year=2011|pages=36–40|issn=15455009|doi=10.1002/pbc.22943}}</ref>

The doses are given below:<ref name="TagaShimomura20113">{{cite journal|last1=Taga|first1=Takashi|last2=Shimomura|first2=Yasuto|last3=Horikoshi|first3=Yasuo|last4=Ogawa|first4=Atsushi|last5=Itoh|first5=Masaki|last6=Okada|first6=Masahiko|last7=Ueyama|first7=Junichi|last8=Higa|first8=Takeshi|last9=Watanabe|first9=Arata|last10=Kanegane|first10=Hirokazu|last11=Iwai|first11=Asayuki|last12=Saiwakawa|first12=Yutaka|last13=Kogawa|first13=Kazuhiro|last14=Yamanaka|first14=Junko|last15=Tsurusawa|first15=Masahito|title=Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study|journal=Pediatric Blood & Cancer|volume=57|issue=1|year=2011|pages=36–40|issn=15455009|doi=10.1002/pbc.22943}}</ref>

'''''MC regimen:'''''

*Ara-C at 100 mg/m2 /day continuous infusion for 5 days and
*Mitoxantrone at 3.5 mg/m2 by 60 min infusion on days 2–4

'''''EC regimen'''''

*High-dose Ara-C 1 g/m2 every 12 hrs on days 1–5,
*Etoposide 66 mg/m2 by 2 h infusion on days 2–4), and

'''''AVC2 regimen'''''

*Ara-C at 100 mg/m2 /day on days 1–5,
*Pirarubicin 35 mg/m2 by 60 min infusion on day 2, and
*Vincristine at 0.7 mg/m2 on day 5

In relapsed state, re-induction with [[fludarabine]] and Ara-C combination or same AVC regimen can be utilized. Allogenic bone marrow transplant (Allo-BMT) from a suitable donor is justified if the patients achieved second complete remission. Currently, there is no recommended definitive therapy for non-Down syndrome with AMKL cohort. Novel therapeutic interventions are undertaken.<ref name="De MarchiAraki20192">{{cite journal|last1=De Marchi|first1=Federico|last2=Araki|first2=Marito|last3=Komatsu|first3=Norio|title=Molecular features, prognosis, and novel treatment options for pediatric acute megakaryoblastic leukemia|journal=Expert Review of Hematology|volume=12|issue=5|year=2019|pages=285–293|issn=1747-4086|doi=10.1080/17474086.2019.1609351}}</ref>

*Some study groups proposed that non-[[Down syndrome]] with AMKL is a high-risk condition; therefore, allogeneic [[hematopoietic stem cell]] transplantation (Allo-HSCT) during first complete remission is recommended to benefit the patients. In contrast, no benefit of Allo-HSCT is evident over chemotherapy without remission.<ref name="AthaleRazzouk2001">{{cite journal|last1=Athale|first1=Uma H.|last2=Razzouk|first2=Bassem I.|last3=Raimondi|first3=Susana C.|last4=Tong|first4=Xin|last5=Behm|first5=Frederick G.|last6=Head|first6=David R.|last7=Srivastava|first7=Deo K.|last8=Rubnitz|first8=Jeffrey E.|last9=Bowman|first9=Laura|last10=Pui|first10=Ching-Hon|last11=Ribeiro|first11=Raul C.|title=Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience|journal=Blood|volume=97|issue=12|year=2001|pages=3727–3732|issn=1528-0020|doi=10.1182/blood.V97.12.3727}}</ref>

*In AML-BFM 04 trial, patients were randomized to receive induction therapy with either (Ara-C), [[liposomal daunorubicin]], and etoposide (ADxE) or Ara-C, [[idarubicin]], and etoposide (AIE) regimen. Consolidation therapy with [[2-chloro-2-deoxyadenosine]] (2-CDA) and Ara-C and idarubicin was preceded by second induction therapy with HAM (high-dose Ara-C, mitoxantrone, cytarabine i.th). However, no significant results were obtained regarding event-free survival (EFS) and overall survival (OS).<ref name="SchweitzerZimmermann2015">{{cite journal|last1=Schweitzer|first1=Jana|last2=Zimmermann|first2=Martin|last3=Rasche|first3=Mareike|last4=von Neuhoff|first4=Christine|last5=Creutzig|first5=Ursula|last6=Dworzak|first6=Michael|last7=Reinhardt|first7=Dirk|last8=Klusmann|first8=Jan-Henning|title=Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial|journal=Annals of Hematology|volume=94|issue=8|year=2015|pages=1327–1336|issn=0939-5555|doi=10.1007/s00277-015-2383-2}}</ref>

==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]
[[Category:Needs content]]

Acute megakaryoblastic leukemia classification

2021-04-26T18:38:10Z

Roukoz Abou Karam:

__NOTOC__
{{Acute megakaryoblastic leukemia}}

{{CMG}}; {{AE}}
==Overview==
There is no established system for the classification of Acute megakaryoblastic leukemia.

==Classification==
There is an established system for the classification of acute megakaryoblastic leukemia, for more information visit [[Acute myeloid leukemia classification|acute myeloid leukemia classification.]]

==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]

Acute megakaryoblastic leukemia classification

2021-04-26T18:37:53Z

Roukoz Abou Karam:

__NOTOC__
{{Acute megakaryoblastic leukemia}}

{{CMG}}; {{AE}}
==Overview==
There is no established system for the classification of Acute megakaryoblastic leukemia.

==Classification==
There is an established system for the classification of acute megakaryoblastic leukemia, for more information visit [[Acute myeloid leukemia classification|acute myeloid leukemia.]]

==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]

Acute megakaryoblastic leukemia classification

2021-04-26T18:35:45Z

Roukoz Abou Karam:

__NOTOC__
{{Acute megakaryoblastic leukemia}}

{{CMG}}; {{AE}}
==Overview==
There is no established system for the classification of Acute megakaryoblastic leukemia.

==Classification==
There is no established system for the classification of Acute megakaryoblastic leukemia.

==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]

Template:Acute megakaryoblastic leukemia

2021-04-26T18:26:09Z

Roukoz Abou Karam:

{| class="infobox bordered" style="width: 15em; text-align: left; font-size: 90%; background:AliceBlue"
|-
| colspan="1" style="text-align:center; background:DarkGray" |

'''Acute megakaryoblastic leukemia Microchapters
'''
|- bgcolor="LightGrey"
!

|- bgcolor="LightCoral"
!
[[Acute megakaryoblastic leukemia|Home]]
|-
!

|- bgcolor="Pink"
!
[[Acute megakaryoblastic leukemia overview|Overview]]
|-
!

|- bgcolor="Pink"
!
[[Acute megakaryoblastic leukemia historical perspective|Historical Perspective]]
|-
!

|- bgcolor="Pink"
!
[[Acute megakaryoblastic leukemia classification|Classification]]
|-
!

|- bgcolor="Pink"
!
[[Acute megakaryoblastic leukemia pathophysiology|Pathophysiology]]
|-
!

|- bgcolor="Pink"
!
[[Acute megakaryoblastic leukemia causes|Causes]]
|-
!

|- bgcolor="Pink"
!
[[Acute megakaryoblastic leukemia differential diagnosis|Differentiating Acute megakaryoblastic leukemia from other Diseases]]
|-
!

|- bgcolor="Pink"
!
[[Acute megakaryoblastic leukemia epidemiology and demographics|Epidemiology and Demographics]]
|-
!

|- bgcolor="Pink"
!
[[Acute megakaryoblastic leukemia risk factors|Risk Factors]]
|-
!

|- bgcolor="Pink"
!
[[Acute megakaryoblastic leukemia screening|Screening]]
|-
!

|- bgcolor="Pink"
!
[[Acute megakaryoblastic leukemia natural history, complications and prognosis|Natural History, Complications and Prognosis]]
|-
!

|- bgcolor="CornFlowerBlue"
!
Diagnosis
|-
!

|- bgcolor="LightSkyBlue"
!
[[Acute megakaryoblastic leukemia diagnostic study of choice|Diagnostic Study of Choice]]
|-
!

|- bgcolor="LightSkyBlue"
!
[[Acute megakaryoblastic leukemia history and symptoms|History and Symptoms]]
|-
!

|- bgcolor="LightSkyBlue"
!
[[Acute megakaryoblastic leukemia physical examination|Physical Examination]]
|-
!

|- bgcolor="LightSkyBlue"
!
[[Acute megakaryoblastic leukemia laboratory findings|Laboratory Findings]]
|-
!

|- bgcolor="LightSkyBlue"
!
[[Acute megakaryoblastic leukemia electrocardiogram|Electrocardiogram]]
|-
!

|- bgcolor="LightSkyBlue"
!
[[Acute megakaryoblastic leukemia other diagnostic studies|Other Diagnostic Studies]]
|-
!

|- bgcolor="CadetBlue"
!
Treatment
|-
!

|- bgcolor="PaleTurquoise"
!
[[Acute megakaryoblastic leukemia medical therapy|Medical Therapy]]
|-
!

|- bgcolor="PaleTurquoise"
!
[[Acute megakaryoblastic leukemia surgery|Surgery]]
|-
!

|- bgcolor="PaleTurquoise"
!
[[Acute megakaryoblastic leukemia cost-effectiveness of therapy|Cost-Effectiveness of Therapy]]
|-
!

|- bgcolor="PaleTurquoise"
!
[[Acute megakaryoblastic leukemia future or investigational therapies|Future or Investigational Therapies]]
|-
!

|- bgcolor="CadetBlue"
!
Case Studies
|-
!

|- bgcolor="PaleTurquoise"
!
[[Acute megakaryoblastic leukemia case study one|Case #1]]
|-
!

|- bgcolor="PaleGoldenrod "
!
{{PAGENAME}} On the Web
|-
!

|- bgcolor="LightYellow"
!
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Most recent articles]
|-
!

|- bgcolor="LightYellow"
!
[http://scholar.google.com/scholar?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search&sa=N&tab=ps Most cited articles]
|-
!

|- bgcolor="LightYellow"
!
[http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}%20AND%20systematic%5Bsb%5D Review articles]
|-
!

|- bgcolor="LightYellow"
!
[http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla:en-US:official&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+more:health_continuing_education&cx=disease_for_health_professionals&sa=N&oi=coopctx&resnum=0&ct=col3&cd=2 CME Programs]
|-
!

|- bgcolor="LightYellow"
!
[http://www.google.com/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+ppt&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a Powerpoint slides]
|-
!

|- bgcolor="LightYellow"
!
[http://images.google.com/images?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wi Images]
|-
!

|- bgcolor="LightYellow"
!
American Roentgen Ray Society Images of {{PAGENAME}}
:[http://goldminer.arrs.org/search.php?query={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} All Images]
:[http://goldminer.arrs.org/search.php?query={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}} X-ray}}}} X-rays]
:[http://goldminer.arrs.org/search.php?query={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}} Ultrasound}}}} Echo & Ultrasound]
:[http://goldminer.arrs.org/search.php?query={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}} CT}}}} CT Images]
:[http://goldminer.arrs.org/search.php?query={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}} MRI}}}} MRI]
|-
!

|- bgcolor="LightYellow"
!
[http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Ongoing Trials at Clinical Trials.gov]
|-
!

|- bgcolor="LightYellow"
!
[http://www.guideline.gov/search/searchresults.aspx?Type=3&txtSearch={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&num=20 US National Guidelines Clearinghouse]
|-
!

|- bgcolor="LightYellow"
!
[http://www.nice.org.uk/search/guidancesearchresults.jsp?keywords={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&searchType=guidance NICE Guidance]
|-
!

|- bgcolor="LightYellow"
!
[http://google2.fda.gov/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&x=0&y=0&client=FDA&site=FDA&lr=&proxystylesheet=FDA&output=xml_no_dtd&getfields=* FDA on {{PAGENAME}}]
|-
!

|- bgcolor="LightYellow"
!
[http://www.cdc.gov/search.do?queryText={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&searchButton.x=33&searchButton.y=6&action=search CDC on {{PAGENAME}}]
|-
!

|- bgcolor="LightYellow"
!
[http://news.google.com/news?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wn {{PAGENAME}} in the news]
|-
!

|- bgcolor="LightYellow"
!
[http://blogsearch.google.com/blogsearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wb Blogs on {{PAGENAME}}]
|-
!

|- bgcolor="LightYellow"
!
[http://maps.google.com/maps?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|map+top+hospital+Acute megakaryoblastic leukemia}}}}&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&ie=UTF-8&sa=N&hl=en&tab=wl Directions to Hospitals Treating Acute megakaryoblastic leukemia]
|-
!

|- bgcolor="LightYellow"
!
[http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla%3Aen-US%3Aofficial&hs=QWo&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+AND+risk+score+OR+risk+calculator&btnG=Search Risk calculators and risk factors for {{PAGENAME}}]
|-
!

|}

Acute megakaryoblastic leukemia laboratory findings

2021-04-26T14:23:45Z

Roukoz Abou Karam:

__NOTOC__
{{Acute megakaryoblastic leukemia}}

{{CMG}}; {{AE}}

==Overview==

==Laboratory Findings==

The diagnosis of AMKL (M7) is based on the following:

#[[Bone marrow]] [[biopsy]] demonstrating 30% or more leukemic cells of megakaryocytic lineage
#Conducting tests that detect [[platelet-specific antibodies]] which could be [[monoclonal]] or [[polyclonal]].
#Bone marrow biopsy is recommended in patients who developed [[myelofibrosis]]. Visualization of blasts and mature megakaryocytes on biopsy sections is diagnostic.

==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]
[[Category:Needs content]]

Acute megakaryoblastic leukemia physical examination

2021-04-26T14:17:39Z

Roukoz Abou Karam:

__NOTOC__
{{Acute megakaryoblastic leukemia}}

{{CMG}}; {{AE}}

==Overview==

==Physical Examination==

*Physical exam findings include:<ref name="AthaleKaste2002">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref><ref name="Paredes-AguileraRomero-Guzman2003">{{cite journal|last1=Paredes-Aguilera|first1=Rogelio|last2=Romero-Guzman|first2=Lina|last3=Lopez-Santiago|first3=Norma|last4=Trejo|first4=Rosa Arana|title=Biology, clinical, and hematologic features of acute megakaryoblastic leukemia in children|journal=American Journal of Hematology|volume=73|issue=2|year=2003|pages=71–80|issn=0361-8609|doi=10.1002/ajh.10320}}</ref>

[[Down syndrome]] features are present in patients with Down syndrome associated AMKL.

 
==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]
#[[Pallor]]
#[[Lymphadenopathy]]
#[[Splenomegaly]]
#[[Hepatomegaly]]

Acute megakaryoblastic leukemia physical examination

2021-04-26T14:17:16Z

Roukoz Abou Karam:

__NOTOC__
{{Acute Megakaryoblastic Leukemia}}

{{CMG}}; {{AE}}

==Overview==

==Physical Examination==

*Physical exam findings include:<ref name="AthaleKaste2002">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref><ref name="Paredes-AguileraRomero-Guzman2003">{{cite journal|last1=Paredes-Aguilera|first1=Rogelio|last2=Romero-Guzman|first2=Lina|last3=Lopez-Santiago|first3=Norma|last4=Trejo|first4=Rosa Arana|title=Biology, clinical, and hematologic features of acute megakaryoblastic leukemia in children|journal=American Journal of Hematology|volume=73|issue=2|year=2003|pages=71–80|issn=0361-8609|doi=10.1002/ajh.10320}}</ref>

[[Down syndrome]] features are present in patients with Down syndrome associated AMKL.

 
==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]
#[[Pallor]]
#[[Lymphadenopathy]]
#[[Splenomegaly]]
#[[Hepatomegaly]]

Acute megakaryoblastic leukemia physical examination

2021-04-26T14:16:43Z

Roukoz Abou Karam:

__NOTOC__
{{Acute Megakaryoblastic Leukemia}}

{{CMG}}; {{AE}}

==Overview==

==Physical Examination==

*Physical exam findings include:<ref name="AthaleKaste2002">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref><ref name="Paredes-AguileraRomero-Guzman2003">{{cite journal|last1=Paredes-Aguilera|first1=Rogelio|last2=Romero-Guzman|first2=Lina|last3=Lopez-Santiago|first3=Norma|last4=Trejo|first4=Rosa Arana|title=Biology, clinical, and hematologic features of acute megakaryoblastic leukemia in children|journal=American Journal of Hematology|volume=73|issue=2|year=2003|pages=71–80|issn=0361-8609|doi=10.1002/ajh.10320}}</ref>

#[[Pallor]]
#[[Lymphadenopathy]]
#[[Splenomegaly]]
#[[Hepatomegaly]]
#Bruising.

[[Down syndrome]] features are present in patients with Down syndrome associated AMKL.

__NOTOC__
{{Acute megakaryoblastic leukemia}}

 
==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]
[[Category:Needs content]]

Acute megakaryoblastic leukemia history and symptoms

2021-04-26T14:15:43Z

Roukoz Abou Karam:

__NOTOC__
{{Acute megakaryoblastic leukemia}}

{{CMG}}; {{AE}}

==Overview==

*[[Acute megakaryoblastic leukemia]] (AMKL) has a wide array of presentations. The onset is either acute or insidious. The degree of [[pancytopenia]] varies among patients.<ref name="pmid2978961">{{cite journal| author=Zipursky A, Peeters M, Poon A| title=Megakaryoblastic leukemia and Down's syndrome: a review. | journal=Pediatr Hematol Oncol | year= 1987 | volume= 4 | issue= 3 | pages= 211-30 | pmid=2978961 | doi=10.3109/08880018709141272 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2978961 }}</ref> Other features include [[fever]], irritability, [[headache]], fatigue, bone pain,<ref name="pmid12749007">{{cite journal| author=Paredes-Aguilera R, Romero-Guzman L, Lopez-Santiago N, Trejo RA| title=Biology, clinical, and hematologic features of acute megakaryoblastic leukemia in children. | journal=Am J Hematol | year= 2003 | volume= 73 | issue= 2 | pages= 71-80 | pmid=12749007 | doi=10.1002/ajh.10320 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12749007 }}</ref> [[hepatosplenomegaly]] (HSM), and [[lymphadenopathy]],<ref name="JayasudhaNair2014">{{cite journal|last1=Jayasudha|first1=A. V.|last2=Nair|first2=Rekha A.|last3=Jacob|first3=Priya Mary|last4=Renu|first4=S.|last5=Anila|first5=K. R.|last6=Sindhu Nair|first6=P.|last7=Priya Kumari|first7=T.|last8=Kusuma Kumary|first8=P.|title=Clinical and Hematological Profile of Acute Megakaryoblastic Leukemia: A 2 Year Study|journal=Indian Journal of Hematology and Blood Transfusion|volume=31|issue=2|year=2014|pages=169–173|issn=0971-4502|doi=10.1007/s12288-014-0413-1}}</ref><ref name="AthaleKaste2002">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref> pallor, generalized pain, temporal swelling, [[bruising]], and difficulty walking.<ref name="AthaleKaste20023">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref>

*Greater than 50% of [[leukemia]] patients demonstrate skeletal features and are mostly related to the AMKL subtype.<ref name="AthaleKaste20024">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref>

 
__NOTOC__
{{Acute megakaryoblastic leukemia}}

 
==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]
[[Category:Needs content]]

Acute megakaryoblastic leukemia history and symptoms

2021-04-26T14:15:25Z

Roukoz Abou Karam:

__NOTOC__
{{Acute megakaryoblastic leukemia]}}

{{CMG}}; {{AE}}

==Overview==

*[[Acute megakaryoblastic leukemia]] (AMKL) has a wide array of presentations. The onset is either acute or insidious. The degree of [[pancytopenia]] varies among patients.<ref name="pmid2978961">{{cite journal| author=Zipursky A, Peeters M, Poon A| title=Megakaryoblastic leukemia and Down's syndrome: a review. | journal=Pediatr Hematol Oncol | year= 1987 | volume= 4 | issue= 3 | pages= 211-30 | pmid=2978961 | doi=10.3109/08880018709141272 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2978961 }}</ref> Other features include [[fever]], irritability, [[headache]], fatigue, bone pain,<ref name="pmid12749007">{{cite journal| author=Paredes-Aguilera R, Romero-Guzman L, Lopez-Santiago N, Trejo RA| title=Biology, clinical, and hematologic features of acute megakaryoblastic leukemia in children. | journal=Am J Hematol | year= 2003 | volume= 73 | issue= 2 | pages= 71-80 | pmid=12749007 | doi=10.1002/ajh.10320 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12749007 }}</ref> [[hepatosplenomegaly]] (HSM), and [[lymphadenopathy]],<ref name="JayasudhaNair2014">{{cite journal|last1=Jayasudha|first1=A. V.|last2=Nair|first2=Rekha A.|last3=Jacob|first3=Priya Mary|last4=Renu|first4=S.|last5=Anila|first5=K. R.|last6=Sindhu Nair|first6=P.|last7=Priya Kumari|first7=T.|last8=Kusuma Kumary|first8=P.|title=Clinical and Hematological Profile of Acute Megakaryoblastic Leukemia: A 2 Year Study|journal=Indian Journal of Hematology and Blood Transfusion|volume=31|issue=2|year=2014|pages=169–173|issn=0971-4502|doi=10.1007/s12288-014-0413-1}}</ref><ref name="AthaleKaste2002">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref> pallor, generalized pain, temporal swelling, [[bruising]], and difficulty walking.<ref name="AthaleKaste20023">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref>

*Greater than 50% of [[leukemia]] patients demonstrate skeletal features and are mostly related to the AMKL subtype.<ref name="AthaleKaste20024">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref>

 
__NOTOC__
{{Acute megakaryoblastic leukemia}}

 
==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]
[[Category:Needs content]]

Acute megakaryoblastic leukemia natural history, complications and prognosis

2021-04-26T14:11:03Z

Roukoz Abou Karam:

__NOTOC__
{{Acute megakaryoblastic leukemia}}

{{CMG}}; {{AE}}

==Overview==

==Natural History==
Due to the rarity of this subtype of hematological malignancy, limited data is available on the natural course or [[prognosis]].

*Clonal proliferation of early [[megakaryoblasts]] in the bone marrow results in acute megakaryoblastic leukemia (AMKL).<ref name="pmid11001891">{{cite journal| author=Tallman MS, Neuberg D, Bennett JM, Francois CJ, Paietta E, Wiernik PH | display-authors=etal| title=Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. | journal=Blood | year= 2000 | volume= 96 | issue= 7 | pages= 2405-11 | pmid=11001891 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11001891 }}</ref> It has a bimodal onset of presentation—occurs both in the pediatric age group (<4 years) and adults.<ref name="GassmannLöffler2009">{{cite journal|last1=Gassmann|first1=Winfried|last2=Löffler|first2=Helmut|title=Acute Megakaryoblastic Leukemia|journal=Leukemia & Lymphoma|volume=18|issue=sup1|year=2009|pages=69–73|issn=1042-8194|doi=10.3109/10428199509075307}}</ref>
*In childhood, it is more prevalent in patients with Down syndrome. While it is rare in adults, approximately 0.6% (24/3603) reported in the [[GIMEMA trial]].<ref name="PaganoPulsoni2002">{{cite journal|last1=Pagano|first1=L|last2=Pulsoni|first2=A|last3=Vignetti|first3=M|last4=Mele|first4=L|last5=Fianchi|first5=L|last6=Petti|first6=MC|last7=Mirto|first7=S|last8=Falcucci|first8=P|last9=Fazi|first9=P|last10=Broccia|first10=G|last11=Specchia|first11=G|last12=Di Raimondo|first12=F|last13=Pacilli|first13=L|last14=Leoni|first14=P|last15=Ladogana|first15=S|last16=Gallo|first16=E|last17=Venditti|first17=A|last18=Avanzi|first18=G|last19=Camera|first19=A|last20=Liso|first20=V|last21=Leone|first21=G|last22=Mandelli|first22=F|title=Acute megakaryoblastic leukemia: experience of GIMEMA trials|journal=Leukemia|volume=16|issue=9|year=2002|pages=1622–1626|issn=0887-6924|doi=10.1038/sj.leu.2402618}}</ref>
*Cases of AMKL secondary to [[chronic myelogenous leukemia]] and [[essential thrombocytosis]] have been reported in the medical literature.<ref>{{cite journal|journal=ecancermedicalscience|issn=17546605|doi=10.3332/ecancer.2013.375}}</ref><ref name="RadaelliMazza2002">{{cite journal|last1=Radaelli|first1=Franca|last2=Mazza|first2=Rita|last3=Curioni|first3=Elisabetta|last4=Ciani|first4=Alberto|last5=Pomati|first5=Mauro|last6=Maiolo|first6=Anna-Teresa|title=Acute megakaryocytic leukemia in essential thrombocythemia: an unusual evolution?|journal=European Journal of Haematology|volume=69|issue=2|year=2002|pages=108–111|issn=09024441|doi=10.1034/j.1600-0609.2002.02734.x}}</ref>

==Complications==

#Periorbital swelling
#[[Periosteal elevation]]
#Osteolytic lesions, especially in long bones, e.g., femur<ref name="AthaleKaste2002">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref>
#[[Osteoporosis]] with pathologic fractures<ref name="AthaleKaste20022">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref><ref name="KushnerWeinstein1980">{{cite journal|last1=Kushner|first1=David C.|last2=Weinstein|first2=Howard J.|last3=Kirkpatrick|first3=John A.|title=The radiologic diagnosis of leukemia and lymphoma in children|journal=Seminars in Roentgenology|volume=15|issue=4|year=1980|pages=316–334|issn=0037198X|doi=10.1016/0037-198X(80)90027-9}}</ref>
#[[Sweet syndrome]] (SS)<ref name="pmid8479086">{{cite journal| author=Yokoyama K, Kojima M, Komatsumoto S, Nara M, Ohyashiki K, Ikeda Y | display-authors=etal| title=[Acute megakaryoblastic leukemia associated with Sweet's syndrome, including review of the literature]. | journal=Rinsho Ketsueki | year= 1993 | volume= 34 | issue= 3 | pages= 341-7 | pmid=8479086 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8479086 }}</ref>
#[[Leukemia cutis]]<ref name="pmid1758056">{{cite journal| author=Tsurumi H, Takahashi T, Koshino Y, Oyama M, Matsutomo K, Yasuda M | display-authors=etal| title=[Acute megakaryoblastic leukemia with leukemia cutis, meningeal leukemia, and myelofibrosis]. | journal=Rinsho Ketsueki | year= 1991 | volume= 32 | issue= 11 | pages= 1475-80 | pmid=1758056 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1758056 }}</ref>
#[[Hypercalcemia]]<ref name="pmid19415024">{{cite journal| author=Qayed M, Ahmed I, Valentini RP, Cushing B, Rajpurkar M| title=Hypercalcemia in pediatric acute megakaryocytic leukemia: case report and review of the literature. | journal=J Pediatr Hematol Oncol | year= 2009 | volume= 31 | issue= 5 | pages= 373-6 | pmid=19415024 | doi=10.1097/MPH.0b013e31819a5d29 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19415024 }}</ref>

==Prognosis==
Apart from AMKL in [[Down syndrome]] patients, the prognosis of AMKL is poor. The efficacy profile of AMKL in Down syndrome patients is favorable, but it comes with a lot of treatment-related toxicity.

*According to the Children’s Oncology Group (COG) AML0431 trial results, the 5-year event-free survival and [[overall survival]] rates were 90% and 93% in 204 eligible Down syndrome with AMKL patients.<ref name="TaubBerman2017">{{cite journal|last1=Taub|first1=Jeffrey W.|last2=Berman|first2=Jason N.|last3=Hitzler|first3=Johann K.|last4=Sorrell|first4=April D.|last5=Lacayo|first5=Norman J.|last6=Mast|first6=Kelley|last7=Head|first7=David|last8=Raimondi|first8=Susana|last9=Hirsch|first9=Betsy|last10=Ge|first10=Yubin|last11=Gerbing|first11=Robert B.|last12=Wang|first12=Yi-Cheng|last13=Alonzo|first13=Todd A.|last14=Campana|first14=Dario|last15=Coustan-Smith|first15=Elaine|last16=Mathew|first16=Prasad|last17=Gamis|first17=Alan S.|title=Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial|journal=Blood|volume=129|issue=25|year=2017|pages=3304–3313|issn=0006-4971|doi=10.1182/blood-2017-01-764324}}</ref>

*Similarly, the reported 3-year overall survival rate was 100% among 3 AMKL with Down syndrome patients while (47±12%) in non-Down syndrome patients.<ref name="QiMao2020">{{cite journal|last1=Qi|first1=Haixiao|last2=Mao|first2=Yan|last3=Cao|first3=Qian|last4=Sun|first4=Xingzhen|last5=Kuai|first5=Wenxia|last6=Song|first6=Junhong|last7=Ma|first7=Li|last8=Hong|first8=Ze|last9=Hu|first9=Jian|last10=Zhou|first10=Guoping|title=Clinical Characteristics and Prognosis of 27 Patients with Childhood Acute Megakaryoblastic Leukemia|journal=Medical Science Monitor|volume=26|year=2020|issn=1643-3750|doi=10.12659/MSM.922662}}</ref>

*The 5-year overall survival rate in AMKL was 10.6% versus 17.5% in non-M7 [[Acute Myeloid leukemia|Acute myeloid leukemia]] subtypes.<ref name="GiriPathak2014">{{cite journal|last1=Giri|first1=Smith|last2=Pathak|first2=Ranjan|last3=Prouet|first3=Philippe|last4=Li|first4=Bojia|last5=Martin|first5=Mike G.|title=Acute megakaryocytic leukemia is associated with worse outcomes than other types of acute myeloid leukemia|journal=Blood|volume=124|issue=25|year=2014|pages=3833–3834|issn=0006-4971|doi=10.1182/blood-2014-09-603415}}</ref> Currently, [[chemotherapy]] and [[Allo-BMT|allogenic bone marrow transplant]] (Allo-BMT) are main therapy. Treatment-related toxicity is a big challenge. To address this issue, elaborated large future clinical studies are required.

==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]
[[Category:Needs content]]

Acute megakaryoblastic leukemia natural history, complications and prognosis

2021-04-26T14:10:35Z

Roukoz Abou Karam:

__NOTOC__
{{Acute megakaryoblastic leukemia}}

{{CMG}}; {{AE}}

==Overview==

==Natural History:==
Due to the rarity of this subtype of hematological malignancy, limited data is available on the natural course or [[prognosis]].

*Clonal proliferation of early [[megakaryoblasts]] in the bone marrow results in acute megakaryoblastic leukemia (AMKL).<ref name="pmid11001891">{{cite journal| author=Tallman MS, Neuberg D, Bennett JM, Francois CJ, Paietta E, Wiernik PH | display-authors=etal| title=Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. | journal=Blood | year= 2000 | volume= 96 | issue= 7 | pages= 2405-11 | pmid=11001891 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11001891 }}</ref> It has a bimodal onset of presentation—occurs both in the pediatric age group (<4 years) and adults.<ref name="GassmannLöffler2009">{{cite journal|last1=Gassmann|first1=Winfried|last2=Löffler|first2=Helmut|title=Acute Megakaryoblastic Leukemia|journal=Leukemia & Lymphoma|volume=18|issue=sup1|year=2009|pages=69–73|issn=1042-8194|doi=10.3109/10428199509075307}}</ref>
*In childhood, it is more prevalent in patients with Down syndrome. While it is rare in adults, approximately 0.6% (24/3603) reported in the [[GIMEMA trial]].<ref name="PaganoPulsoni2002">{{cite journal|last1=Pagano|first1=L|last2=Pulsoni|first2=A|last3=Vignetti|first3=M|last4=Mele|first4=L|last5=Fianchi|first5=L|last6=Petti|first6=MC|last7=Mirto|first7=S|last8=Falcucci|first8=P|last9=Fazi|first9=P|last10=Broccia|first10=G|last11=Specchia|first11=G|last12=Di Raimondo|first12=F|last13=Pacilli|first13=L|last14=Leoni|first14=P|last15=Ladogana|first15=S|last16=Gallo|first16=E|last17=Venditti|first17=A|last18=Avanzi|first18=G|last19=Camera|first19=A|last20=Liso|first20=V|last21=Leone|first21=G|last22=Mandelli|first22=F|title=Acute megakaryoblastic leukemia: experience of GIMEMA trials|journal=Leukemia|volume=16|issue=9|year=2002|pages=1622–1626|issn=0887-6924|doi=10.1038/sj.leu.2402618}}</ref>
*Cases of AMKL secondary to [[chronic myelogenous leukemia]] and [[essential thrombocytosis]] have been reported in the medical literature.<ref>{{cite journal|journal=ecancermedicalscience|issn=17546605|doi=10.3332/ecancer.2013.375}}</ref><ref name="RadaelliMazza2002">{{cite journal|last1=Radaelli|first1=Franca|last2=Mazza|first2=Rita|last3=Curioni|first3=Elisabetta|last4=Ciani|first4=Alberto|last5=Pomati|first5=Mauro|last6=Maiolo|first6=Anna-Teresa|title=Acute megakaryocytic leukemia in essential thrombocythemia: an unusual evolution?|journal=European Journal of Haematology|volume=69|issue=2|year=2002|pages=108–111|issn=09024441|doi=10.1034/j.1600-0609.2002.02734.x}}</ref>

==Complications:==

#Periorbital swelling
#[[Periosteal elevation]]
#Osteolytic lesions, especially in long bones, e.g., femur<ref name="AthaleKaste2002">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref>
#[[Osteoporosis]] with pathologic fractures<ref name="AthaleKaste20022">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref><ref name="KushnerWeinstein1980">{{cite journal|last1=Kushner|first1=David C.|last2=Weinstein|first2=Howard J.|last3=Kirkpatrick|first3=John A.|title=The radiologic diagnosis of leukemia and lymphoma in children|journal=Seminars in Roentgenology|volume=15|issue=4|year=1980|pages=316–334|issn=0037198X|doi=10.1016/0037-198X(80)90027-9}}</ref>
#[[Sweet syndrome]] (SS)<ref name="pmid8479086">{{cite journal| author=Yokoyama K, Kojima M, Komatsumoto S, Nara M, Ohyashiki K, Ikeda Y | display-authors=etal| title=[Acute megakaryoblastic leukemia associated with Sweet's syndrome, including review of the literature]. | journal=Rinsho Ketsueki | year= 1993 | volume= 34 | issue= 3 | pages= 341-7 | pmid=8479086 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8479086 }}</ref>
#[[Leukemia cutis]]<ref name="pmid1758056">{{cite journal| author=Tsurumi H, Takahashi T, Koshino Y, Oyama M, Matsutomo K, Yasuda M | display-authors=etal| title=[Acute megakaryoblastic leukemia with leukemia cutis, meningeal leukemia, and myelofibrosis]. | journal=Rinsho Ketsueki | year= 1991 | volume= 32 | issue= 11 | pages= 1475-80 | pmid=1758056 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1758056 }}</ref>
#[[Hypercalcemia]]<ref name="pmid19415024">{{cite journal| author=Qayed M, Ahmed I, Valentini RP, Cushing B, Rajpurkar M| title=Hypercalcemia in pediatric acute megakaryocytic leukemia: case report and review of the literature. | journal=J Pediatr Hematol Oncol | year= 2009 | volume= 31 | issue= 5 | pages= 373-6 | pmid=19415024 | doi=10.1097/MPH.0b013e31819a5d29 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19415024 }}</ref>

==Prognosis:==
Apart from AMKL in [[Down syndrome]] patients, the prognosis of AMKL is poor. The efficacy profile of AMKL in Down syndrome patients is favorable, but it comes with a lot of treatment-related toxicity.

*According to the Children’s Oncology Group (COG) AML0431 trial results, the 5-year event-free survival and [[overall survival]] rates were 90% and 93% in 204 eligible Down syndrome with AMKL patients.<ref name="TaubBerman2017">{{cite journal|last1=Taub|first1=Jeffrey W.|last2=Berman|first2=Jason N.|last3=Hitzler|first3=Johann K.|last4=Sorrell|first4=April D.|last5=Lacayo|first5=Norman J.|last6=Mast|first6=Kelley|last7=Head|first7=David|last8=Raimondi|first8=Susana|last9=Hirsch|first9=Betsy|last10=Ge|first10=Yubin|last11=Gerbing|first11=Robert B.|last12=Wang|first12=Yi-Cheng|last13=Alonzo|first13=Todd A.|last14=Campana|first14=Dario|last15=Coustan-Smith|first15=Elaine|last16=Mathew|first16=Prasad|last17=Gamis|first17=Alan S.|title=Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial|journal=Blood|volume=129|issue=25|year=2017|pages=3304–3313|issn=0006-4971|doi=10.1182/blood-2017-01-764324}}</ref>

*Similarly, the reported 3-year overall survival rate was 100% among 3 AMKL with Down syndrome patients while (47±12%) in non-Down syndrome patients.<ref name="QiMao2020">{{cite journal|last1=Qi|first1=Haixiao|last2=Mao|first2=Yan|last3=Cao|first3=Qian|last4=Sun|first4=Xingzhen|last5=Kuai|first5=Wenxia|last6=Song|first6=Junhong|last7=Ma|first7=Li|last8=Hong|first8=Ze|last9=Hu|first9=Jian|last10=Zhou|first10=Guoping|title=Clinical Characteristics and Prognosis of 27 Patients with Childhood Acute Megakaryoblastic Leukemia|journal=Medical Science Monitor|volume=26|year=2020|issn=1643-3750|doi=10.12659/MSM.922662}}</ref>

*The 5-year overall survival rate in AMKL was 10.6% versus 17.5% in non-M7 [[Acute Myeloid leukemia|Acute myeloid leukemia]] subtypes.<ref name="GiriPathak2014">{{cite journal|last1=Giri|first1=Smith|last2=Pathak|first2=Ranjan|last3=Prouet|first3=Philippe|last4=Li|first4=Bojia|last5=Martin|first5=Mike G.|title=Acute megakaryocytic leukemia is associated with worse outcomes than other types of acute myeloid leukemia|journal=Blood|volume=124|issue=25|year=2014|pages=3833–3834|issn=0006-4971|doi=10.1182/blood-2014-09-603415}}</ref> Currently, [[chemotherapy]] and [[Allo-BMT|allogenic bone marrow transplant]] (Allo-BMT) are main therapy. Treatment-related toxicity is a big challenge. To address this issue, elaborated large future clinical studies are required.

==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]
[[Category:Needs content]]

Acute megakaryoblastic leukemia epidemiology and demographics

2021-04-26T14:09:58Z

Roukoz Abou Karam:

__NOTOC__
{{Acute megakaryoblastic leukemia}}

{{CMG}}; {{AE}}
==Overview==

==Epidemiology and Demographics==

* AMKL is the most common subtype of AML reported in [[Down syndrome]] patients.<ref name="XavierGe2009">{{cite journal|last1=Xavier|first1=Ana C.|last2=Ge|first2=Yubin|last3=Taub|first3=Jeffrey W.|title=Down Syndrome and Malignancies: A Unique Clinical Relationship|journal=The Journal of Molecular Diagnostics|volume=11|issue=5|year=2009|pages=371–380|issn=15251578|doi=10.2353/jmoldx.2009.080132}}</ref> It is more common in children compared with adults. The [[prevalence]] in children and adults is ~15% and 0.6%, respectively.<ref name="XavierGe20092">{{cite journal|last1=Xavier|first1=Ana C.|last2=Ge|first2=Yubin|last3=Taub|first3=Jeffrey W.|title=Down Syndrome and Malignancies: A Unique Clinical Relationship|journal=The Journal of Molecular Diagnostics|volume=11|issue=5|year=2009|pages=371–380|issn=15251578|doi=10.2353/jmoldx.2009.080132}}</ref><ref name="PaganoPulsoni2002">{{cite journal|last1=Pagano|first1=L|last2=Pulsoni|first2=A|last3=Vignetti|first3=M|last4=Mele|first4=L|last5=Fianchi|first5=L|last6=Petti|first6=MC|last7=Mirto|first7=S|last8=Falcucci|first8=P|last9=Fazi|first9=P|last10=Broccia|first10=G|last11=Specchia|first11=G|last12=Di Raimondo|first12=F|last13=Pacilli|first13=L|last14=Leoni|first14=P|last15=Ladogana|first15=S|last16=Gallo|first16=E|last17=Venditti|first17=A|last18=Avanzi|first18=G|last19=Camera|first19=A|last20=Liso|first20=V|last21=Leone|first21=G|last22=Mandelli|first22=F|title=Acute megakaryoblastic leukemia: experience of GIMEMA trials|journal=Leukemia|volume=16|issue=9|year=2002|pages=1622–1626|issn=0887-6924|doi=10.1038/sj.leu.2402618}}</ref>

*Down syndrome patients carry a 200 fold increased risk of developing AMKL vs. non-Down syndrome patients.<ref name="ZipurskyPeeters20092">{{cite journal|last1=Zipursky|first1=Alvin|last2=Peeters|first2=Marie|last3=Poon|first3=Annette|title=Megakaryoblastic Leukemia and Down's Syndrome: A Review|journal=Pediatric Hematology and Oncology|volume=4|issue=3|year=2009|pages=211–230|issn=0888-0018|doi=10.3109/08880018709141272}}</ref> Similarly, another review proposed a 500 fold increased risk.<ref name="AthaleRazzouk2001">{{cite journal|last1=Athale|first1=Uma H.|last2=Razzouk|first2=Bassem I.|last3=Raimondi|first3=Susana C.|last4=Tong|first4=Xin|last5=Behm|first5=Frederick G.|last6=Head|first6=David R.|last7=Srivastava|first7=Deo K.|last8=Rubnitz|first8=Jeffrey E.|last9=Bowman|first9=Laura|last10=Pui|first10=Ching-Hon|last11=Ribeiro|first11=Raul C.|title=Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience|journal=Blood|volume=97|issue=12|year=2001|pages=3727–3732|issn=1528-0020|doi=10.1182/blood.V97.12.3727}}</ref> It almost exclusively occurs in the first 3 years of life.<ref name="XavierGe20094">{{cite journal|last1=Xavier|first1=Ana C.|last2=Ge|first2=Yubin|last3=Taub|first3=Jeffrey W.|title=Down Syndrome and Malignancies: A Unique Clinical Relationship|journal=The Journal of Molecular Diagnostics|volume=11|issue=5|year=2009|pages=371–380|issn=15251578|doi=10.2353/jmoldx.2009.080132}}</ref><ref name="ZipurskyPeeters20094">{{cite journal|last1=Zipursky|first1=Alvin|last2=Peeters|first2=Marie|last3=Poon|first3=Annette|title=Megakaryoblastic Leukemia and Down's Syndrome: A Review|journal=Pediatric Hematology and Oncology|volume=4|issue=3|year=2009|pages=211–230|issn=0888-0018|doi=10.3109/08880018709141272}}</ref>
*[[Transient leukemia]] (TL) occurs in approximately 10% of Down syndrome infants, which is also attributed to transient [[myeloproliferative disorder]].<ref name="Zipursky2003">{{cite journal|last1=Zipursky|first1=Alvin|title=Transient leukaemia - a benign form of leukaemia in newborn infants with trisomy 21|journal=British Journal of Haematology|volume=120|issue=6|year=2003|pages=930–938|issn=00071048|doi=10.1046/j.1365-2141.2003.04229.x}}</ref><ref name="PineGuo2007">{{cite journal|last1=Pine|first1=Sharon R.|last2=Guo|first2=Qianxu|last3=Yin|first3=Changhong|last4=Jayabose|first4=Somasundaram|last5=Druschel|first5=Charlotte M.|last6=Sandoval|first6=Claudio|title=Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome|journal=Blood|volume=110|issue=6|year=2007|pages=2128–2131|issn=0006-4971|doi=10.1182/blood-2007-01-069542}}</ref> In most cases, TL spontaneously resolves; however, during the first four years of life, it progresses to acute megakaryoblastic leukemia in 13% to 33% of patients.<ref name="KlusmannCreutzig2008">{{cite journal|last1=Klusmann|first1=Jan-Henning|last2=Creutzig|first2=Ursula|last3=Zimmermann|first3=Martin|last4=Dworzak|first4=Michael|last5=Jorch|first5=Norbert|last6=Langebrake|first6=Claudia|last7=Pekrun|first7=Arnulf|last8=Macakova-Reinhardt|first8=Katarina|last9=Reinhardt|first9=Dirk|title=Treatment and prognostic impact of transient leukemia in neonates with Down syndrome|journal=Blood|volume=111|issue=6|year=2008|pages=2991–2998|issn=0006-4971|doi=10.1182/blood-2007-10-118810}}</ref>

==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]
[[Category:Needs content]]

Acute megakaryoblastic leukemia differential diagnosis

2021-04-26T14:09:13Z

Roukoz Abou Karam:

__NOTOC__
{{Acute megakaryoblastic leukemia}}

{{CMG}}; {{AE}}
==Overview==

==Differentiating acute megakaryoblastic leukemia from other Diseases==

Distinguishing features from other subtypes of AML are following:

*[[Thrombocytopenia]] is more common and severe in AMKL compared with [[myelodysplastic syndrome]] (MDS). Blast cells in the bone marrow are <30% in MDS versus >30% in AMKL.<ref name="ZipurskyThorner1994">{{cite journal|last1=Zipursky|first1=A.|last2=Thorner|first2=P.|last3=De Harven|first3=E.|last4=Christensen|first4=H.|last5=Doyle|first5=J.|title=Myelodysplasia and acute megakaryoblastic leukemia in down's syndrome|journal=Leukemia Research|volume=18|issue=3|year=1994|pages=163–171|issn=01452126|doi=10.1016/0145-2126(94)90111-2}}</ref>
*Presence of megakaryocytic specific antigens ([[CD41,]] [[CD61]])<ref name="O Olatunji2018">{{cite journal|last1=O Olatunji|first1=Philip|title=A case of acute megakaryoblastic leukaemia (FAB M7), a rare type of acute myeloid leukemia (AML), in a teenager|journal=Malawi Medical Journal|volume=30|issue=4|year=2018|pages=298|issn=1995-7262|doi=10.4314/mmj.v30i4.15}}</ref> and markers ([[glycoprotein 1b]]) and platelets [[peroxidase]] activity. [[Karyotype]] analysis also helpful due to its complex and unusual karyotypic presentation (t(1;22)(p13;q13).<ref name="DöhnerEstey2010">{{cite journal|last1=Döhner|first1=Hartmut|last2=Estey|first2=Elihu H.|last3=Amadori|first3=Sergio|last4=Appelbaum|first4=Frederick R.|last5=Büchner|first5=Thomas|last6=Burnett|first6=Alan K.|last7=Dombret|first7=Hervé|last8=Fenaux|first8=Pierre|last9=Grimwade|first9=David|last10=Larson|first10=Richard A.|last11=Lo-Coco|first11=Francesco|last12=Naoe|first12=Tomoki|last13=Niederwieser|first13=Dietger|last14=Ossenkoppele|first14=Gert J.|last15=Sanz|first15=Miguel A.|last16=Sierra|first16=Jorge|last17=Tallman|first17=Martin S.|last18=Löwenberg|first18=Bob|last19=Bloomfield|first19=Clara D.|title=Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet|journal=Blood|volume=115|issue=3|year=2010|pages=453–474|issn=0006-4971|doi=10.1182/blood-2009-07-235358}}</ref><ref name="De MarchiAraki2019">{{cite journal|last1=De Marchi|first1=Federico|last2=Araki|first2=Marito|last3=Komatsu|first3=Norio|title=Molecular features, prognosis, and novel treatment options for pediatric acute megakaryoblastic leukemia|journal=Expert Review of Hematology|volume=12|issue=5|year=2019|pages=285–293|issn=1747-4086|doi=10.1080/17474086.2019.1609351}}</ref>

===Differential Diagnoses:<ref name="DöhnerEstey20105">{{cite journal|last1=Döhner|first1=Hartmut|last2=Estey|first2=Elihu H.|last3=Amadori|first3=Sergio|last4=Appelbaum|first4=Frederick R.|last5=Büchner|first5=Thomas|last6=Burnett|first6=Alan K.|last7=Dombret|first7=Hervé|last8=Fenaux|first8=Pierre|last9=Grimwade|first9=David|last10=Larson|first10=Richard A.|last11=Lo-Coco|first11=Francesco|last12=Naoe|first12=Tomoki|last13=Niederwieser|first13=Dietger|last14=Ossenkoppele|first14=Gert J.|last15=Sanz|first15=Miguel A.|last16=Sierra|first16=Jorge|last17=Tallman|first17=Martin S.|last18=Löwenberg|first18=Bob|last19=Bloomfield|first19=Clara D.|title=Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet|journal=Blood|volume=115|issue=3|year=2010|pages=453–474|issn=0006-4971|doi=10.1182/blood-2009-07-235358}}</ref>===

====[[Acute myeloid leukemia]] otherwise not specified as per WHO classification:====

#''Acute myeloid leukemia with minimal differentiation''
#''Acute myeloid leukemia without maturation''
#''Acute myeloid leukemia with maturation''
#''Acute myelomonocytic leukemia''
#''Acute monoblastic/monocytic leukemia''
#'' Acute erythroid leukemia''
#''Pure erythroid leukemia''
#''Erythroleukemia, erythroid/myeloid''
#'' Acute basophilic leukemia''
#''Acute panmyelosis with myelofibrosis (a.k.a acute myelofibrosis)''

'''[[Myeloid sarcoma]]'''
 
==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]
[[Category:Needs content]]

Acute megakaryoblastic leukemia pathophysiology

2021-04-26T14:08:13Z

Roukoz Abou Karam:

__NOTOC__
{{Acute megakaryoblastic leukemia}}
{{CMG}}; {{AE}}

==Overview==

==Pathophysiology==

*It is associated with [[GATA1]], and risks are increased in individuals with [[Down syndrome]].<ref name="pmid12586620">{{cite journal |author=Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A |title=GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome |journal=Blood |volume=101 |issue=11 |pages=4301–4 |year=2003 |pmid=12586620 |doi=10.1182/blood-2003-01-0013 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=12586620}}</ref> However, not all cases are associated with Down syndrome,<ref name="pmid18275433">{{cite journal |author=Hama A, Yagasaki H, Takahashi Y, ''et al'' |title=Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome |journal=Br. J. Haematol. |volume=140 |issue=5 |pages=552–61 |year=2008 |pmid=18275433 |doi=10.1111/j.1365-2141.2007.06971.x |url=http://dx.doi.org/10.1111/j.1365-2141.2007.06971.x}}</ref> and other [[genes]] can also be associated with AMKL.<ref name="pmid17360941">{{cite journal |author=Gu TL, Mercher T, Tyner JW, ''et al'' |title=A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia |journal=Blood |volume=110 |issue=1 |pages=323–33 |year=2007 |pmid=17360941 |doi=10.1182/blood-2006-10-052282 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=17360941}}</ref>

*According to the report of the [[French-American-British]] Cooperative Group, this category of AML (M7 subtype) is associated with 30% or more blasts in the bone marrow. Blasts are identified as being of megakaryocyte lineage by; expression of [[megakaryocyte]] specific [[antigen]]s and platelet [[peroxidase]] reaction on [[electron microscopy]].<ref name="Bennett19852">{{cite journal|last1=Bennett|first1=John M.|title=Criteria for the Diagnosis of Acute Leukemia of Megakaryocyte Lineage (M7)|journal=Annals of Internal Medicine|volume=103|issue=3|year=1985|pages=460|issn=0003-4819|doi=10.7326/0003-4819-103-3-460}}</ref>

*[[Myelofibrosis]] is usually associated with AMKL; however, the exact underlying pathophysiology is controversial. The investigators did not find any direct correlation between acute myelofibrosis and the [[fibroblasts]] obtained from the bone marrow of patients with AMKL. Nevertheless, it was proposed that some humoral factors may play a key role in developing bone marrow fibrosis.<ref name="ClareElson1982">{{cite journal|last1=Clare|first1=Nanette|last2=Elson|first2=David|last3=Manhoff|first3=Louis|title=Cytogenetic Studies of Peripheral Myeloblasts and Bone Marrow Fibroblasts in Acute Myelofibrosis|journal=American Journal of Clinical Pathology|volume=77|issue=6|year=1982|pages=762–766|issn=0002-9173|doi=10.1093/ajcp/77.6.762}}</ref>

*[[Transforming Growth Factor-β]] (TG-β) was identified to be the significant contributor in AMKL associated myelofibrosis in addition to some other unknown factors due to the strong stimulatory effects on [[collagen]].<ref name="TeruiNiitsu1990">{{cite journal|last1=Terui|first1=T|last2=Niitsu|first2=Y|last3=Mahara|first3=K|last4=Fujisaki|first4=Y|last5=Urushizaki|first5=Y|last6=Mogi|first6=Y|last7=Kohgo|first7=Y|last8=Watanabe|first8=N|last9=Ogura|first9=M|last10=Saito|first10=H|title=The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis|journal=Blood|volume=75|issue=7|year=1990|pages=1540–1548|issn=0006-4971|doi=10.1182/blood.V75.7.1540.1540}}</ref>

 

==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]

Acute megakaryoblastic leukemia pathophysiology

2021-04-26T14:08:01Z

Roukoz Abou Karam:

__NOTOC__
{{Acute megakaryoblastic leukemia}}
{{CMG}}; {{AE}} {{Israrkhan}}

==Overview==

==Pathophysiology==

*It is associated with [[GATA1]], and risks are increased in individuals with [[Down syndrome]].<ref name="pmid12586620">{{cite journal |author=Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A |title=GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome |journal=Blood |volume=101 |issue=11 |pages=4301–4 |year=2003 |pmid=12586620 |doi=10.1182/blood-2003-01-0013 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=12586620}}</ref> However, not all cases are associated with Down syndrome,<ref name="pmid18275433">{{cite journal |author=Hama A, Yagasaki H, Takahashi Y, ''et al'' |title=Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome |journal=Br. J. Haematol. |volume=140 |issue=5 |pages=552–61 |year=2008 |pmid=18275433 |doi=10.1111/j.1365-2141.2007.06971.x |url=http://dx.doi.org/10.1111/j.1365-2141.2007.06971.x}}</ref> and other [[genes]] can also be associated with AMKL.<ref name="pmid17360941">{{cite journal |author=Gu TL, Mercher T, Tyner JW, ''et al'' |title=A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia |journal=Blood |volume=110 |issue=1 |pages=323–33 |year=2007 |pmid=17360941 |doi=10.1182/blood-2006-10-052282 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=17360941}}</ref>

*According to the report of the [[French-American-British]] Cooperative Group, this category of AML (M7 subtype) is associated with 30% or more blasts in the bone marrow. Blasts are identified as being of megakaryocyte lineage by; expression of [[megakaryocyte]] specific [[antigen]]s and platelet [[peroxidase]] reaction on [[electron microscopy]].<ref name="Bennett19852">{{cite journal|last1=Bennett|first1=John M.|title=Criteria for the Diagnosis of Acute Leukemia of Megakaryocyte Lineage (M7)|journal=Annals of Internal Medicine|volume=103|issue=3|year=1985|pages=460|issn=0003-4819|doi=10.7326/0003-4819-103-3-460}}</ref>

*[[Myelofibrosis]] is usually associated with AMKL; however, the exact underlying pathophysiology is controversial. The investigators did not find any direct correlation between acute myelofibrosis and the [[fibroblasts]] obtained from the bone marrow of patients with AMKL. Nevertheless, it was proposed that some humoral factors may play a key role in developing bone marrow fibrosis.<ref name="ClareElson1982">{{cite journal|last1=Clare|first1=Nanette|last2=Elson|first2=David|last3=Manhoff|first3=Louis|title=Cytogenetic Studies of Peripheral Myeloblasts and Bone Marrow Fibroblasts in Acute Myelofibrosis|journal=American Journal of Clinical Pathology|volume=77|issue=6|year=1982|pages=762–766|issn=0002-9173|doi=10.1093/ajcp/77.6.762}}</ref>

*[[Transforming Growth Factor-β]] (TG-β) was identified to be the significant contributor in AMKL associated myelofibrosis in addition to some other unknown factors due to the strong stimulatory effects on [[collagen]].<ref name="TeruiNiitsu1990">{{cite journal|last1=Terui|first1=T|last2=Niitsu|first2=Y|last3=Mahara|first3=K|last4=Fujisaki|first4=Y|last5=Urushizaki|first5=Y|last6=Mogi|first6=Y|last7=Kohgo|first7=Y|last8=Watanabe|first8=N|last9=Ogura|first9=M|last10=Saito|first10=H|title=The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis|journal=Blood|volume=75|issue=7|year=1990|pages=1540–1548|issn=0006-4971|doi=10.1182/blood.V75.7.1540.1540}}</ref>

 

==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]

Acute megakaryoblastic leukemia classification

2021-04-26T14:06:17Z

Roukoz Abou Karam:

__NOTOC__
{{Acute megakaryoblastic leukemia}}

{{CMG}}; {{AE}}
==Overview==
There is no established system for the classification of Acute megakaryoblastic leukemia.

==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hematology]]

User:Israrkhan

2021-04-26T13:55:09Z

Roukoz Abou Karam: Created page with "__NOTOC__ ==Israr Khan, M.D.== Contact: [mailto:israrkhan.dawar@gmail.com] == Current Position == Associate Editor, ''WikiDoc.org''"

__NOTOC__

==Israr Khan, M.D.==

Contact: [mailto:israrkhan.dawar@gmail.com] 

== Current Position ==
Associate Editor, ''WikiDoc.org''

Pulmonology status update

2021-04-20T13:54:39Z

Roukoz Abou Karam: /* Primary Care Topics */

__NOTOC__

{{CMG}}; {{AE}} {{Hudakarman}}
{{Organ System Project}}
System leader: '''[[User:Roukoz Abou Karam|Roukoz Abou Karam, M.D.]]'''
==Status Updates==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Resident survival guide Progress
|-
|Completed
|9
|-
|In progress
|1
|-
|Remaining
|2
|-
! colspan="2" style="background:#efefef;" |Primary care chapter Progress
|-
|Completed
|6
|-
|In progress
|5
|-
|Remaining
|0
|}

==Primary Care Topics==

{| class="wikitable sortable"
! colspan="4" |Primary care chapters
! colspan="3" |Primary care resident survival guides
|-
!Specialty
!Topic
!Author
!Status
!Resident Survival Guide Page
!Author
!Status
|-
|Pulmonary||[[Asthma|Asthma exacerbation]]
|
|Complete||[[Asthma exacerbation resident survival guide]]||Abdurahman, Vidit||Complete
|-
|Pulmonary||[[Chronic obstructive pulmonary disease|COPD exacerbation]]
|Roukoz Abou Karam
|Complete||[[COPD exacerbation resident survival guide]]|| ||Complete
|-
|Pulmonary
|[[Cough]]
|Abiodun Akanmode
|Complete
|[[Cough resident survival guide]]
|Sara Haddadi
|In progress
|-
|Pulmonary
|[[Dyspnea]]
|Roukoz Abou Karam
|In progress
|[[Dyspnea resident survival guide]]
|Eiman
|Needs review
|-
|Pulmonary
|[[Chest pain]]
|Aisha Adigun
|Complete
|[[Chest pain resident survival guide]]
|
|Complete
|-
|Pulmonary
|[[Hemoptysis]]
|
|Complete
|[[Hemoptysis resident survival guide]]
|Teresa
|Complete
|-
|Pulmonary||[[Anaphylaxis]]
|Dushka Riaz
|Complete||[[Anaphylaxis resident survival guide]]||Vidit||Complete
|-
|Pulmonary||[[Acute respiratory distress syndrome]]
|Roukoz Abou Karam
|Complete||[[Acute respiratory distress syndrome resident survival guide]]||Ayokunle||Complete
|-
|Pulmonary||[[Pleural effusion]]
|Dushka Riaz
|Complete||[[Pleural effusion resident survival guide]]||Twinkle||Complete
|-
|Pulmonary||[[Pulmonary embolism]]
|
|Complete||[[Pulmonary embolism resident survival guide]]|| ||Complete
|-
|Pulmonary
|[[Lung mass]]
|
|Complete
|[[Lung mass resident survival guide]]
|Akshun Kalia
|Complete
|} 

==Status Update==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Progress
|-
|Completed
|41
|-
|In progress
|9
|-
|Remaining
|20
|}
==List of Chapters Requiring Content==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="21" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonolgy
| style="padding: 5px 5px; background: #F5F5F5;" |[[Amniotic fluid embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchoscopy]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hepatopulmonary syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hydrothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |in progress
| style="padding: 5px 5px; background: #F5F5F5;" |Kunwardeep
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hypoxemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Mediastinal disorders
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mediastinal mass|Mediastinal masses]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Pleural disorders
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pleural plaque]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pleurodynia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Pressure associated lung diseases
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Altitude sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Barotrauma]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Nitrogen narcosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary function tests]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary nodule]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Idiopathic pulmonary hemosiderosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary lymphangioleiomyomatosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|}

==In progress chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="22" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonology
| style="padding: 5px 5px; background: #F5F5F5;" |[[Decompression sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Hazem
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Air embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mounika Lakumalla
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmed Elsaiey
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hepatopulmonary syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Soroush
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Tracheitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Rija Gul
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumoconiosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Berylliosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Omid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Farmer's lung]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Aisha
| style="padding: 5px 5px; background: #F5F5F5;" |Ali Musadiq
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Decompression sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Jaspinder Kaur
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmed Elsaiey
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Chylothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Joanna Ekabua
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz Abou Karam
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Thoracentesis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ayeesha
| style="padding: 5px 5px; background: #F5F5F5;" |Ali Musadiq
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Flock worker's lung]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usman Shah
| style="padding: 5px 5px; background: #F5F5F5;" |Sara Mohsin
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-

|}

==Completed chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="45" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonology
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cystic fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Shamila
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary hypertension]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ajay
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory failure]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Khurram/Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary edema]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Famaz/Manpreet
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Neurogenic pulmonary edema]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Shamila
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchiectasis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hemoptysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Occupational lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Restrictive lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Obstructive lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Interstitial lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf/Anmol
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Idiopathic pulmonary fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmad E
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary alveolar proteinosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mahda
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cryptogenic organizing pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Manpreet
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Interstitial pneumonitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Chandra
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Small cell lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mesothelioma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mazia/feham/fatima
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid/Fehman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hypersensitivity pneumonitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sargun
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Non small cell lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mohsin
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Adenocarcinoma of the lung|Adenocarcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sudarshana
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Large cell carcinoma of the lung|Large cell carcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Aditiya
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Squamous cell carcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lung mass]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Akshun
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cyanosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Chandra/Medhat/Amandeep
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory acidosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Krishna
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory alkalosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Madhu
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Diaphragmatic paralysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mahda
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchogenic cyst]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Joanna Ekabua
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Eosinophilic pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Medhat
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Fat embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Fehman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mechanical ventilation]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ajay
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Atelectasis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sudarshana
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pancoast tumor]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mazia
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Blood gas analysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Medhat
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[CO poisoning]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Fatima
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Aspiration pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory patterns]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Eiman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hyperventilation]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Amresh/Akshun/Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|}

Hematology status update

2021-04-19T15:36:44Z

Roukoz Abou Karam: /* List of Chapters Requiring Content */

__NOTOC__

{{CMG}}; {{AE}} {{Hudakarman}}
{{Organ System Project}}
System Leader: {{AEL}}
==Status Updates==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Resident survival guide Progress
|-
|Completed
|2
|-
|In progress
|2
|-
|Remaining
|12
|-
! colspan="2" style="background:#efefef;" |Primary care chapter Progress
|-
|Completed
|5
|-
|In progress
|4
|-
|Remaining
|5
|}

==Primary Care==
{| class="wikitable sortable"
! colspan="4" |Primary care chapter
! colspan="3" |Primary care resident survival guides
|-
!Specialty
!Topic
!Author
!Status
!Resident Survival Guide Page
!Author
!Status
|-
|Hematology
|[[Easy bruising]]
|Raviteja Guddeti
|Needs content
|[[Easy bruising resident survival guide]]
|Sanjana
|Needs English Review
|-
|Hematology
|[[Thrombophilia]]
|Sogand Goudarzi
|Needs review
|[[Thrombophilia resident survival guide]]
|Rina Ghorpade
|Complete
|-
|Hematology||[[Anemia]]
|Mehrian Jafarizade
|Complete
|[[Anemia resident survival guide]]||Chetan||Needs English review
|-
|Hematalogy
|[[Fatigue]]
|M.Umer Tariq
|Needs content
|[[Fatigue resident survival guide]]
|Monika, Tayyeba
|Complete/Needs English review
|-
|Hematalogy
|[[Pica]]
|
|Needs content
|[[Pica resident survival guide]]
|Sanjana
|Needs English review
|-
|Hematology
|[[Polycythemia]]
|Debduti
|Needs content
|[[Polycythemia resident survival guide]]
|Alieh Behjat
|Complete
|-
|Hematology||[[Aplastic anemia]]
|Nazia Fuad
|Needs review
|[[Aplastic anemia resident survival guide]]||Chetan||Needs Review
|-
|Hematology||[[Hemolytic anemia]]
|Shyam Patel
|Needs review
|[[Hemolytic anemia resident survival guide]]||Sanjana
|Complete
|-
|Hematology||[[Heparin induced thrombocytopenia]]
|Aric C. Hall
|Needs review
|[[HIT resident survival guide]]||Karol||Needs Review
|-
|Hematology
|[[Immune Thrombocytopenia]]
|Maryam Barkhordarian
|In progress
|[[Immune Thrombocytopenia resident survival guide]]
|
|Needs content?
|-
|Hematology
|[[Venous thromboembolism|VTE]]
|Syed Hassan A. Kazmi
|Complete
|[[VTE prevention resident survival guide]]
|
|Needs review
|-
|Hematology
|[[Acute Leukemia]]
|Alieh Behjat
|Needs content
|[[Acute leukemia resident survival guide]]
|Alieh Behjat
|Needs English review
|-
|Hematology||[[Pancytopenia]]
|Cafer Zorkun
|Needs review
|[[Pancytopenia resident survival guide]]|| ||Complete
|-
|Hematology||[[Thrombocytopenia]]
|Farbod Zahedi Tajrishi
|Needs review
|[[Thrombocytopenia resident survival guide]]||Ogheneochuko||Complete
|-
|Hematology||[[Febrile neutropenia]]
|
|Needs review
|[[Febrile neutropenia resident survival guide]]||Rim||Needs review
|-
|Hematology||[[Bleeding disorders]]
|Sogand Goudarzi
|Needs review
|[[Bleeding disorder resident survival guide]]|| ||Needs review
|-
|Hematology||[[DIC]]
|Omer Kamal
|Needs review
|[[DIC resident survival guide]]||Ogheneochuko||Complete
|-
|Hematology||[[Transfusion therapy]]
|
|Needs content
|[[Transfusion therapy resident survival guide]]||Ayokunle||Complete
|}

==Status Update==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Progress
|-
|Completed
|4
|-
|In progress
|4
|-
|Remaining
|16
|}
==List of Chapters Requiring Content==
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="25" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Hematology
| style="padding: 5px 5px; background: #F5F5F5;" |
*Acanthocytosis

*
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |

*[[Microangiopathic hemolytic anemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Myelophthisic anemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[ACUITY HORIZONS bleeding criteria]]

*
*
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*
*[[Purpura]]
**Papular
**Infectious
**[[Purpura fulminans]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Thrombotic microangiopathies|Thrombotic micropangiopathy]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Angiopathy|Angiopathies]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Acute megakaryoblastic leukemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Completed
| style="padding: 5px 5px; background: #F5F5F5;" |Israr Khan
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |in progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Neutrophilia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Autoimmune lymphoproliferative syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Lymphocytosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Monocytosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[https://www.wikidoc.org/index.php/Eosinophilia Eosiniphilia]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Basophilia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Aisha Adigun
| style="padding: 5px 5px; background: #F5F5F5;" |Homa
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Castleman's disease]]

*
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Evans syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Asplenia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|
|-
|}

==In progress chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="22" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Hematology
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hemophilia]]
*[[Hemophilia A (patient information)|Hemophilia A]]
*[[Hemophilia B (patient information)|Hemophilia B]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Muhammad Adnan Heider
| style="padding: 5px 5px; background: #F5F5F5;" |Abdelrahman
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" | 

*[[22q11.2 deletion syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ayushi Jane
| style="padding: 5px 5px; background: #F5F5F5;" |Ramyar
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Anemia of prematurity]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Asra Firdous
| style="padding: 5px 5px; background: #F5F5F5;" |Ramyar
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Myelophthisic anemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mahda
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Diamond-Blackfan anemia]]

*
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Roghiae Marandi
| style="padding: 5px 5px; background: #F5F5F5;" |Musadiq
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-

|}

==Completed chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="22" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Hematology
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Antithrombin III deficiency]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Sogand, M.khuram afzal
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |Needs Review
| style="padding: 5px 5px; background: #F5F5F5;" |Ramyar
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Neutropenia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Daniel A. Gerber
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |Needs Review
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |Needs Review
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Fanconi anemia]]

*
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Shayam Patel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |Needs Review
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|}

Pulmonology status update

2021-04-19T15:36:06Z

Roukoz Abou Karam: /* List of Chapters Requiring Content */

__NOTOC__

{{CMG}}; {{AE}} {{Hudakarman}}
{{Organ System Project}}
System leader: '''[[User:Roukoz Abou Karam|Roukoz Abou Karam, M.D.]]'''
==Status Updates==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Resident survival guide Progress
|-
|Completed
|9
|-
|In progress
|1
|-
|Remaining
|2
|-
! colspan="2" style="background:#efefef;" |Primary care chapter Progress
|-
|Completed
|6
|-
|In progress
|5
|-
|Remaining
|0
|}

==Primary Care Topics==

{| class="wikitable sortable"
! colspan="4" |Primary care chapters
! colspan="3" |Primary care resident survival guides
|-
!Specialty
!Topic
!Author
!Status
!Resident Survival Guide Page
!Author
!Status
|-
|Pulmonary||[[Asthma|Asthma exacerbation]]
|
|Complete||[[Asthma exacerbation resident survival guide]]||Abdurahman, Vidit||Complete
|-
|Pulmonary||[[Chronic obstructive pulmonary disease|COPD exacerbation]]
|Roukoz Abou Karam
|Complete||[[COPD exacerbation resident survival guide]]|| ||Complete
|-
|Pulmonary
|[[Cough]]
|Abiodun Akanmode
|Complete
|[[Cough resident survival guide]]
|Sara Haddadi
|In progress
|-
|Pulmonary
|[[Dyspnea]]
|Roukoz Abou Karam
|In progress
|[[Dyspnea resident survival guide]]
|Eiman
|Needs review
|-
|Pulmonary
|[[Chest pain]]
|Aisha Adigun
|Complete
|[[Chest pain resident survival guide]]
|
|Complete
|-
|Pulmonary
|[[Hemoptysis]]
|
|Complete
|[[Hemoptysis resident survival guide]]
|Teresa
|Complete
|-
|Pulmonary||[[Anaphylaxis]]
|Dushka Riaz
|In progress||[[Anaphylaxis resident survival guide]]||Vidit||Complete
|-
|Pulmonary||[[Acute respiratory distress syndrome]]
|Roukoz Abou Karam
|Complete||[[Acute respiratory distress syndrome resident survival guide]]||Ayokunle||Complete
|-
|Pulmonary||[[Pleural effusion]]
|Dushka Riaz
|Complete||[[Pleural effusion resident survival guide]]||Twinkle||Complete
|-
|Pulmonary||[[Pulmonary embolism]]
|
|Complete||[[Pulmonary embolism resident survival guide]]|| ||Complete
|-
|Pulmonary
|[[Lung mass]]
|
|Complete
|[[Lung mass resident survival guide]]
|Akshun Kalia
|Complete
|} 

==Status Update==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Progress
|-
|Completed
|41
|-
|In progress
|9
|-
|Remaining
|20
|}
==List of Chapters Requiring Content==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="21" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonolgy
| style="padding: 5px 5px; background: #F5F5F5;" |[[Amniotic fluid embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchoscopy]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hepatopulmonary syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hydrothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |in progress
| style="padding: 5px 5px; background: #F5F5F5;" |Kunwardeep
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hypoxemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Mediastinal disorders
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mediastinal mass|Mediastinal masses]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Pleural disorders
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pleural plaque]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pleurodynia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Pressure associated lung diseases
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Altitude sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Barotrauma]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Nitrogen narcosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary function tests]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary nodule]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Idiopathic pulmonary hemosiderosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary lymphangioleiomyomatosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|}

==In progress chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="22" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonology
| style="padding: 5px 5px; background: #F5F5F5;" |[[Decompression sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Hazem
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Air embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mounika Lakumalla
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmed Elsaiey
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hepatopulmonary syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Soroush
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Tracheitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Rija Gul
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumoconiosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Berylliosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Omid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Farmer's lung]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Aisha
| style="padding: 5px 5px; background: #F5F5F5;" |Ali Musadiq
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Decompression sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Jaspinder Kaur
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmed Elsaiey
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Chylothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Joanna Ekabua
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz Abou Karam
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Thoracentesis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ayeesha
| style="padding: 5px 5px; background: #F5F5F5;" |Ali Musadiq
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Flock worker's lung]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usman Shah
| style="padding: 5px 5px; background: #F5F5F5;" |Sara Mohsin
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-

|}

==Completed chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="45" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonology
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cystic fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Shamila
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary hypertension]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ajay
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory failure]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Khurram/Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary edema]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Famaz/Manpreet
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Neurogenic pulmonary edema]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Shamila
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchiectasis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hemoptysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Occupational lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Restrictive lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Obstructive lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Interstitial lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf/Anmol
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Idiopathic pulmonary fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmad E
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary alveolar proteinosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mahda
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cryptogenic organizing pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Manpreet
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Interstitial pneumonitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Chandra
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Small cell lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mesothelioma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mazia/feham/fatima
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid/Fehman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hypersensitivity pneumonitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sargun
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Non small cell lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mohsin
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Adenocarcinoma of the lung|Adenocarcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sudarshana
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Large cell carcinoma of the lung|Large cell carcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Aditiya
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Squamous cell carcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lung mass]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Akshun
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cyanosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Chandra/Medhat/Amandeep
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory acidosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Krishna
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory alkalosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Madhu
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Diaphragmatic paralysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mahda
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchogenic cyst]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Joanna Ekabua
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Eosinophilic pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Medhat
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Fat embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Fehman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mechanical ventilation]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ajay
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Atelectasis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sudarshana
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pancoast tumor]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mazia
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Blood gas analysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Medhat
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[CO poisoning]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Fatima
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Aspiration pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory patterns]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Eiman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hyperventilation]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Amresh/Akshun/Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|}

User:KunwardeepArora

2021-04-10T16:10:10Z

Roukoz Abou Karam: Created page with "__NOTOC__ ==Kunwardeep Singh Arora, M.B.B.S== Contact: == Current Position == Associate Editor, ''WikiDoc.org''"

__NOTOC__

==Kunwardeep Singh Arora, M.B.B.S==
Contact:

== Current Position ==
Associate Editor, ''WikiDoc.org''

User:KunwardeepSingh

2021-04-10T16:06:10Z

Roukoz Abou Karam: /* =Kunwardeep Singh Arora, M.B.B.S */

__NOTOC__

==Kunwardeep Singh Arora, M.B.B.S==

Contact:

User:KunwardeepSingh

2021-04-10T16:04:09Z

Roukoz Abou Karam: Created page with "__NOTOC__ ===Kunwardeep Singh Arora, M.B.B.S== Contact:"

__NOTOC__

===Kunwardeep Singh Arora, M.B.B.S==

Contact:

Pulmonology status update

2021-04-01T15:18:32Z

Roukoz Abou Karam:

__NOTOC__

{{CMG}}; {{AE}} {{Hudakarman}}
{{Organ System Project}}
System leader: '''[[User:Roukoz Abou Karam|Roukoz Abou Karam, M.D.]]'''
==Status Updates==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Resident survival guide Progress
|-
|Completed
|9
|-
|In progress
|1
|-
|Remaining
|2
|-
! colspan="2" style="background:#efefef;" |Primary care chapter Progress
|-
|Completed
|6
|-
|In progress
|5
|-
|Remaining
|0
|}

==Primary Care Topics==

{| class="wikitable sortable"
! colspan="4" |Primary care chapters
! colspan="3" |Primary care resident survival guides
|-
!Specialty
!Topic
!Author
!Status
!Resident Survival Guide Page
!Author
!Status
|-
|Pulmonary||[[Asthma|Asthma exacerbation]]
|
|Complete||[[Asthma exacerbation resident survival guide]]||Abdurahman, Vidit||Complete
|-
|Pulmonary||[[Chronic obstructive pulmonary disease|COPD exacerbation]]
|Roukoz Abou Karam
|Complete||[[COPD exacerbation resident survival guide]]|| ||Complete
|-
|Pulmonary
|[[Cough]]
|Abiodun Akanmode
|Complete
|[[Cough resident survival guide]]
|Sara Haddadi
|In progress
|-
|Pulmonary
|[[Dyspnea]]
|Roukoz Abou Karam
|In progress
|[[Dyspnea resident survival guide]]
|Eiman
|Needs review
|-
|Pulmonary
|[[Chest pain]]
|Aisha Adigun
|Complete
|[[Chest pain resident survival guide]]
|
|Complete
|-
|Pulmonary
|[[Hemoptysis]]
|
|Complete
|[[Hemoptysis resident survival guide]]
|Teresa
|Complete
|-
|Pulmonary||[[Anaphylaxis]]
|Dushka Riaz
|In progress||[[Anaphylaxis resident survival guide]]||Vidit||Complete
|-
|Pulmonary||[[Acute respiratory distress syndrome]]
|Roukoz Abou Karam
|Complete||[[Acute respiratory distress syndrome resident survival guide]]||Ayokunle||Complete
|-
|Pulmonary||[[Pleural effusion]]
|Dushka Riaz
|Complete||[[Pleural effusion resident survival guide]]||Twinkle||Complete
|-
|Pulmonary||[[Pulmonary embolism]]
|
|Complete||[[Pulmonary embolism resident survival guide]]|| ||Complete
|-
|Pulmonary
|[[Lung mass]]
|
|Complete
|[[Lung mass resident survival guide]]
|Akshun Kalia
|Complete
|} 

==Status Update==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Progress
|-
|Completed
|41
|-
|In progress
|9
|-
|Remaining
|20
|}
==List of Chapters Requiring Content==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="21" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonolgy
| style="padding: 5px 5px; background: #F5F5F5;" |[[Amniotic fluid embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchoscopy]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hepatopulmonary syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hydrothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hypoxemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Mediastinal disorders
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mediastinal mass|Mediastinal masses]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Pleural disorders
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pleural plaque]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pleurodynia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Pressure associated lung diseases
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Altitude sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Barotrauma]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Nitrogen narcosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary function tests]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary nodule]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Idiopathic pulmonary hemosiderosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary lymphangioleiomyomatosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|}

==In progress chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="22" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonology
| style="padding: 5px 5px; background: #F5F5F5;" |[[Decompression sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Hazem
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Air embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mounika Lakumalla
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmed Elsaiey
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hepatopulmonary syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Soroush
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Tracheitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Rija Gul
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumoconiosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Berylliosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Omid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Farmer's lung]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Aisha
| style="padding: 5px 5px; background: #F5F5F5;" |Ali Musadiq
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Decompression sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Jaspinder Kaur
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmed Elsaiey
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Chylothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Joanna Ekabua
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz Abou Karam
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Thoracentesis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ayeesha
| style="padding: 5px 5px; background: #F5F5F5;" |Ali Musadiq
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Flock worker's lung]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usman Shah
| style="padding: 5px 5px; background: #F5F5F5;" |Sara Mohsin
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-

|}

==Completed chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="45" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonology
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cystic fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Shamila
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary hypertension]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ajay
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory failure]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Khurram/Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary edema]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Famaz/Manpreet
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Neurogenic pulmonary edema]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Shamila
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchiectasis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hemoptysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Occupational lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Restrictive lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Obstructive lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Interstitial lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf/Anmol
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Idiopathic pulmonary fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmad E
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary alveolar proteinosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mahda
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cryptogenic organizing pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Manpreet
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Interstitial pneumonitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Chandra
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Small cell lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mesothelioma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mazia/feham/fatima
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid/Fehman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hypersensitivity pneumonitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sargun
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Non small cell lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mohsin
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Adenocarcinoma of the lung|Adenocarcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sudarshana
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Large cell carcinoma of the lung|Large cell carcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Aditiya
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Squamous cell carcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lung mass]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Akshun
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cyanosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Chandra/Medhat/Amandeep
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory acidosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Krishna
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory alkalosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Madhu
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Diaphragmatic paralysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mahda
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchogenic cyst]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Joanna Ekabua
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Eosinophilic pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Medhat
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Fat embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Fehman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mechanical ventilation]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ajay
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Atelectasis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sudarshana
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pancoast tumor]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mazia
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Blood gas analysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Medhat
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[CO poisoning]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Fatima
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Aspiration pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory patterns]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Eiman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hyperventilation]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Amresh/Akshun/Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|}

Hematology status update

2021-04-01T14:41:44Z

Roukoz Abou Karam: /* List of Chapters Requiring Content */

__NOTOC__

{{CMG}}; {{AE}} {{Hudakarman}}
{{Organ System Project}}
System Leader: {{AEL}}
==Status Updates==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Resident survival guide Progress
|-
|Completed
|2
|-
|In progress
|2
|-
|Remaining
|12
|-
! colspan="2" style="background:#efefef;" |Primary care chapter Progress
|-
|Completed
|5
|-
|In progress
|4
|-
|Remaining
|5
|}

==Primary Care==
{| class="wikitable sortable"
! colspan="4" |Primary care chapter
! colspan="3" |Primary care resident survival guides
|-
!Specialty
!Topic
!Author
!Status
!Resident Survival Guide Page
!Author
!Status
|-
|Hematology
|[[Easy bruising]]
|Raviteja Guddeti
|Needs content
|[[Easy bruising resident survival guide]]
|Sanjana
|Needs English Review
|-
|Hematology
|[[Thrombophilia]]
|Sogand Goudarzi
|Needs review
|[[Thrombophilia resident survival guide]]
|Rina Ghorpade
|Complete
|-
|Hematology||[[Anemia]]
|Mehrian Jafarizade
|Complete
|[[Anemia resident survival guide]]||Chetan||Needs English review
|-
|Hematalogy
|[[Fatigue]]
|M.Umer Tariq
|Needs content
|[[Fatigue resident survival guide]]
|Monika, Tayyeba
|Complete/Needs English review
|-
|Hematalogy
|[[Pica]]
|
|Needs content
|[[Pica resident survival guide]]
|Sanjana
|Needs English review
|-
|Hematology
|[[Polycythemia]]
|Debduti
|Needs content
|[[Polycythemia resident survival guide]]
|Alieh Behjat
|Complete
|-
|Hematology||[[Aplastic anemia]]
|Nazia Fuad
|Needs review
|[[Aplastic anemia resident survival guide]]||Chetan||Needs Review
|-
|Hematology||[[Hemolytic anemia]]
|Shyam Patel
|Needs review
|[[Hemolytic anemia resident survival guide]]||Sanjana
|Complete
|-
|Hematology||[[Heparin induced thrombocytopenia]]
|Aric C. Hall
|Needs review
|[[HIT resident survival guide]]||Karol||Needs Review
|-
|Hematology
|[[Immune Thrombocytopenia]]
|Maryam Barkhordarian
|In progress
|[[Immune Thrombocytopenia resident survival guide]]
|
|Needs content?
|-
|Hematology
|[[Venous thromboembolism|VTE]]
|Syed Hassan A. Kazmi
|Complete
|[[VTE prevention resident survival guide]]
|
|Needs review
|-
|Hematology
|[[Acute Leukemia]]
|Alieh Behjat
|Needs content
|[[Acute leukemia resident survival guide]]
|Alieh Behjat
|Needs English review
|-
|Hematology||[[Pancytopenia]]
|Cafer Zorkun
|Needs review
|[[Pancytopenia resident survival guide]]|| ||Complete
|-
|Hematology||[[Thrombocytopenia]]
|Farbod Zahedi Tajrishi
|Needs review
|[[Thrombocytopenia resident survival guide]]||Ogheneochuko||Complete
|-
|Hematology||[[Febrile neutropenia]]
|
|Needs review
|[[Febrile neutropenia resident survival guide]]||Rim||Needs review
|-
|Hematology||[[Bleeding disorders]]
|Sogand Goudarzi
|Needs review
|[[Bleeding disorder resident survival guide]]|| ||Needs review
|-
|Hematology||[[DIC]]
|Omer Kamal
|Needs review
|[[DIC resident survival guide]]||Ogheneochuko||Complete
|-
|Hematology||[[Transfusion therapy]]
|
|Needs content
|[[Transfusion therapy resident survival guide]]||Ayokunle||Complete
|}

==Status Update==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Progress
|-
|Completed
|4
|-
|In progress
|4
|-
|Remaining
|16
|}
==List of Chapters Requiring Content==
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="25" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Hematology
| style="padding: 5px 5px; background: #F5F5F5;" |
*Acanthocytosis

*
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |

*[[Microangiopathic hemolytic anemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Myelophthisic anemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[ACUITY HORIZONS bleeding criteria]]

*
*
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*
*[[Purpura]]
**Papular
**Infectious
**[[Purpura fulminans]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Thrombotic microangiopathies|Thrombotic micropangiopathy]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Angiopathy|Angiopathies]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Acute megakaryoblastic leukemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |in progress
| style="padding: 5px 5px; background: #F5F5F5;" |Israr Khan
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Neutrophilia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Autoimmune lymphoproliferative syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Lymphocytosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Monocytosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[https://www.wikidoc.org/index.php/Eosinophilia Eosiniphilia]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Basophilia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Aisha Adigun
| style="padding: 5px 5px; background: #F5F5F5;" |Homa
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Castleman's disease]]

*
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Evans syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Asplenia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|
|-
|}

==In progress chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="22" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Hematology
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hemophilia]]
*[[Hemophilia A (patient information)|Hemophilia A]]
*[[Hemophilia B (patient information)|Hemophilia B]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Muhammad Adnan Heider
| style="padding: 5px 5px; background: #F5F5F5;" |Abdelrahman
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" | 

*[[22q11.2 deletion syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ayushi Jane
| style="padding: 5px 5px; background: #F5F5F5;" |Ramyar
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Anemia of prematurity]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Asra Firdous
| style="padding: 5px 5px; background: #F5F5F5;" |Ramyar
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Myelophthisic anemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mahda
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Diamond-Blackfan anemia]]

*
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Roghiae Marandi
| style="padding: 5px 5px; background: #F5F5F5;" |Musadiq
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-

|}

==Completed chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="22" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Hematology
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Antithrombin III deficiency]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Sogand, M.khuram afzal
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |Needs Review
| style="padding: 5px 5px; background: #F5F5F5;" |Ramyar
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Neutropenia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Daniel A. Gerber
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |Needs Review
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |Needs Review
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Fanconi anemia]]

*
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Shayam Patel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |Needs Review
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|}

Pulmonology status update

2021-04-01T14:36:06Z

Roukoz Abou Karam:

__NOTOC__

{{CMG}}; {{AE}} {{Hudakarman}}
{{Organ System Project}}
System leader: '''[[User:Roukoz Abou Karam|Roukoz Abou Karam, M.D.]]'''
==Status Updates==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Resident survival guide Progress
|-
|Completed
|9
|-
|In progress
|1
|-
|Remaining
|2
|-
! colspan="2" style="background:#efefef;" |Primary care chapter Progress
|-
|Completed
|6
|-
|In progress
|5
|-
|Remaining
|0
|}

==Primary Care Topics==

{| class="wikitable sortable"
! colspan="4" |Primary care chapters
! colspan="3" |Primary care resident survival guides
|-
!Specialty
!Topic
!Author
!Status
!Resident Survival Guide Page
!Author
!Status
|-
|Pulmonary||[[Asthma|Asthma exacerbation]]
|
|Complete||[[Asthma exacerbation resident survival guide]]||Abdurahman, Vidit||Complete
|-
|Pulmonary||[[Chronic obstructive pulmonary disease|COPD exacerbation]]
|Roukoz Abou Karam
|Complete||[[COPD exacerbation resident survival guide]]|| ||Complete
|-
|Pulmonary
|[[Cough]]
|Abiodun Akanmode
|Complete
|[[Cough resident survival guide]]
|Sara Haddadi
|In progress
|-
|Pulmonary
|[[Dyspnea]]
|Roukoz Abou Karam
|In progress
|[[Dyspnea resident survival guide]]
|Eiman
|Needs review
|-
|Pulmonary
|[[Chest pain]]
|Aisha Adigun
|In progress
|[[Chest pain resident survival guide]]
|
|Complete
|-
|Pulmonary
|[[Hemoptysis]]
|
|Complete
|[[Hemoptysis resident survival guide]]
|Teresa
|Complete
|-
|Pulmonary||[[Anaphylaxis]]
|
|Complete||[[Anaphylaxis resident survival guide]]||Vidit||Complete
|-
|Pulmonary||[[Acute respiratory distress syndrome]]
|Roukoz Abou Karam
|Complete||[[Acute respiratory distress syndrome resident survival guide]]||Ayokunle||Complete
|-
|Pulmonary||[[Pleural effusion]]
|Dushka Riaz
|Complete||[[Pleural effusion resident survival guide]]||Twinkle||Complete
|-
|Pulmonary||[[Pulmonary embolism]]
|
|Complete||[[Pulmonary embolism resident survival guide]]|| ||Complete
|-
|Pulmonary
|[[Lung mass]]
|
|Complete
|[[Lung mass resident survival guide]]
|Akshun Kalia
|Complete
|} 

==Status Update==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Progress
|-
|Completed
|41
|-
|In progress
|9
|-
|Remaining
|20
|}
==List of Chapters Requiring Content==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="21" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonolgy
| style="padding: 5px 5px; background: #F5F5F5;" |[[Amniotic fluid embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchoscopy]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hepatopulmonary syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hydrothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hypoxemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Mediastinal disorders
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mediastinal mass|Mediastinal masses]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Pleural disorders
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pleural plaque]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pleurodynia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Pressure associated lung diseases
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Altitude sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Barotrauma]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Nitrogen narcosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary function tests]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary nodule]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Idiopathic pulmonary hemosiderosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary lymphangioleiomyomatosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|}

==In progress chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="22" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonology
| style="padding: 5px 5px; background: #F5F5F5;" |[[Decompression sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Hazem
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Air embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mounika Lakumalla
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmed Elsaiey
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hepatopulmonary syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Soroush
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Tracheitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Rija Gul
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumoconiosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Berylliosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Omid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Farmer's lung]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Aisha
| style="padding: 5px 5px; background: #F5F5F5;" |Ali Musadiq
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Decompression sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Jaspinder Kaur
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmed Elsaiey
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Chylothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Joanna Ekabua
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz Abou Karam
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Thoracentesis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ayeesha
| style="padding: 5px 5px; background: #F5F5F5;" |Ali Musadiq
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Flock worker's lung]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usman Shah
| style="padding: 5px 5px; background: #F5F5F5;" |Sara Mohsin
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-

|}

==Completed chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="45" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonology
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cystic fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Shamila
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary hypertension]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ajay
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory failure]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Khurram/Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary edema]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Famaz/Manpreet
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Neurogenic pulmonary edema]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Shamila
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchiectasis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hemoptysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Occupational lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Restrictive lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Obstructive lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Interstitial lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf/Anmol
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Idiopathic pulmonary fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmad E
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary alveolar proteinosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mahda
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cryptogenic organizing pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Manpreet
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Interstitial pneumonitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Chandra
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Small cell lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mesothelioma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mazia/feham/fatima
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid/Fehman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hypersensitivity pneumonitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sargun
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Non small cell lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mohsin
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Adenocarcinoma of the lung|Adenocarcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sudarshana
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Large cell carcinoma of the lung|Large cell carcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Aditiya
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Squamous cell carcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lung mass]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Akshun
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cyanosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Chandra/Medhat/Amandeep
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory acidosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Krishna
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory alkalosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Madhu
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Diaphragmatic paralysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mahda
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchogenic cyst]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Joanna Ekabua
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Eosinophilic pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Medhat
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Fat embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Fehman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mechanical ventilation]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ajay
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Atelectasis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sudarshana
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pancoast tumor]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mazia
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Blood gas analysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Medhat
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[CO poisoning]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Fatima
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Aspiration pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory patterns]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Eiman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hyperventilation]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Amresh/Akshun/Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|}

Thyroid adenoma overview

2021-03-26T15:23:33Z

Roukoz Abou Karam:

__NOTOC__
{{Thyroid adenoma}}
{{CMG}}; {{AE}} {{Ammu}}
==Overview==
Thyroid [[adenoma]] is a [[benign]] [[tumor]] of the [[thyroid gland]]. Thyroid [[adenoma]] was first discovered by Fabricius, in 1619 when he described that [[thyroid]] enlargement causes midline [[neck]] swelling. Thyroid [[adenoma]] may be classified according to the [[histology]] into 3 subtypes/groups follicular [[adenoma]], [[papillary]] [[adenoma]], and signet cell [[adenoma]]. Thyroid [[adenoma]] arises from [[epithelial cell]]s of [[thyroid gland]], that are normally involved in secretion of [[thyroxine]] hormone. The most common gene involved in the [[pathogenesis]] of thyroid [[adenoma]] is ''THADA'' [[gene]]. Common causes of thyroid [[adenoma]] include iodine deficiency, chronic [[inflammation]], and [[genetic mutation]] of ''THADA'' gene. Thyroid [[adenoma]] must be differentiated from other thyroid disorders such as [[multinodular goiter]], [[grave's disease]], [[Hashimoto's disease]], medullary cell carcinoma, [[De Quervain's thyroiditis]], thyroid lymphoma, and acute suppurative thyroiditis. The incidence of thyroid [[adenoma]] is estimated to be 9 million cases annually in United States. Females are more commonly affected with thyroid [[adenoma]] than males. Common risk factors in the development of thyroid adenoma are family history of thyroid [[adenoma]], exposure to [[radiation]], lack of [[iodine]] in diet, smoking, and [[Hashimoto's thyroiditis]]. Depending on the extent of the [[tumor]] at the time of [[diagnosis]], the [[prognosis]] may vary. However, the [[prognosis]] is generally regarded as excellent. The hallmark of thyroid [[adenoma]] is swelling in front of the neck. A positive history of [[radiation]] exposure and family history of thyroid [[adenoma]] is suggestive of thyroid [[adenoma]]. The most common symptoms thyroid adenoma include [[cough]] and [[dysphonia|hoarseness of voice]]. On [[ultrasound]], thyroid [[adenoma]] is characterized by [[halo sign]] or smooth margin of thyroid, hyperechoic nodules, and normal reactive cervical nodes. [[Fine needle aspiration]] [[biopsy]] may be helpful in diagnosis of thyroid [[adenoma]]. Findings on [[fine needle aspiration]] [[biopsy]] suggestive of thyroid [[adenoma]] include cystic changes, [[fibrosis]], and areas of [[hemorrhage]]. The mainstay of therapy for thyroid [[adenoma]] is supportive therapy and regular monitoring.

==Historical Perspective==
Thyroid adenoma was first discovered by Fabricius, in 1619 when he described that thyroid enlargement causes midline neck swelling.

==Classification==
Thyroid [[adenoma]] may be classified according to the [[histology]] into 3 subtypes/groups follicular [[adenoma]], [[papillary]] adenoma, and signet cell [[adenoma]].

==Pathophysiology==
Thyroid adenoma arises from [[epithelial cell]]s of [[thyroid]] gland, that are normally involved in secretion of [[thyroxine]] hormone. The most common gene involved in the [[pathogenesis]] of thyroid [[adenoma]] is ''THADA'' gene.
==Causes==
Common causes of thyroid [[adenoma]] include [[iodine deficiency]], [[chronic inflammation]], and [[genetic mutation]] of ''THADA'' gene.

==Differentiating thyroid adenoma from other Conditions==
Thyroid [[adenoma]] must be differentiated from other thyroid disorders such as [[multinodular goiter]], [[grave's disease]], [[Hashimoto's disease]], medullary cell carcinoma, [[De Quervain's thyroiditis]], thyroid lymphoma, and acute suppurative thyroiditis.
==Epidemiology and Demographics==
The incidence of thyroid [[adenoma]] is estimated to be 9 million cases annually in United States. Females are more commonly affected with thyroid [[adenoma]] than males.
==Risk Factors==
Common risk factors in the development of thyroid adenoma are family history of thyroid adenoma, exposure to [[radiation]], lack of iodine in diet, smoking, and [[Hashimoto's thyroiditis]].

==Natural History, Complications and Prognosis==
Depending on the extent of the [[tumor]] at the time of [[diagnosis]], the [[prognosis]] of thyroid [[adenoma]] may vary. However, the prognosis is generally regarded as excellent. Common [[complications]] of thyroid [[adenoma]] include [[hyperthyroidism]],[[thyrotoxicosis]], [[hemorrhage]], thyroid cyst, and [[superior vena cava obstruction]].
==Diagnosis==
===Study of Choice===
There is no single diagnostic study of choice for the [[diagnosis]] of thyroid [[adenoma]], but thyroid nodules can be diagnosed based on an [[ultrasound]] examination of the neck, a screening serum [[TSH]] level, and [[fine needle aspiration]] [[biopsy]].

===History and Symptoms===
The hallmark of thyroid [[adenoma]] is [[swelling]] infront of the neck. A positive history of [[radiation]] exposure and family history of thyroid [[adenoma]] is suggestive of thyroid adenoma. The most common symptoms thyroid adenoma include [[cough]] and [[dysphonia|hoarseness of voice]].

===Physical Examination===
Patients with thyroid [[adenoma]] usually appear normal. [[Physical examination]] of patients with thyroid [[adenoma]] is usually remarkable for solitary, non-tender [[nodule]] in the midline of [[neck]], which is smooth, soft, and mobile.
===Laboratory Findings===
Laboratory findings consistent with the diagnosis of thyroid [[adenoma]] include decreased [[thyroid stimulating hormone]], elevated [[calcitonin]], and [[hypocalcemia|decreased calcium]].
===Ultrasound===
On [[ultrasound]], thyroid [[adenoma]] is characterized by [[halo sign]] or smooth margin of [[thyroid]], hyperechoic nodules, and normal reactive cervical nodes.
===Other Imaging Findings===
Other diagnostic studies for thyroid [[adenoma]] include [[thyroid]] scan, which demonstrates hot, cold, and functioning nodule.
===Biopsy===
[[Fine needle aspiration]] [[biopsy]] may be helpful in diagnosis of thyroid [[adenoma]]. Findings on [[fine needle aspiration]] [[biopsy]] suggestive of thyroid [[adenoma]] include cystic changes, [[fibrosis]], and areas of hemorrhage.

==Treatment==
===Medical Therapy===
The mainstay of therapy for thyroid adenoma is supportive therapy and regular monitoring.
===Surgery===
Thyroid [[lobectomy]] is recommended for all patients who develop pressure [[Symptom|symptoms]] of thyroid [[adenoma]].
===Prevention===
There is no established method for [[prevention]] of thyroid [[adenoma]].
==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Disease]]
[[Category:Endocrinology]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Endocrinology]]
[[Category:Surgery]]

Sandbox:Roukoz

2021-03-26T15:09:01Z

Roukoz Abou Karam:

__NOTOC__

Cardiac surgery<ref name="pmid23447502">{{cite journal| author=Aya HD, Cecconi M, Hamilton M, Rhodes A| title=Goal-directed therapy in cardiac surgery: a systematic review and meta-analysis. | journal=Br J Anaesth | year= 2013 | volume= 110 | issue= 4 | pages= 510-7 | pmid=23447502 | doi=10.1093/bja/aet020 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23447502 }} </ref>

Pulmonology status update

2021-02-25T16:07:49Z

Roukoz Abou Karam:

__NOTOC__

{{CMG}}; {{AE}} {{Hudakarman}}
{{Organ System Project}}
System leader: '''[[User:Roukoz Abou Karam|Roukoz Abou Karam, M.D.]]'''
==Status Updates==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Resident survival guide Progress
|-
|Completed
|9
|-
|In progress
|1
|-
|Remaining
|2
|-
! colspan="2" style="background:#efefef;" |Primary care chapter Progress
|-
|Completed
|6
|-
|In progress
|5
|-
|Remaining
|0
|}

==Primary Care Topics==

{| class="wikitable sortable"
! colspan="4" |Primary care chapters
! colspan="3" |Primary care resident survival guides
|-
!Specialty
!Topic
!Author
!Status
!Resident Survival Guide Page
!Author
!Status
|-
|Pulmonary||[[Asthma|Asthma exacerbation]]
|
|Complete||[[Asthma exacerbation resident survival guide]]||Abdurahman, Vidit||Complete
|-
|Pulmonary||[[Chronic obstructive pulmonary disease|COPD exacerbation]]
|Roukoz Abou Karam
|Complete||[[COPD exacerbation resident survival guide]]|| ||Complete
|-
|Pulmonary
|[[Cough]]
|Abiodun Akanmode
|Complete
|[[Cough resident survival guide]]
|Sara Haddadi
|In progress
|-
|Pulmonary
|[[Dyspnea]]
|Roukoz Abou Karam
|In progress
|[[Dyspnea resident survival guide]]
|Eiman
|Needs review
|-
|Pulmonary
|[[Chest pain]]
|Aisha Adigun
|In progress
|[[Chest pain resident survival guide]]
|
|Complete
|-
|Pulmonary
|[[Hemoptysis]]
|
|Complete
|[[Hemoptysis resident survival guide]]
|Teresa
|Complete
|-
|Pulmonary||[[Anaphylaxis]]
|
|Complete||[[Anaphylaxis resident survival guide]]||Vidit||Complete
|-
|Pulmonary||[[Acute respiratory distress syndrome]]
|Roukoz Abou Karam
|Complete||[[Acute respiratory distress syndrome resident survival guide]]||Ayokunle||Complete
|-
|Pulmonary||[[Pleural effusion]]
|Dushka Riaz
|In progress||[[Pleural effusion resident survival guide]]||Twinkle||Complete
|-
|Pulmonary||[[Pulmonary embolism]]
|
|Complete||[[Pulmonary embolism resident survival guide]]|| ||Complete
|-
|Pulmonary
|[[Lung mass]]
|
|Complete
|[[Lung mass resident survival guide]]
|Akshun Kalia
|Complete
|} 

==Status Update==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Progress
|-
|Completed
|41
|-
|In progress
|9
|-
|Remaining
|20
|}
==List of Chapters Requiring Content==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="21" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonolgy
| style="padding: 5px 5px; background: #F5F5F5;" |[[Amniotic fluid embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchoscopy]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hepatopulmonary syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hydrothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hypoxemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Mediastinal disorders
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mediastinal mass|Mediastinal masses]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Pleural disorders
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pleural plaque]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pleurodynia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Pressure associated lung diseases
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Altitude sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Barotrauma]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Nitrogen narcosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary function tests]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary nodule]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Idiopathic pulmonary hemosiderosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary lymphangioleiomyomatosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|}

==In progress chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="22" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonology
| style="padding: 5px 5px; background: #F5F5F5;" |[[Decompression sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Hazem
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Air embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mounika Lakumalla
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmed Elsaiey
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hepatopulmonary syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Soroush
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Tracheitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Rija Gul
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumoconiosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Berylliosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Omid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Farmer's lung]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Aisha
| style="padding: 5px 5px; background: #F5F5F5;" |Ali Musadiq
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Decompression sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Jaspinder Kaur
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmed Elsaiey
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Chylothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Joanna Ekabua
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz Abou Karam
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Thoracentesis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ayeesha
| style="padding: 5px 5px; background: #F5F5F5;" |Ali Musadiq
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Flock worker's lung]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usman Shah
| style="padding: 5px 5px; background: #F5F5F5;" |Sara Mohsin
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-

|}

==Completed chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="45" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonology
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cystic fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Shamila
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary hypertension]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ajay
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory failure]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Khurram/Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary edema]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Famaz/Manpreet
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Neurogenic pulmonary edema]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Shamila
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchiectasis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hemoptysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Occupational lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Restrictive lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Obstructive lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Interstitial lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf/Anmol
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Idiopathic pulmonary fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmad E
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary alveolar proteinosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mahda
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cryptogenic organizing pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Manpreet
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Interstitial pneumonitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Chandra
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Small cell lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mesothelioma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mazia/feham/fatima
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid/Fehman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hypersensitivity pneumonitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sargun
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Non small cell lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mohsin
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Adenocarcinoma of the lung|Adenocarcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sudarshana
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Large cell carcinoma of the lung|Large cell carcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Aditiya
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Squamous cell carcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lung mass]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Akshun
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cyanosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Chandra/Medhat/Amandeep
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory acidosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Krishna
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory alkalosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Madhu
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Diaphragmatic paralysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mahda
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchogenic cyst]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Joanna Ekabua
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Eosinophilic pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Medhat
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Fat embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Fehman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mechanical ventilation]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ajay
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Atelectasis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sudarshana
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pancoast tumor]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mazia
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Blood gas analysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Medhat
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[CO poisoning]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Fatima
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Aspiration pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory patterns]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Eiman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hyperventilation]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Amresh/Akshun/Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|}

Pulmonology status update

2021-02-16T16:24:02Z

Roukoz Abou Karam:

__NOTOC__

{{CMG}}; {{AE}} {{Hudakarman}}
{{Organ System Project}}
System leader: '''[[User:Roukoz Abou Karam|Roukoz Abou Karam, M.D.]]'''
==Status Updates==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Resident survival guide Progress
|-
|Completed
|9
|-
|In progress
|1
|-
|Remaining
|2
|-
! colspan="2" style="background:#efefef;" |Primary care chapter Progress
|-
|Completed
|6
|-
|In progress
|5
|-
|Remaining
|0
|}

==Primary Care Topics==

{| class="wikitable sortable"
! colspan="4" |Primary care chapters
! colspan="3" |Primary care resident survival guides
|-
!Specialty
!Topic
!Author
!Status
!Resident Survival Guide Page
!Author
!Status
|-
|Pulmonary||[[Asthma|Asthma exacerbation]]
|
|Complete||[[Asthma exacerbation resident survival guide]]||Abdurahman, Vidit||Complete
|-
|Pulmonary||[[Chronic obstructive pulmonary disease|COPD exacerbation]]
|Roukoz Abou Karam
|Complete||[[COPD exacerbation resident survival guide]]|| ||Complete
|-
|Pulmonary
|[[Cough]]
|Abiodun Akanmode
|Complete
|[[Cough resident survival guide]]
|Sara Haddadi
|In progress
|-
|Pulmonary
|[[Dyspnea]]
|Roukoz Abou Karam
|In progress
|[[Dyspnea resident survival guide]]
|Eiman
|Needs review
|-
|Pulmonary
|[[Chest pain]]
|Aisha Adigun
|In progress
|[[Chest pain resident survival guide]]
|
|Complete
|-
|Pulmonary
|[[Hemoptysis]]
|
|Complete
|[[Hemoptysis resident survival guide]]
|Teresa
|Complete
|-
|Pulmonary||[[Anaphylaxis]]
|
|Complete||[[Anaphylaxis resident survival guide]]||Vidit||Complete
|-
|Pulmonary||[[Acute respiratory distress syndrome]]
|Roukoz Abou Karam
|In progress||[[Acute respiratory distress syndrome resident survival guide]]||Ayokunle||Complete
|-
|Pulmonary||[[Pleural effusion]]
|Dushka Riaz
|In progress||[[Pleural effusion resident survival guide]]||Twinkle||Complete
|-
|Pulmonary||[[Pulmonary embolism]]
|
|Complete||[[Pulmonary embolism resident survival guide]]|| ||Complete
|-
|Pulmonary
|[[Lung mass]]
|
|Complete
|[[Lung mass resident survival guide]]
|Akshun Kalia
|Complete
|} 

==Status Update==
{| class="wikitable" border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
|+
! colspan="2" style="background:#efefef;" |Progress
|-
|Completed
|41
|-
|In progress
|9
|-
|Remaining
|20
|}
==List of Chapters Requiring Content==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="21" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonolgy
| style="padding: 5px 5px; background: #F5F5F5;" |[[Amniotic fluid embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchoscopy]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hepatopulmonary syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hydrothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hypoxemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Mediastinal disorders
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mediastinal mass|Mediastinal masses]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Pleural disorders
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pleural plaque]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pleurodynia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Pressure associated lung diseases
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Altitude sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Barotrauma]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Nitrogen narcosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary function tests]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary nodule]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Idiopathic pulmonary hemosiderosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary lymphangioleiomyomatosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|}

==In progress chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="22" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonology
| style="padding: 5px 5px; background: #F5F5F5;" |[[Decompression sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Hazem
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Air embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mounika Lakumalla
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmed Elsaiey
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hepatopulmonary syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Soroush
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Tracheitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Rija Gul
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumoconiosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Berylliosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |Omid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Farmer's lung]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Aisha
| style="padding: 5px 5px; background: #F5F5F5;" |Ali Musadiq
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Decompression sickness]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Jaspinder Kaur
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmed Elsaiey
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Chylothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Joanna Ekabua
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz Abou Karam
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Thoracentesis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ayeesha
| style="padding: 5px 5px; background: #F5F5F5;" |Ali Musadiq
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Flock worker's lung]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usman Shah
| style="padding: 5px 5px; background: #F5F5F5;" |Sara Mohsin
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-

|}

==Completed chapters==

{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
| rowspan="45" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Pulmonology
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cystic fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Shamila
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary hypertension]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ajay
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory failure]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Khurram/Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary edema]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Famaz/Manpreet
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Neurogenic pulmonary edema]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Shamila
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchiectasis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hemoptysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Occupational lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hadeel
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Restrictive lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Obstructive lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Interstitial lung disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf/Anmol
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Idiopathic pulmonary fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmad E
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pulmonary alveolar proteinosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mahda
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cryptogenic organizing pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Manpreet
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Interstitial pneumonitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Chandra
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Small cell lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mesothelioma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mazia/feham/fatima
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumothorax]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid/Fehman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hypersensitivity pneumonitis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sargun
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Non small cell lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mohsin
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Adenocarcinoma of the lung|Adenocarcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sudarshana
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Large cell carcinoma of the lung|Large cell carcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Aditiya
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Squamous cell carcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lung mass]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Akshun
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Cyanosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Chandra/Medhat/Amandeep
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory acidosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Krishna
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory alkalosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Madhu
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Diaphragmatic paralysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mahda
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Bronchogenic cyst]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Joanna Ekabua
| style="padding: 5px 5px; background: #F5F5F5;" |Roukoz
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lung cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Dildar
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Eosinophilic pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Medhat
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Fat embolism]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Fehman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Mechanical ventilation]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Ajay
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Atelectasis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sudarshana
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pancoast tumor]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Mazia
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Blood gas analysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Medhat
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[CO poisoning]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Fatima
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Aspiration pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Sadaf
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Pneumonia]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Hamid
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Respiratory patterns]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Eiman
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |[[Hyperventilation]]
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned
| style="padding: 5px 5px; background: #F5F5F5;" |Amresh/Akshun/Usama
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |Complete
| style="padding: 5px 5px; background: #F5F5F5;" |In progress
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|}